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General Introduction 
General Introduction 
Fertility has been an important issue in all recorded history of mankind. Ample proof of this 
may be seen in the worshipping of diverse fertility gods in different cultures. For example, 
the ancient Egyptians already made offerings to fertility gods, like Hathor and created 
phallus symbols. From a biological and population point of view reproduction is important 
in species as a compensation for death. 
To remain without offspring is a grave burden for couples facing fertility problems. In 50 
percent of fertility problems a male factor is involved. Even now the aetiology of male 
subfertility remains unclear in about 40 percent of cases. This is due to the fact that male 
subfertility studies were not undertaken systematically before the 1960s. 
Since the sexual revolution it gradually became easier to perform studies on male fertility. 
This factor, and the evidence-based medicine as a pervasive force in all fields of medicine, 
has stimulated the research on male subfertility during the last decades. 
There are two main causes for the current interest in the genetics of male factor 
subfertility. Firstly we are witnessing an explosion of knowledge on the genetics of 
reproductive medicine. Secondly, since the introduction of intracytoplasmic sperm injection 
(ICSI) there has been concern about its risks to the offspring especially genetic 
abnormalities. These aspects have stimulated us to study the clinical and molecular 
genetic aspects of male subfertility and its clinical implications. 
Male Subfertility 
Prevalence and aetiology 
In the Netherlands, every one in seven couples does not achieve a pregnancy within one 
year of active sexual intercourse. At the end of their reproductive lifespan, 2 to 7 percent 
remain childless. Subfertility may have various causes in either partner. According to the 
World Health Organization (WHO, 1992), in 20 percent of all cases the problem is 
predominantly male and in 38 percent predominantly female. 
Male fertility requires normal spermatogenesis, epididymal maturation, storage of sperm, 
accessory gland function and sperm transport together with appropriately timed 
intercourse. The suboptimal reproductive capacities of one partner may become evident in 
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case of subfertility of the other partner. Male subfertility is frequently associated with a 
gross reduction in the number of sperm (oligozoospermia) or less frequently with the 
complete absence of sperm in the ejaculate (azoospermia), with abnormal motility of 
sperm (asthenozoospermia) or with abnormal morphology of the sperm 
(teratozoospermia). The results of semen analysis are an important indication of (sub-) 
fertility in males but are usually not considered to be sufficient for the diagnosis. The WHO 
defined male subfertility as lack of conception after at least 12 months of unprotected 
intercourse in combination with at least two separate semen samples, collected several 
weeks apart, that are not meeting the WHO criteria. However, many investigators (van 
Dop eta/., 1998; Cohlen, 1997) have suggested less strict criteria than the WHO. 
Table I. Reference range of semen parameters (WHO, 1992) 
Semen Parameter 
Seminal plasma volume 
Concentration 
Total progressive motility 
Normal morphology 
Reference range 
>2.0 ml 
> 20.0 x 106 per ml 
>50% 
>10% 
Male subfertility may be categorised as: pretesticular, testicular and post testicular factors 
(see for review; de Kretser, 1997). Infection, trauma, cryptorchidism, varicocele, 
chemotherapy, malignancy, vasectomy and genetic factors are important causes of male 
factor subfertility. However, in up to 40% of subfertile males the aetiology remains 
unknown. In these cases the question arises whether this could be explained by (yet 
unknown) genetic factors. 
Andrological investigation traditionally relies on a thorough history, physical examination, 
endocrinologic work-up and semen analysis. Since the introduction of ICSI this 
andrological investigation has been widened with the search for genetic causes of male 
subfertility. A genetic origin of male subfertility may explain the aetiology and may also 
indicate possible risks to the ICSI offspring before treatment. 
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Genetic aspects of male subfertility 
Male factor subfertility can occur either as an isolated disorder or within the framework of a 
known complex disorder or syndrome. Male subfertility can be caused by diverse genetic 
abnormalities. In the following sections (1) the familial occurrence of male subfertility (2) 
chromosomal abnormalities in male subfertility (3) microdeletions of the Y-chromosome 
and (4) monogenetic factors and candidate genes in male subfertility will be discussed. 
The familial occurrence of male subfertility 
In 1984 Budde et at., performed the first family study on male subfertility. An increased 
frequency of fertility problems among brothers of subfertile men was described. They 
hypothesised that this could be caused by an autosomal recessive or X-linked inheritance. 
Lilford et at., 1994 also showed an increased frequency of male fertility problems among 
brothers. In this study segregation analysis showed that male subfertility has an autosomal 
recessive mode of inheritance in over half of the cases and that probably several genes 
are involved. Recently, a study by Meschede eta/., (2000) confirmed the familial clustering 
of male subfertility, but they proposed a multifactorial inheritance. In all these studies the 
prevalence of male fertility problems among families in the population is unknown. 
Therefore we started a survey on the familial occurrence of male subfertility. In this study 
(Chapter 1) we will also investigate the accuracy of the family history on fertility problems. 
To study the supposed pattern of inheritance in male subfertility the prevalence of 
subfertility among relatives of subfertile men will be compared with this prevalence among 
relatives of the randomly selected men (Chapter 2). We will also demonstrate possible 
phenotypic differences between subfertile men with and without a positive family history. 
With the help of the clinically well-defined group of severe subfertile men we identified a 
family showing 5 subfertile maternal nephews. In Chapter 3 we report on this family and 
describe the results including the X-linkage analysis in this family. The group of well-
defined severe subfertile men described in chapter 2 is the clinical basis for molecular 
genetic studies, presented in Chapter 4 and Chapter 5. 
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Chromosomal abnormalities in male subfertility 
Starting with the description of Klinefelter syndrome by Jacobs and colleagues (1959) 
many studies have examined the role of chromosomal abnormalities in male subfertility. 
Reported frequencies of chromosomal aberrations range from 2.2% in subfertile men 
(sperm count< 20x1 06 per ml) and 6.0% in males with severe oligozoospermia to 19.6% in 
azoospermic men (Chandley et a/., 1979). In a study by Tuerlings et a/., (1998) it was 
shown that 4.0% of the 1792 male ICSI candidates revealed a chromosomal abnormality, 
predominately sex chromosome aberrations (47,XXY) and Robertsonian translocations 
(between chromosomes 13 and 14). In general, the frequency of karyotypic abnormalities 
among subfertile males increases when the number of spermatozoa decreases. 
Microdeletions of the Y chromosome 
Tiepolo and Zuffardi (1976) were the first to describe the azoospermia factor (AZF) region 
of the Y chromosome based on the observation of cytogenetic deletions in infertile men. 
Many studies have investigated the role of this region in spermatogenesis. Until now it has 
been suggested that some of the genes in the Yq11 region control spermatogenesis (Ma 
eta/., 1993; Reijo eta/., 1995; Lahn and Page, 1997). This region can be divided in three 
nonoverlapping regions of theY chromosome: AZFa, b and c (Vogt eta/., 1996). 
Microdeletions of the Y chromosome occur in 1% to 29% of subfertile men (Van der Ven 
eta/., 1996; Foresta eta/., 1997; Kremer eta/., 1997). The frequency is dependent on the 
definition of male subfertility and on the choice of Sequence Tagged Sites used for 
screening. The AZFc locus containing the DAZ gene cluster is the most frequently deleted 
region of the Y chromosome in men with non-obstructive infertility (Kostiner eta/., 1998; 
Simoni et a/., 1998). Histologically these deletions are associated with various 
spermatogenetic alterations, such as: Sertoli Cell Only syndrome, maturation arrest and 
hypospermatogenesis. 
After the introduction of ICSI, men with a microdeletion of theY chromosome could father 
children despite their severe oligozoospermia or azoospermia, using ejaculated or surgical 
retrieved spermatozoa. Microdeletions in subfertile fathers as well as their sons, born after 
ICSI, have been reported (Kent-First eta/., 1996). In a clinically well characterised cohort 
of male ICSI candidates (Kremer et a/., 1997) showed that all 7 of the 111 men with a 
microdeletion in the AZFc region of the Y chromosome had severe oligozoospermia, but 
normal clinical andrological findings and normal FSH levels. 
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The candidate gene for male subfertility DAZLA (Deleted in AZoospermia Like Autosomal) 
on human chromosome 3 shares a high degree of homology with the DAZ gene (Deleted 
in AZoospermia) on the Y-chromosome. It is suggested that the DAZ genes arose from 
the transposition of DAZLA to theY-chromosome followed by repeated amplification and 
pruning (Saxena et a/., 1996). Its testis specific expression and its homology to DAZ 
support the role of DAZLA in spermatogenesis. Disruption of the DAZLA gene in mice 
leads to loss of germ cells in both ovary and testis and absence of gamete production, 
demonstrating that DAZLA is essential for the differentiation of germ cells in mice (Ruggiu 
eta/., 1997). 
We hypothesised that mutations in the human DAZLA gene are responsible for some of 
the (familial) cases of male subfertility. In Chapter 4 we describe the search for mutations 
in the DAZLA gene in severe subfertile men using Single Strand Confirmation 
Polymorphism (SSCP) and sequencing techniques. 
Monogenetic factors and candidate genes in male subfertility 
From animal studies in drosophila and mice, it is known that perhaps thousands of genes 
are involved in spermatogenesis (Hackstein et al., 2000). On the other hand, a number of 
well-known monogenic disorders present with male subfertility (see for review Tuerlings et 
a/. 1998; Meschede, 1997; for reproductive endocrine review see Fauser, 1995). 
Monogenic disorders can cause male subfertility, but many of them are accompanied by 
other clinical symptoms such as an impaired general health or mental and sexual 
developmental delay. 
One of the more common monogenic disorders involved in male factor subfertility is cystic 
fibrosis (CF) which is caused by mutations in the CFTR gene. Cystic Fibrosis (CF) is the 
most common autosomal disease in the western world. The classical CF symptoms are 
progressive lung disease and pancreatic insufficiency, elevated sweat electrolyte values 
and congenital bilateral absence of the vas deferens (CBAVD) resulting in obstructive 
azoospermia. Ninety seven percent of male patients with classical CF are infertile 
(azoospermia) due to bilateral absence of the vas deferens. It is now clear that specific 
mutations of the CFTR gene may manifest as isolated CBAVD in the absence of other 
symptoms. Approximately 80 percent of men with CBAVD without clinical symptoms of 
CF, have detectable mutations in the CFTR gene locus (Dumur et at., 1996). 
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To date, little is known about the frequency and causes of isolated congenital unilateral 
absence of the vas deferens (CUAVD) or of cystic changes in the Wolffian duct system. In 
addition, we know little about the frequency of CFTR mutations in these men. The CFTR 
gene might play a direct role in spermatogenesis or sperm maturation (Casals eta/., 1995; 
Van der Ven et a/., 1996). They found that 14 out of 80 (17.5%) males with fertility 
problems due to variable abnormalities of sperm quality had at least one CFTR mutation. 
This was significantly higher than the expected CFTR carrier frequency, estimated at 4 
percent, in their general population. These results could not be confirmed in a study by 
Tuerlings eta/., (1998a) on the frequency of CFTR mutations in male ICSI candidates with 
severe oligoasthenoteratozoospermia. 
Some other candidate genes for male subfertility have been proposed like the Follicle 
Stimulating Hormone (FSH) receptor gene. FSH is considered to be essential for 
spermatogenesis, while Luteinizing Hormone regulates steroidogenesis. An inactivating 
point mutation of the FSH receptor gene has been reported in some men with elevated 
serum FSH concentrations and abnormal sperm parameters (Tapanainen eta/., 1997). In 
a study of 28 men with high FSH levels, no mutations were found in the FSH receptor 
gene (Tuerlings et al., 1998b). 
Another candidate gene, the Y chromosomal gene USP9Y, has been studied recently. A 
de novo point mutation in this Y chromosomal gene USP9Y is described in an 
azoospermic man (Sun et at., 1999). 
Furthermore, Aiman et at., (1979) postulated that defects in the AR gene could lead to 
partial or complete spermatogenic failure. This AR gene, located on the long arm of the X 
chromosome at Xq11-12, contains a polymorphic CAG repeat sequence in the first exon, 
which encodes a series of glutamine residues in the region of the AR protein associated 
with DNA (Brown et at., 1989). In vitro, the length of the CAG repeat sequence is inversely 
correlated with AR transcriptional activity (Kazemi-Esfarjani eta/., 1995). A relatively short 
CAG repeat is linked to an increased risk of prostate cancer, an androgen-dependent 
tumour (Giovannucci et a/., 1997), whereas a length of 38-62 CAG repeats leads to 
Kennedy's disease, a condition associated with bulbar muscular atrophy, low virilization 
and depressed spermatogenesis (Nagashima, 1988; La Spada et at., 1991 ). Several 
groups reported conflicting results on the role of the CAG repeat length in the AR gene in 
cases of male subfertility (Dowsing et a/., 1999; Dadze et a/., 2000). Because of these 
conflicting results we will report in Chapter 5 on the hypothetical association between the 
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expansion of the CAG repeat of the AR gene and subfertility among a group of Dutch 
subfertile men. 
Treatment of male subfertility 
Figure 1. Injection of a single sperm into the oocyte: IntraCytoplasmic Sperm Injection 
Prior to the era of assisted reproduction, most couples suffering from male subfertility had 
a relatively poor prognosis and chances of achieving a pregnancy were low to zero. 
Treatment of male subfertility was rarely evidence based and varied from variation in 
periods of abstinence, antibiotics in case of the presence of leukocytes in sperm, hormone 
therapy, functional foods, to surgical intervention in case of varicoceles. Many of these 
therapies are now regarded as questionable or obsolete (Nieschlag and Behre, 2000). 
Only men with a deficiency of gonadotropic hormones may be successfully treated with 
hormones but this condition is a very rare cause of male subfertility. Low or absent 
production of gonadotropic hormones causes inadequate production of testosterone and 
leads to impotence and impaired spermatogenesis in the Sertoli cells. Primary deficiency 
of these gonadotropic hormones delays puberty; in these cases puberty can be induced 
by testosterone treatment. However, this treatment will not induce fertility. If offspring is 
desired they need to be treated with pulsatile Gonadotropin Releasing Hormones (GnRH) 
(Nieschlag and Behre, 2000). Another rare cause of hypogonadotropic hypogonadism is 
hyperprolactinemia, which can be treated with dopaminergic drugs. The treatment of 
couples facing male subfertility nowadays does not focus on improving sperm parameters, 
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but tries to get the sperm as close as possible to the oocyte. The lack of treatment options 
to improve semen parameters has stimulated the use of artificial reproductive techniques 
(ART) in male subfertility. 
The ART techniques can be subdivided into two main groups; 1) in vivo techniques: Intra 
Uterine Insemination (lUI) and 2) in vitro techniques: In Vitro Fertilisation (IVF) and 
IntraCytoplasmic Sperm Injection (ICSI). Especially the introduction of ICSI has brought 
about a revolutionary change. Alternative options are adoption, donor insemination or 
accepting infertility. The couple and the physician have to weight out benefits and 
disadvantages of these treatments such as success rates, complications and cost-
effectiveness. 
The various treatment options and their success rates depend on diverse factors: female 
age, primary or secondary infertility and semen parameters. The amount of motile 
spermatozoa in the ejaculate and/or after preparation of the spermatozoa determines the 
treatment that is advised to the subfertile couple. In subfertile men with sperm 
concentrations below 1 x1 06/ml after preparation, the prognosis of lUI is very poor 
(Nieschlag and Behre, 2000). In a recent study by van Voorhis et a/., (2001) it is 
suggested that an average total motile sperm count of 10 million may be a useful treshold 
value to decide that a couple should be treated with lUI or IVF. One should consider that 
lUI is performed easily, requires minimal equipment and remains practically without 
complications. In comparison with more invasive and more costly treatments like IVF, the 
single treatment cycle with lUI is worse (Goverde eta/., 2000). In couples suffering from a 
slight form of male subfertility the efficacy of six consecutive with lUI is comparable to the 
efficacy of a single treatment of IVF, however with lower financial costs. Therefore, it is 
important to explain to couples that lUI must not be considered as one single treatment but 
rather as a series of successive trials. 
In vitro fertilisation and embryo transfer 
Louise Brown was the first child born after a successful in vitro fertilisation (IVF) and 
embryo transfer (ET) procedure (Steptoe and Edwards, 1978). The technique of IVF 
requires the collection of oocytes, initially by laparoscopy and later by transvaginal 
ultrasound-guided puncture of preovulatory follicles. Oocytes are obtained from the 
follicular fluid and incubated with motile sperm. Following fertilisation embryos are cultured 
and 2 or 3 days later they are transferred into the uterus (embryo transfer). 
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This treatment made it possible to treat couples with long-standing subfertility. In the early 
days IVF was indicated solely in case of tubal disease, later on endometriosis, 
unexplained subfertility and moderate male factor subfertility were induced. In a cochrane 
review study (van Rumste et a/., 2001) it is concluded that fertilisation rates are 
significantly better with ICSI than IVF in couples with borderline semen. Whereas the 
decision to perform ICSI rather than IVF is obvious in many situations, the choice may 
become difficult in borderline cases. The predictive accuracy of conventional semen 
analysis for sufficient fertilisation after IVF is not exactly known. 
Intracytoplasmic sperm injection (ICSI) 
Several procedures have been developed to overcome the fertilisation failure in severe 
oligoasthenozoospermia. These include partial zona drilling (Gordon and Talansky, 1986; 
Cohen eta/., 1989; Cohen eta/., 1991) and subzonal insemination (SUZI; Laws-King A. et 
a/., 1987). All these techniques were not very successful. 
In 1992 the first report of ICSI resulting in a human pregnancy appeared (Palermo eta/., 
1992). In the ICSI procedure the oocyte is fixed with the polar body visible at the top or 
bottom of a holding pipette. The technique has proven to be very successful in treating 
couples with severe male subfertility. As early as 1976, Uehara and Yanagimachi have 
shown microinjection of a single sperm into the cytoplasm of a retrieved oocyte. Worldwide 
thousands of children have been born after ICSI treatment and ongoing pregnancy rates of 
up to 35% per ICSI cycle have been reported (Van Steirteghem et a/., 1993). The 
indications for ICSI are severe oligoasthenoteratozoospermia (OAT, in the Netherlands 
less than 1 x1 06 motile sperm, WHO, 1992) or total fertilisation failure in two IVF 
procedures. 
One of the main advantages of ICSI relates to the small number of sperm that is required 
(i.e. one per egg). In addition, ICSI can also be successful in case of microscopically 
abnormal sperm, total absence of motility or even in case of immature sperm (Nieschlag, 
2001 ). 
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Surgical retrieval sperm 
Originally, sperm was only retrieved from ejaculated semen or frozen-thawed semen. 
Soon after the introduction of ICSI it became evident that fertilisation can be achieved 
using epididymal sperm or even testicular retrieved sperm (Nagy et at., 1995). In contrast 
using epididymal sperm in IVF had very poor fertilisation rates. Later, it was shown that 
children were born after ICSI using round spermatids (Tesarik et at., 1995). Most recently, 
a pregnancy was reported after ICSI using a secondary spermatocyte (Sofikitis et a/., 
1998). From these results it can be deduced that spermatozoa do not have to go through 
the full length of the genital tract before to be able to fertilise, but that also immature germ 
cells can establish fertilisation. 
Epididymal sperm is retrieved by surgical needle aspiration (microsurgical epididymal 
sperm aspiration, MESA; or Percutaneous epididymal sperm aspiration, PESA) and 
testicular sperm by testicular sperm extraction (TESE). MESA is used in cases of 
obstructive azoospermia, while TESE can be used in cases of non-obstructive 
azoospermia as well. The only indication of using spermatids for ICSI may be in case of 
azoospermia with failure of spermatogenesis. There is only limited experience with 
surgically retrieved sperm, especially in using immature germ cells, and the number of 
children born after these techniques is small. As a consequence, very little is known about 
the (potential) risks. This is the reason that in The Netherlands it is not permissible at 
present to use spermatozoa from testicular origin and the use of epididymal sperm is only 
allowed in an experimental study. 
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Counselling and outcome of intracytoplasmic sperm injection 
Counselling of male subfertility and ICSI 
Several authors emphasised the importance of "genetic" counselling in ICSI candidates 
(Tuerlings et al., 1997; Pauer et at., 1997). Counselling the ICSI couple on the origin of 
male subfertility, the genetic aspects of male subfertility and the outcome of ICSI can help 
them to make their own and well-informed decision on their reproductive future. The 
information on the origin of male subfertility and the genetic aspects are discussed above. 
The couple should also be informed about the present knowledge on the outcome of ICSI. 
Potential problems related to ICSI may be divided into two categories (Patrizio, 1995). 
1) Problems related to the ICSI technique: (a) the manipulative procedure itself, (b) 
injection of foreign material, such as plasmid DNA, infectious particles and paternal 
mitochondria, (c ) mechanical activation of the oocyt and (d) exclusion of the pre-
zygotic selection processes. 
2) Problems not directly related to the ICSI technique (the use of abnormal sperm): (a) 
an increased frequency of constitutional chromosomal abnormalities (Tuerlings et 
at., 1998c) and/or (b) chromosomal abnormalities in sperm (Moosani et at., 1995), 
and (c) an underlying 'genetic' disorder which causes male subfertility (e.g. cystic 
fibrosis andY chromosome deletions) (Dumur et at., 1996; Kremer et at., 1997), (d) 
gamete maturation could be impaired in epididymal or testicular sperm (Ariel et at., 
1994). 
The conditions mentioned in the second group mainly concern the use of ICSI without 
understanding the exact aetiology of the fertility problem. 
One of these theoretical risks has prompted us to investigate its nature. There is a risk that 
ICSI increases the transmission of paternal mitochondrial, bypassing the supposed 
mechanism (Kaneda et at., 1995) by which paternal mtDNA is removed from the embryo. 
Knowledge of the fate and transmission of paternal mitochondrial DNA is important since 
mutations in mitochondrial DNA have been described in oligozoospermic males. 
Transmission of this mutated mitochondrial DNA may lead to mitochondrial DNA diseases 
to children born after this technique. In chapter 6 we describe this study on the origin of 
mtDNA in placenta, umbilical cord, blood and buccal swabs of children born following ICSI. 
After the counselling procedure a couple has to make a decision on their reproductive 
future. If the genetic investigation revealed no abnormalities they have to make their 
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decision on the current knowledge on the safety of the ICSI procedure. But if there is a 
genetic aberration like a chromosomal abnormality in the subfertile man the couple also 
has to take into account the possible risks related to this chromosomal abnormality. For 
example, carriers of balanced translocations can produce offspring with either a normal, 
chromosomally balanced or a chromosomally unbalanced karyotype. In the latter case this 
can result in an early developmental embryonic arrest, a spontaneous abortion, a still birth 
or birth of a child with a combination of (multiple) congenital anomalies and psychomotor 
retardation in any degree. In a study by Giltay et a/., (1999) it is shown that despite the 
genetic risks related to a chromosome abnormality in subfertile men, the majority (56%) of 
the couples did not refrain from the ICSI treatment. 
Couples dealing with microdeletions of theY chromosome also have to make decisions on 
their reproductive future. Since the introduction of ICSI these men can father children and 
presumably transmit the deletion as well as the related fertility problem to their sons. 
These couples can choose for ICSI, artificial insemination with donor insemination or no 
treatment. In chapter 7 we report on the decision-making and the relationship between 
some aspects of the process of genetic counselling and the final decision. 
Outcome and Follow-up of /CS/ 
The introduction of ICSI in 1992 was embraced as a major breakthrough for the treatment 
of male factor subfertility. It should be noticed that randomised clinical trials and data 
collection on the ICSI offspring did not accompany the rapid introduction of ICSI. Up till 
now there is only a limited number of studies on the follow-up of ICSI. Most papers 
illustrate the success rate of ICSI treatment, but there is no information at all except some 
case reports about success rates in couples with severe oligozoospermia due to 
microdeletions of the Y chromosome. In chapter 8 we describe the outcome of ICSI 
treatment using sperm from a men with a microdeletion of the Y chromosome compared 
with the ICSI treatment using sperm from oligozoospermic men without this deletion. 
At this moment most follow-up studies show no increased risk of congenital abnormalities 
after ICSI. However Bonduelle eta/., (1998a) report that there is a significant increase of 
de novo chromosomal abnormalities (1.66%) after ICSI, mainly sex chromosomal 
abnormalities (0.8%). This increased frequency may be caused by (1) the increased 
frequency of aneuploidy in spermatozoa (Ohashi et a/., 2001) or (2) the non-random 
positioning in human sperm following ICSI (Terada eta/., 2000). 
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Reclassification of birth defects of the prospective follow-up study from Brussels showed 
an increased risk of having a major birth defect (Kurinczuk eta/., 1997). There are also 
controversial results from studies on the development of children born after ICSI. Bowen et 
a/., 1998 showed an increased risk of mild delays in mental development at 1 year in 
children, especially in boys, conceived by ICSI. These results are not confirmed in a larger 
study by the Brussels group (Bonduelle et al., 1998b). 
More follow-up data on ICSI should be evaluated because of theoretical risks, the novelty 
of the procedure and the limited number of controversial follow-up results. Therefore we 
report on the safety of ICSI by retrospectively comparing data of ICSI to IVF in chapter 9. 
Scope of the thesis 
In this thesis we study the genetic aspects of male subfertility in the following three parts. 
Part 1: 
Part II: 
Part Ill: 
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In this part we present the results of the family studies in male subfertility. 
We continue in this part with our molecular genetic search for genes 
involved in male subfertility. An X-linkage analysis and the investigation 
of the DAZLA and the androgen receptor gene will be shown. 
In this last part we will describe the clinical implications of these genetic 
factors in male subfertility like counselling, decision making and the 
outcome of ICSI. 
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Abstract 
Objective: To determine the prevalence of male subfertility among relatives in the 
population using a family history. Subsequently we studied the validity of the family history 
used in this survey. 
Design: Survey 
Setting: Questionnaires were sent to a group of 474 randomly selected men, aged 25-40 
years, to collect data on subfertility among themselves and their relatives. A non-
responder study and a personal interview were performed to evaluate the accuracy of the 
data obtained in this survey. 
Main outcome Measure: Prevalence of subfertility 
Results: Two hundred and forty three men (51.3%) completed the questionnaire. The 
reported prevalence of subfertility among the different relatives is significantly lower than 
among responders. Among brothers the reported prevalence is significantly five times 
lower, 3.6% versus 15.3% respectively. The non-responder study and the personal 
interview showed that these differences were not caused by a low response to this survey 
or by the use of a questionnaire instead of a personal interview. 
Conclusions: Subfertility among relatives is underestimated using a family history, 
probably due to the taboo on discussing subfertility. Knowledge of subfertility travels 
selectively among families causing substantial misclassification. Clinicians and 
researchers should be aware that family history taking is likely to lead to underestimation 
of subfertility among relatives. 
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Introduction 
In the Netherlands, every one in seven couples (14.2%) does not achieve a pregnancy 
within one year of active sexual intercourse (Beurskens eta/., 1995). Subfertility may have 
various causes in either partner. According to the World Health Organization (WHO, 
1992), in 20 percent of all cases the problem is predominantly male and in 38 percent 
predominantly female. To date the causes of defective spermatogenesis often remains 
unknown. Recently, much attention has been given to genetic causes of male subfertility 
such as chromosomal aberrations (Tuerlings et a/., 1997), microdeletions of the Y-
chromosome and other possible monogenetic causes. This attention is stimulated by the 
concern of potential transmission of genetic defects to the offspring via intracytoplasmic 
sperm injection (ICSI). 
The family history can be used to study genetic aspects of male subfertility. In addition the 
family history can provide important clues for diagnosing, counseling and treatment of the 
patient. The prevalence of male subfertility among relatives when using a family history is 
unknown. Nevertheless, several authors suggest that the family history should be used in 
research and fertility practice (Lilford eta!., 1994; Meschede eta!., 2000; Tuerlings eta!., 
1998). Therefore a survey was carried out on the familial occurrence of male subfertility to 
obtain knowledge on the prevalence of subfertility among relatives. 
Materials & Methods 
Questionnaire 
We sent 474 questionnaires to a random sample of men, aged 25-40 years, living in the 
town of Boxmeer. Boxmeer is a typical Dutch municipality of average size and socio-
economic status, with its own industry, agriculture and commerce. The city is situated in 
the southeast of the Netherlands and our university hospital is the tertiary medical center 
for this region. Using a questionnaire we collected information on medical and family 
history up to second-degree family members and we focussed on subfertility. In the 
Netherlands this is defined as a lack of conception after at least 12 months of unprotected 
intercourse. 
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The responders and their relatives were considered proven fertile if they had established a 
pregnancy or had children without reporting subfertility. People were considered unproven 
fertile if they did not report subfertility and had no children because (a) the childlessness 
was reported to be voluntary, (b) there was no heterosexual relationship, (c) the relative 
died before 25 years of age and (d) the relative was mentally retarded. Finally, when 
classification was still not possible, fertility was scored as unknown. 
The prevalence of subfertility was calculated in the total group and in the subgroup at risk 
for subfertility. In this at risk subgroup (people who try or have tried to get pregnant) we 
excluded people with unproven fertility and unknown factors. 
Non-responder study and side study 
A reminder was sent to non-responders two weeks after the questionnaire. In addition we 
tried to phone all non-responding men. In this telephone inquiry the men were asked again 
to respond to the questionnaire. If they did not want to respond, non-responder data were 
gathered on (a) the reason for not responding, (b) their own fertility status and (c) if they 
had any relatives with subfertility. 
A side study was performed to investigate the reproducibility of the data obtained with the 
questionnaire compared to data collected during a personal interview. We contacted 80 
responders and asked them to participate in this personal interview. 
Data from this non-responder investigation and the side study were used to investigate the 
accuracy of the data obtained in this survey. 
Statistical methods 
The prevalence of subfertility of different types of relatives was calculated. The prevalence 
was compared between responders and their relatives by calculation of odds ratios (OR) 
and their 95% confidence intervals (CI). In the side study we calculated kappa values, 
which indicate the chance-adjusted reproducibility of the data using a personal interview 
instead of a questionnaire. A kappa value of 1 indicates 100% reproducibility. 
The study was performed simultaneously with a study on the prevalence of benign 
urological diseases and the Institutional Review Board approved these studies. 
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Table I. Fertility status among proband and relatives according to the family history 
Family member Proven fertility• Fertility problems Fertility problems Unproven fertilitl 
in totalb at risk subgroup< 
Proband 116 (47.7%) 21 (8.6%) 211137 (15.3%) 106 (43.6%) 
Brother 216 (56.7%) 8 (2.1%) 8/224 (3.6%) 142 (37.3%) 
Sister 237 (69.7%) 8 (2.4%) 8/245 (3.3%) 58 (17.1%) 
Maternal uncle 522 (82.5%) 16 (2.5%) 16/538 (3.0%) 86 (13.6%) 
Maternal aunt 550 (85.7%) 16 (2.5%) 16/566 (2.8%) 51 (7.9%) 
Paternal uncle 568 (85.0%) 8 (1.2%) 8/576 (1.4%) 70 (10.5%) 
Paternal aunt 555 (85.8%) 22 (3.4%) 22/577 (3.8%) 52 (8.0%) 
Non-Responder 35 (34.7%) 3 (3.0%) 3138 (7.9%) 58 (57.4%) 
Unknown 
0 
15 (3.9%) 
37 (10.9%) 
9 (1.4%) 
25 (3.9%) 
22 (3.3%) 
18 (2.8%) 
5 (5.0%) 
Total 
243 
381 
340 
633 
642 
668 
647 
101 
OR(95%CI)" 
0.2 (0.08-0.5) 
0.2 (0.07-0.5) 
0.2 (0.08-0.4) 
0.2 (0.08-0.3) 
0.08 (0.03-0.2) 
0.2 (0.1-0.4) 
0.8 (0.2-2.4) 
• Proven Fertility: People who are pregnant or have children without reporting fertility problems 
b Fertility problems in total: People with or without children reporting fertility problems due to male and/or female or unknown factors with respect to the whole group 
c Fertility problems in the at risk subgroup: People with or without children reporting fertility problems due to male and/or female or unknown factors with respect to the 
subgroup at risk for fertility problems (=fertile people and people with fertility problems) 
d Unproven fertility: People with no heterosexual relationship or reporting that they are voluntary childless 
• Odds rates (OR) and 95% confidence intervals (CI) of fertility problems among relatives versus fertility problems among probands 
Results 
In total 264 out of 474 (55.7%) men responded. Two-hundred and nine responders 
completed all questions, 34 men did not gave details on their second-degree relatives and 
21 men only completed the medical history form and did not gave any details on the family 
history. In our study we included all 243 men, who completed the questionnaire on their 
first-degree relatives. 
The mean age of responders was 33.3 (SO 4.4) years. An abnormal andrologic history 
was present in 16.1 % of the responders: a history of inguinal hernia in 19 (7.8%) men, 
male genital infection in 10 (4.1 %), maldescended testis in 6 (2.5%), surgical correction of 
a varicocele in 3 (1.2%) and 1 (0.4%) man reported a torsion of his testicle. 
Table I shows the fertility status of the responders and their relatives. Subfertility among 
responders was present in 8.6%. The prevalence of subfertility in the at risk subgroup was 
15.3%. 
The subfertility of the responders were reported to be due to: unknown factors (1 0/21; 
47.6%), a female factor (4/21; 19.0%), a combined male and female factor (4/21; 19.0%) 
men and 3 men reported subfertility due to impaired semen quality (14.3%). No subfertility 
was reported among parents and grandparents. 
The prevalence of subfertility among relatives are all significantly lower than among 
responders. Brothers show a 5 times lower prevalence of subfertility than responders. The 
unproven fertility was not significantly different among responders and their brothers, 
43.6% and 37.3% respectively. The reasons for the unproven fertility among brothers 
were: (a) the brothers and their partners were voluntary childless (52.8%) and (b) if 
brothers had no partner (47.2%). 
Non-responder study 
One hundred and one men in the group of 210 non-responders (48.1 %) participated in the 
telephonic non-responder study. The mean age of the non-responders was 32.8 (SO 4.8) 
years, which was not significantly different from the responders. Reasons for not 
responding were lack of time or a misconception that the study did not focus on people 
with unproven fertility. 
Table I also shows the results from the non-responder investigation. The non-responders 
showed no significant difference in prevalence of subfertility versus responders, but had a 
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significantly higher prevalence (57.4%) of unproven fertility. The non-responders also 
reported a low prevalence of subfertility among a// relatives (7.9%). 
Side study 
Forty of the 80 contacted responders participated in this study. Subfertility in responders 
and their relatives were reported more often using a personal interview. However, kappa 
values for the reported subfertility were high among responders, first-degree relatives and 
second-degree relatives: 0.96, 0.87 and 0.77 respectively. This indicates that a 
questionnaire shows a good reproducibility with the data obtained by a personal interview. 
Discussion 
In this study we report the prevalence of subfertility among relatives, when data are 
collected using the family history. The prevalence of subfertility among responders in this 
survey (15.3%) is in the same range as earlier reports (Beurskens eta/., 1995; Hull eta/., 
1985). However, the reported prevalence of subfertility among relatives is significantly 
lower than among responders. For instance brothers, who do not differ significantly in age 
from the responders, show a 5 times lower prevalence of subfertility (OR 5.0; 2.0-12.5). 
The prevalence of subfertility is also significantly lower among second-degree relatives. 
In our view the prevalence of subfertility among relatives in this study is invalid. As in the 
population we would expect at least the same prevalence of subfertility among relatives or 
higher, because of the possible genetic factor(s) involved in male subfertility. How can we 
then explain the lower reported prevalence of subfertility among relatives? The non-
responder study and the personal interview showed that these differences were not 
caused by a low response to this survey or the use of a questionnaire. 
The fertility of the young generation of the responders may be lower than the fertility of the 
older generation of second-degree relatives. This can be due to female subfertility caused 
by the higher female age when having the first child, nowadays. And in men it is 
suggested that during the last decades the semen quality is diminishing, which may cause 
an increase of male subfertility (Auger et a/., 1995; Carlsen et al., 1992 ; Irvine et 
a/., 1996). But this hypothesis does not explain the difference found between responders 
and first-degree relatives. 
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Another explanation, for the differences found between responders and relatives, is 
misclassification. Relatives with subfertility may have been wrongly classified in this study 
as unproven fertile, proven fertile or unknown, because the responder is not aware of the 
presence of subfertility among relatives. This information bias or "taboo" bias can be 
caused by the difficulty of discussing subfertility with family members. For instance in 
research on donor insemination it is shown that the stigma associated with subfertility 
forces secrecy and lack of openness (Turner eta/., 2000). 
Lilford eta/., (1994) and Meschede eta/., (2000) reported no subfertility among relatives in 
their fertile control groups and a higher frequency of subfertility among male relatives of 
infertile men. Underestimation of subfertility in the control group and a more accurate 
estimation of subfertility among relatives of subfertile men may cause this difference. The 
taboo bias involved in subfertility may also be the reason why permission to contact 
subfertile relatives in these family studies on male subfertility is often withheld. 
The accuracy of the family history as a diagnostic tool has also been investigated in 
disorders like cancer, myocardial infarction and Alzheimer's disease. The general finding 
in these studies is that the family history can contribute to medical decision-making 
(Sijmons eta/., 2000; Dewey eta/., 2000; Kulig eta/., 2000). However, family history is not 
always reliable. Verification using medical records of relatives may be necessary to 
prevent misclassification and to correctly interpret the family history (Kee eta!., 1993). 
In conclusion, news about subfertility may travel selectively throughout families causing 
information bias. In future research subfertility in families should be evaluated, if possible, 
by direct contact to family members. At this moment clinicians and researchers should be 
aware that taking a family history on subfertility is likely to underestimate subfertility among 
relatives. 
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Abstract 
Genetic factors can cause male subfertility. A case-control study was carried out to 
investigate familial occurrence of male subfertility and the phenotypic characteristics of 
familial and non-familial male subfertility. 
The medical data and family histories of 253 severe subfertile men, candidates for 
intracytoplasmic sperm injection, were compared to the data from 243 randomly selected 
men. 
Genetic aberrations including a chromosomal abnormality or a microdeletion of the Y-
chromosome are present in 13.8% of the severe subfertile men. The prevalence of male 
fertility problems among brothers and maternal uncles of subfertile men is significantly 
higher than among controls (brothers 10.4% versus 0.5% and maternal uncles 1.7% 
versus 0.2%). The phenotypes of subfertile men with a positive family history more often 
show normal levels of FSH and LH compared to the phenotypes of subfertile men with a 
negative family history. In addition, subfertile men with a positive family history have a 
lower percentage of motile sperm. 
Male subfertility appears to have a familial occurrence, but misclassification hinders 
quantitative assessment of familial clustering. Furthermore the data suggest, that subfertile 
men with a familial occurrence of male subfertility more often have normal levels of FSH 
and LH. 
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Introduction 
Male subfertility has a wide variety of causes. Some of these involve genetic abnormalities 
like: chromosome abnormalities (Tuerlings et a/., 1998), microdeletions of the Y 
chromosome (Tiepolo and Zuffardi, 1976; Reijo et a/., 1995; Kremer et a/., 1997) and 
diverse monogenetic factors such as Cystic Fibrosis Transmembrane conductance 
Regulator (CFTR) mutations in men with Congenital Bilateral Absence of the Vas 
Deferens (CBAVD) (Dodge, 1995). However, in the majority of subfertile men the aetiology 
remains unknown and the subfertility has to be classified as idiopathic (de Kretser, 1997; 
Dubin and Amelar, 1971 ). This idiopathic male subfertility may have a genetic origin 
considering the observed familial occurrence of male subfertility (Budde eta!., 1984; Lilford 
eta/., 1994; Meschede eta/., 2000). 
From animal studies in drosophila and mice, it is known that perhaps thousands of genes 
are involved in spermatogenesis (Hackstein eta/., 2000). The family history may provide 
an important clue for these genetic causes of male subfertility and the patterns of 
inheritance. This knowledge may contribute to both genetic research and clinical 
management of male subfertility. 
Therefore we studied (a) if subfertility occurs more often among relatives of subfertile men 
than among relatives of randomly selected men and (b) possible phenotypic differences 
between subfertile men with and without a positive family history. 
Materials & Methods 
Patients 
We prospectively collected data from subfertile men visiting our fertility clinic from April 
1998 to April 2000. We included 253 men with an azoospermia or a severe 
OligoAsthenoTeratozoospermia (OAT) with semen parameters that met our 
intracytoplasmic sperm injection (ICSI) criteria. Subfertile men are candidates for ICSI in 
our clinic if their ejaculate contains less than 1.0x1 06 spermatozoa with propulsive motility 
(WHO, 1992). Patients with a previous sterilization or a testicular malignancy in their 
medical history were excluded from this study. 
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At our outpatient clinic we collected the medical data, the family history and performed a 
physical examination. All cases of cryptorchidism or disturbance in descending of one or 
both testicles were scored as maldescended testes. We took blood samples for 
measurements of Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH) and 
Testosterone, chromosome analyses and screening for microdeletions of the Azoospermia 
Factor (AZF) a, b and c region of theY-chromosome (Hoefsloot eta/., 1997). In cases of 
obstructive azoospermia, the patient was directed to the department of Urology for further 
investigation. When a patient was diagnosed with a Congenital Unilateral/Bilateral 
Absence of the Vas Deferens (CU/BAVD) screening of CFTR mutations was performed. 
Before the visit to our outpatient clinic, a questionnaire was sent to the subfertile men to 
collect information on their family history, specifically focussing on fertility problems. All 
patients provided us family history information on first and second-degree family members. 
During the visit we specifically asked the patient about involuntary childlessness and/or 
fertility problems in the family. Family members were considered proven fertile if they had 
established a pregnancy or had children without reporting a fertility problem. They were 
scored as subfertile when they reported fertility problems, with or without children, due to 
male and/or female or unknown factors. People were considered unproven fertile if they 
did not report fertility problems and had no children because (a) the childlessness was 
reported to be voluntary, (b) there was no heterosexual relationship, (c) the relative died 
before 25 years of age or (d) the relative was mentally retarded. Finally, when 
classification was still not possible, fertility was scored as unknown. 
When the patient could not give the actual cause of childlessness of a family member we 
asked him to contact that family member in order to obtain the information. When the 
cause was a male factor we asked the patient to inform his relative about the study and to 
request his permission for a telephone call by one of the researchers. When the family 
member confirmed the male factor we asked him to undergo the same investigations as 
the patient in order to describe the phenotype. 
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Controls 
We sent the same standardised questionnaire we used for the patients, to 474 randomly 
selected men, aged 25-40 years, living in the city of Boxmeer. In our study we included all 
men who completed the questionnaire giving details on their first-degree relatives, 243 of 
474 or 51.3%. Details are described in the survey on the familial occurrence of male 
subfertility (van Golde eta/., 2001, unpublished data). 
Statistics 
For both groups we only included full siblings and relatives in the analyses. Differences 
between patients and controls were calculated with Odds ratios (OR) and their 95% 
confidence intervals (95% Cl). The statistical software package SAS version 6.12 (SAS, 
Cary NC) was used for analyses. 
The study was approved by the local Institutional Review Board. 
Results 
Patients' clinical characteristics 
The patient group consisted of 46 men with an azoospermia, 10 men with an 
asthenozoospermia and 197 men had an OAT. The most frequently encountered clinical 
abnormality was maldescended testes (n = 69), followed by varicocele (n=34), surgical 
correction of an inguinal hernia (n=32) and a history of male adnexitis (n = 26). The mean 
ages of the patients and the controls were similar: 33.0 years ± SO 4.5 years and 33.3 
years ± SO 4.4 years. 
Patients' genetic abnormalities 
There were 35 patients with 36 genetic abnormalities among the 253 patients (13.8%), 
Table I. One man had two genetic defects: he suffered from Kartagener's Syndrome and 
he had a sex chromosomal abnormality, 46, X inv(Y) (p11.2;q11.23). The frequency of 
microdeletions of theY-chromosome in this patient group was 0.8%. 
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Table I. Genetic aetiology of the fertility problem 
Type of genetic abnormalities Number of patients 
Autosomal structural chromosome abnormalitya 
Sex chromosome abnormalitl 
Microdeletion of theY-chromosome 
Syndromal disorder with male subfertilityc 
CFTRd mutations in CBAVD9 
CFTRd mutations in CUAVD1 
Globozoospermia 
a Robertsonian trans locations [2], reciprocal translocation [3], inversion [1] 
b 47,XXY [3]; 47,XY [1]; 45,X/46,XY [1]; 46,X,inv(Y)(p11.2;q11.23) [1] 
c Kartagener's syndrome [2], Klippei-Feil Syndrome [1] 
dCFTR = Cystic Fibrosis Transmembrane conductance Regulator 
e CBAVD = Congenital Bilateral Absence of the Vas Deferens 
1 CUAVD =Congenital Unilateral Absence of the Vas Deferens 
Family history 
6 
6 
2 
3 
14 
2 
3 
The prevalence of male fertility problems is significantly higher among brothers and 
maternal uncles of subfertile men than among brothers and maternal uncles of controls. 
The prevalence of fertility problems is 18/173 (1 0.4%) among brothers of subfertile men 
versus 1/222 (0.5%) among brothers of controls: OR= 26.0 (95% Cl: 3.4-196.8). Among 
maternal uncles the prevalence of fertility problems is 9/523 (1.7%) and 1/534 (0.2%) 
respectively: 0R=9.3 (95% Cl: 1.2-73.9). There is also a statistically significant difference 
between the prevalence of male fertility problems among maternal and paternal uncles of 
subfertile men 9/253 (1.7%) versus 2/582 (0.3%): 0R=5.0 (95% Cl: 1.0-33.7). 
No statistically significant differences were found between the other family members of 
patients and controls. Our study design did not focus on the fertility status of cousins. 
However 10 patients reported that they had one or more cousin with a male subfertility 
problem. These 16 cousins were 15 sons of maternal aunts and only 1 son of a paternal 
aunt. In the control group, no cousins were reported to have a fertility problem. The group 
of subfertile men have fewer siblings than the controls 2.4 and 3.0 respectively, mean 
difference: 0.6 (95%CI: 0.1-0.9). They have fewer brothers, mean difference: 0.3 (95%CI: 
0.1-0.6). 
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Phenotypic characteristics of subfertile men 
The main clinical characteristics of the 253 subfertile men, such as testis volume, semen 
analysis and hormone measurements are shown in Table II. The group is divided into men 
with and men without a positive family history. Family history is considered positive when 
one or more brother(s) or maternal uncle(s) reported male subfertility. 
We found statistical significantly lower FSH- and LH-Ievels among men with a positive 
family history. The difference in FSH-Ievels was 2.5 IU/1 (95%CI: 0.3-4.7) and in LH-Ievel 
1.6 IU/1 (95%CI: 0.9-2.2). Subfertile men with a positive family history more often showed 
normal levels of FSH and LH. Moreover, subfertile men with a positive family history have 
a lower number of motile sperm, with a difference of 6.3% (95% Cl: 0.9-11.6). 
As shown in Table Ill, we were able to obtain the phenotype of 12 male relatives of 12 
patients. In the other 15 patients with a positive family history we were not able to obtain 
direct information. Non co-operation is mostly present among maternal uncles of patients. 
The reasons for the patients not to contact their family members were: the patients did not 
want to inform his family members about their own fertility problem or they did not want to 
confront their relatives with questions concerning fertility. 
For some of the genetic aberrations we found, a brother or uncle of the concerning patient 
had the same aberration (see families 1 and 2). Two patients and their maternal uncles 
had high FSH-Ievels. Apart from the cases of globozoospermia and CBAVD no specific 
phenotype could be recognised. 
Genetic aetiology of male subfertility 
A genetic origin of male subfertility can be considered in subfertile men when there is: (a) a 
genetic abnormality as defined in Table I (13.8%) or (b) a positive family history (12.1%). 
Hypothetically, a genetic origin can be considered in about 1 out of 4 subfertile men. 
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0 Table lla. Testis volume, semen analz:ses and hormone measurements of the cases with a positive familz: historz: 
Testis Volume (ml) Sperm Concentration Motility FSH LH 
Right Left (106/ml) (% propulsive) (lUll) (IU/1) 
Reference range >15 >15 ;? 20 ;?50 2.0-7.5 1.8-9.5 
Azoospermia 16.43 ± 6.27 16.14 ± 5.24 0 0 6.90 ± 4.08* 3.43 ± 1.05* 
(n = 7) (15.0) (15.0) (5.4) (3.5) 
Asthenozoospermia 20.00 ± 7.07 20.00 ± 7.07 32.50 ± 17.67 3.00 ± 2.83* 8.70 ± 2.26 4.85 ± 0.78 
(n = 2) (20.0) (20.0) (32.5) (3.0) (8.7) (4.9) 
OAT 18.71 ± 5.37 17.12 ± 4.85 3.82 ± 3.96 16.56 ± 9.26 7.16 ± 5.51 3.43 ± 0.96* 
(n = 17) (18.0) (15.0) (2.4) (15.0) (5.4) (3.3) 
All 16.19 ± 5.59 17.08 ± 4.96 5.00 ± 9.54 15.06 ± 9.76* 7.21 ± 4.88* 3.54 ± 1.01* 
(n = 26) (18.0) (15.0) (1.6) (15.0) (5.5) (3.5) 
Table lib. Testis volume, semen analyses and hormone measurements of the cases with a negative family history 
Reference range 
Azoospermia 
(n = 39) 
Asthenozoospermia 
(n =8) 
OAT 
(n = 180) 
Testis Volume (ml) Sperm Concentration Motility FSH LH 
(lUll) Right Left (106/ml) (%propulsive) (lUll) 
>15 >15 ;? 20 ;?50 2.0-7.5 1.8-9.5 
15.29 ± 6.39 14.55 ± 6.45 0 0 14.48 ± 13.17* 6.68 ± 6.14* 
(15.0) (15.0) (9.7) (4.8) 
18.75 ± 3.54 18.13 ± 3.72 51.88 ± 34.12 14.50± 7.96* 5.75 ± 3.73 3.70 ± 1.67 
(20.0) (17.5) (37.5) (15.0) (3.95) (3.25) 
16.22 ± 4.08 15.55 ± 4.29 2.74 ± 3.31 21.66±16.79 8.91 ± 5.52 4.86 ± 2.41* 
(15.0) (15.0) (1.5) (20.0) (7.1) (4.2) 
Testosterone 
(nmol/1) 
11-45 
16.23 ± 5.81 
(14.0) 
13.00 ± 0.00 
(13.0) 
17.33 ± 6.88 
(16.5) 
16.67 ± 6.29 
(16.0) 
Testosterone 
(nmol/1) 
11-45 
17.16 ± 8.10 
(17.0) 
14.94 ± 5.13 
(14.0) 
16.41 ± 6.79 
(15.0) 
All 16.15 ± 4.55 15.47 ± 4. 73 4.00 ± 11.40 21.35 ± 16.56* 9.68 ± 7.53* 5.09 ± 3.31 * 16.46 ± 6.93 
(n = 227) (15.0) (15.0) (1.0) (20.0) (7.1) (4.2) (15.0) 
Values are presented as Mean ± SD; values between parentheses are medians 
* Statistically significant differences between subfertile men with or without a positive family history 
Table Ill. Phenotz:~es of subfertile males in ~ositive case families 
ID Member Testes volume (RIL) Spermatozoa 
(*106) 
Motility(%) FSH (IU/1) Karyotype Clinical remarks 
Reference Range >15 ml >20 >50 2.0-7.5 
tp Proband 12/12 2.8 15% 2.8 46,XY Globozoospermia 
tb Brother 15/15 4.0 10% 8.5 46,XY Globozoospermia 
2p Proband 25/25 azoospermia 2.5 46,XY CBAVD 
2b Brother azoospermia NA 46,XY CBAVD 
3p Proband 15/15 1.3 20% 4.7 46,XY Inguinal hernia, epididymitis, maldescended testis 
3b Brother 12/10 0.1 11.0 46,XY Maldescended testis 
4p Proband 15/15 4 30% 7.9 46,XY 
4b Bother NA azoospermia Normal NA Secondary subfertility, obstruction, CUAVD 
5p Proband 25/25 7.5 5% 7.1 46,XY asthenozoospermia 
5b Brother 20/20 30 1% 8.9 46,XY 
6p Proband 15/15 4 30% 8.8 46,XY Hydrocele 
6b Brother 15/12 NA NA 20.8 46,XY Maldescended testis 
7p Proband 15/15 45 <1% 10.3 46,XY Varicocele 
7b Brother 15/15 OAT/ azoospemia 2.3 46,XY Persistent OAT after cystectomy of prostate cyste 
8p Proband 30/25 6 30% 4.4 46,XY,inv(7) Varicocele, inversion of chromosome 7 in more 
(q22.1q31.3) family members 
8b Brother Asthenospermia NA NA NA 
9p Proband 15/15 Azoospermia 3.8 46,XY CBAVD 
9b Brother Azoospermia NA 
tOp Proband 15/15 Azoospermia 13.0 46,XY hypogonadism hypergonadotrope 
tOmu Maternal Uncle 15/15 Azoospermia 27.9 46,XY Maldescended testis 
ttp Proband 12/12 10 15 4.5 46,XY Globozoospermia, Maldescended testis 
ttmu Maternal Uncle 15/20 45 20 4.2 46,XY Globozoospermia 
12p Proband 15/15 Azoospermia 24.7 46,XY Maldescended testis 
12mu Maternal Uncle 12/12 0.4 30% 14.9 
NA = not available 
CU/BAVD =congenital unilateral/bilateral absence of the vas deferens 
p = proband, b = brother, mu = maternal uncle 
(.TI 
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Discussion 
Male subfertility may have a familial occurrence. The higher prevalence of male subfertility 
among brothers and maternal uncles of subfertile men suggest this. The increase of male 
subfertility among brothers of subfertile men may be caused by autosomal recessive 
inheritance, as proposed in the study by Lilford et at., (1994). The prevalence of 
consanguineous marriages among parents of our subfertile men is 5.5%, which may also 
point to an autosomal recessive inheritance. Alternatively, sex limited autosomal dominant 
or X-linked inheritance may also be involved in male subfertility and may as well explain 
the increased frequency of male subfertility among maternal uncles. The finding that there 
is a higher prevalence of male factor subfertility among maternal uncles than among 
paternal uncles contributes to this hypothesis. This is not in line with the results of (Lilford 
et at., 1994; Meschede et at., 2000). It should be noted here that during the study the 
subfertile men reported a total of 15 nephews, all sons of maternal aunts, with male fertility 
problems. As there were no direct questions about subfertility among cousins we do not 
know any numbers for the control group. Therefore conclusions cannot be drawn at this 
moment. 
Our results can be influenced by diverse factors, which contradict the hypothesis on the 
familial occurrence of male subfertility. Subfertile men may be better informed on fertility 
problems in their families than men from the control group, causing recall bias. This may 
explain the differences found in the prevalence of fertility problems between brothers and 
maternal uncles of subfertile men and their controls. Therefore we also compared the 
prevalence of fertility problems among family members with the prevalence of fertility 
problems among responders of the control group, which is in the same range as earlier 
reports and indicates the population risk (Beurskens et at., 1985; van Golde unpublished 
data). No statistically significant differences could be found comparing the prevalence of 
fertility problems among brothers of subfertile men to the prevalence of fertility problems 
among responders of the control group, but there still is an OR of 2.1 (95%CI; 0.8-5.8). To 
search for possible new genetic causes of male subfertility we should exclude all known 
genetic causes in the analysis of the family history. No significant differences can be found 
between relatives of subfertile men and controls when excluding these known genetic 
causes. 
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On the other hand the familial occurrence of male subfertility may even be higher than 
found in this study considering the following factors. The calculated Odds ratios among 
brothers and maternal uncles may even be higher, if fertility problems among brothers and 
maternal uncles of subfertile men using a family history were also underestimated. Non-
paternity is another factor that may lead to underestimation of the calculated odds ratios. If 
male subfertility has a familial occurrence then the opportunities for conception through 
another man are greatest among partners of subfertile men in these families. Finally, men 
may have poor sperm results on sperm analysis but some of them may still father children. 
This study also investigated the phenotypic characteristics of subfertile men. The clinical 
and genetic data revealed the normal frequencies as mentioned in the literature. A new 
finding is that subfertile men with a positive family history more often have normal serum 
concentrations of FSH and LH. This phenomenon is also observed in men with Y 
microdeletions in the AZF c region (Kremer eta/., 1997). 
From the current study we can conclude that male subfertility has a familial occurrence, 
although different kinds of bias may have influenced the results. Further basic and clinical 
research will contribute to our knowledge of genetic aetiology and the clinical approach in 
cases of male subfertility. 
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Abstract 
Objective: Severe oligo- astheno- teratozoospermia (OAT) is a rare disorder occurring in 
approximately 0.3% of all males. The familial occurrence of severe OAT in a male and five 
male relatives related through their mothers is reported. In addition we performed an X 
chromosome linkage study. 
Design: Case report 
Setting: University medical centre. 
Patient(s): six affected family members. 
lntervention(s): Blood and semen samples were collected from all affected males and 
some of their healthy male relatives 
Main outcome measure(s): Pedigree analysis and exclusion of X-linked disorder. 
Results: Familial non-syndromic male factor infertility 
Conclusion(s): The presented family suggests that an autosomal dominant trait of male 
infertility with sex limited expression exists. 
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Introduction 
Severe oligo- astheno- teratozoospermia (OAT; < 1 x 106 spermatozoa /ml with 
progressive motility per ejaculate) or azoospermia is a rare disorder in otherwise healthy 
men. The estimated prevalence is approximately 0.3% in the male population (Kremer et 
a/., 1997). In most cases with severely impaired semen parameters the aetiology remains 
obscure and it has been suggested that genetic factors may play an important role (De 
Kretser, 1997). The current lack of knowledge regarding genetic factors involved in 
spermatogenesis is a source of concern, since the transmission of these unknown factors 
to the offspring by ICSI is real. Large-scale family studies in defined populations that might 
reveal these genetic factors are scarce (Budde eta/., 1984; Lilford eta/., 1994). These 
studies in addition with the case reports of infertile brothers all suggest that a substantive 
part of undiagnosed male infertility cases might arise from autosomal recessive mutations 
(Budde et a/., 1984; Lilford et a/., 1994; Meschede et a/., 2000). Today, little is known 
about autosomal dominant or X-linked factors involved in non-syndromic male infertility. 
We describe here a family in which idiopathic severe OAT or azoospermia is present in 
several third degree relatives, the mothers of these males being sisters (see figure 1 ). We 
are not aware of publications concerning similar large families with idiopathic non-
syndromic male infertility. 
Materials and Methods 
The proband of the family was identified at the fertility clinic of the University Medical 
Centre Nijmegen because of primary infertility. The family history was obtained by 
interview and family members were invited for evaluation of their fertility status, including 
andrological examination, karyotyping and screening for microdeletions of the Y 
chromosome (Hoefsloot et a/., 1997). In addition blood samples were taken, after 
obtaining informed consent, for molecular research purposes. 
DNA from peripheral lymphocytes was isolated according to the procedure of Miller eta/., 
(1988). The family was screened for linkage with the X-chromosomal markers of the ABI 
PRISM Linkage Mapping Set, version 2 (PE Biosystems). These markers were selected 
from the Genethon human linkage map (Dib eta/., 1996) and are spaced every 10 eM, on 
average. 
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This study was performed with the approval of the institutional human investigation 
review board. 
Results 
Case 1 
The proband (111-5, see figure 1), now aged 33, is the third child of non consanguineous 
healthy Dutch parents. He has two healthy brothers. At 5 years of age he had a torsion of 
a testicle for which he was surgical treated. The proband has epilepsy for which he uses 
anti-epileptic medicine. He and his wife presented at our clinic with a history of primary 
infertility of 2 years. His infertility was evaluated at the age of 30. Semen analysis 
revealed severe OAT (3.0 x 106 spermatozoa/mil while andrological examination showed 
no additional abnormalities The hormonal profile is within normal range. He has a normal 
karyotype, while Y chromosomal microdeletion screening did not reveal abnormalities. The 
family history was positive for male infertility. 
Case2 
111-6 is a third degree relative of the probandus (111-7) and he is 45 years old. His parents 
are non-consanguineous and he has one sister, three healthy brothers and a fourth 
brother who also experienced infertility. 111-6 and his 45 year old wife remained childless 
involentary. They first attended our clinic in 1980. Semen parameters were impaired 
during all medical examinations until today (0.6 x 106 spermatozoa/ml). The andrologic 
history shows a surgical correction of a varicocele. Andrological examination including, 
hormonal profile, karyotyping and screening for microdeletions of the Y chromosome did 
not reveal additional abnormalities. 
Case3 
This 43-year-old man (111-9) is the brother of case 2. He and his 43-year-old partner had 
also experienced primary infertility for years. Andrologic history reveals no abnormalities 
except for the severely impaired semen parameters. They remained involuntary childless, 
which they experienced as a grave burden. 
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Figure 1. Pedigree of the probandus (111-5), the filled quadrants represent males with 
male factor infertility 
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A recent semen analysis confirmed the earlier results (0.1 x 106 spermatozoa/ml) and the 
karyotype was 46,XY. Screening for Y chromosome microdeltions revealed an AZFc 
deletion. 
Case4 
Case 4 is a 43-year-old third degree relative (111-20) of case 1. His parents are non-
consanguineous. He has three healthy brothers and a sister. He and his 42-year-old 
partner experienced primary infertility for some years. Their medical doctor informed them 
that it would not be possible for them to get any children. 
The andrologic history reveals a surgical correction of an inguinal hernia at 5 years of age. 
Andrological investigation showed a non-obstructive azoospermia: both testicles have a 
small volume, the ejaculate has a normal volume and the serum FSH level is high. The 
karyotype was 46,XY and screening for microdeletions of the Y chromosome did not 
reveal abnormalities. 
CaseS 
He also is a third degree relative of case 1 (111-31 ), aged 44 years. His parents are non-
consanguineous. He has four sisters, two unaffected brothers and one brother with 
infertility. He had surgical correction of a varicocele but the semen parameters remained 
impaired (1 0 x 106 spermatozoa/ml). Andrologic history and examination of this primary 
infertile male shows no additional abnormalities. The karyotype is 46,XY and no 
microdeletions of theY chromosome could be detected. 
Case 6 
The brother of case 5, is a 43-year-old man (111-33) with severely impaired sperm 
parameters. The andrologic history shows torsion of the right testicle, impaired semen 
parameters (0.1 x 106 spermatozoa/ml) and an increased FSH serum concentration. The 
karyotype is 46,XY and there are no microdeletions of theY chromosome. 
Relative 111-24 and his wife experienced primary infertility for 8 years because of a 
presumed female factor. After IVF treatment they conceived a female twin, now aged 5 
years. The semen parameters at the time of the IVF procedures were reported to be within 
the normal range. All other male relatives in this family did not reported fertility disorders. 
Some of the male relatives who did not report a fertility disorder agreed to have an 
62 
andrological evaluation (individuals 111-1, 111-11, 111-13, 111-15, 111-24 and 111-35, see figure 1 ). 
The examination of these healthy fertile males did not reveal abnormalities except for a 
variococele in 111-35. 
A routine fertility screening of the partners of the affected males did not reveal 
abnormalities. Also, none of the female family members has reported fertility disorders. In 
addition, no development disorders or malformations have been reported in this family. 
DNA analysis 
Screening with markers of the X chromosome revealed that none of the markers, selected 
from the Genethon human linkage map (Dib et a!., 1996) and spaced every 10 eM on 
average, segregated with the disease in the family. 
Discussion 
The presented family shows a clustering of male relatives with severe OAT or 
azoospermia. The heterogeneity of the andrological related diagnosis in this family might 
indicate that the fertility problems in this family are not due to single disorder. However, 
excluding the one male with an AZFc microdeletion, it is unlikely that this clustering of 
males with severe OAT or azoospermia can be explained by chance alone (probability 2x 
1 o-6). The performed molecular analysis with X linked markers shows that the impaired 
spermatogenesis in this pedigree is not due to an X-linked disorder. Therefore, this 
pedigree suggests for the existence of an autosomal dominant trait for a disorder with 
severely impaired spermatogenesis. Although, a multifactorial aetiology cannot be 
excluded completely. 
The reports on familial non-syndromic male factor infertility suggest that inheritable male 
factor infertility concern autosomal recessive disorders (Budde et a/., 1984; Lilford et at., 
1994; Meschede et a/., 2000). However, it seems likely that autosomal dominant or X 
linked non-syndromic male factor infertility also exists. EEC syndrome, myotonic 
dystrophy, Kallmann syndrome and Aarskog syndrome are examples of syndromes 
associated with male factor infertility and these are disorders with an autosomal dominant 
or X-linked inheritance. Chaganti and German reported in 1979 on a non-syndromic 
infertile male with an infertile maternal uncle and an infertile son of a maternal sister. They 
postulated that a gene for meiotic disturbance is segregating in their family. We observed 
in our cohort of ICSI males some small families with brothers and/or maternal uncles 
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and/or sons of maternal sisters with non-syndromic male factor infertility (data not 
published). In addition, we noted the large family with non-syndromic male factor infertility, 
which is presented here. 
In conclusion, the presented family may show an autosomal dominant factor of male 
infertility, with sex limited expression. Further molecular research, especially a genome 
wide screen for linkage, in this family and others may elucidate the gene(s) involved. In our 
view the family history of infertile males should not be limited to first degree relatives but 
should also include questions concerning the fertility status of all second and third degree 
relatives. 
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Abstract 
Purpose: To study the role of the autosomal candidate gene DAZLA (Deleted in 
AZoospermia Like Autosome) in male subfertility. 
Methods: We reviewed clinical data of subfertile men with oligozoospermia or 
azoospermia, mostly candidates for intracytoplasmic sperm injection (ICSI). Mutation 
detection was performed using polymerase chain reaction followed by single strand 
conformation polymorphism analysis. All shifted bands were analysed by sequencing. 
Results: We searched for mutations in 44 subfertile men. Nine subfertile men were 
included, because family history showed that their brothers also faced fertility problems. In 
these men a possible autosomal gene defect may contribute to their fertility problem. 
No mutations were found, except for two polymorph isms in intron 4 and 5. 
Conclusion: At this moment it does not seem relevant to search for possible mutations in 
the DAZLA gene in clinical practice. 
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Introduction 
Genetic factors may play an important role in the aetiology of severe oligozoospermia or 
azoospermia causing male subfertility. Chromosomal aberrations, microdeletions of theY-
chromosome and cystic fibrosis trans-membrane receptor gene (CFTR) mutations have 
been described in men with severe subfertility (Tuerlings et at., 1997). Of particular interest 
is a study from Lilford et a/., (1994) showing a possible autosomal recessive mode of 
inheritance in male subfertility. 
The DAZLA (Deleted in AZoospermia Like Autosomal) gene on human chromosome 3 
shares a high degree of homology with the DAZ (Deleted in AZoospermia) gene, which is 
sometimes deleted in men with azoospermia or severe oligozoospermia. It is suggested 
that the DAZ genes arose from the transposition of DAZLA to theY-chromosome followed 
by repeated amplification and pruning (Saxena et at., 1996). Its testis specific expression 
and its homology to DAZ support the role of DAZLA in spermatogenesis. Disruption of the 
DAZLA gene in mice leads to loss of germ cells in both ovary and testis and absence of 
gamete production, demonstrating that DAZLA is essential for the differentiation of germ 
cells in mice (Ruggiu et at., 1997). 
It might be argued that mutations in the human DAZLA gene are responsible for some of 
the (familial) cases of male subfertility. Since the genomic structure of DAZLA is known 
mutation detection is possible, but to our knowledge no such studies have been reported 
till now. In this study, we searched for mutations in the DAZLA gene in severe subfertile 
men, using Single Strand Confirmation Polymorphism (SSCP) and sequencing 
techniques. 
Materials and Methods 
Patient selection 
The study population was selected from a group of 300 intra cytoplasmic sperm injection 
(ICSI) men attending our fertility clinic since 1996, with abnormal sperm parameters 
varying from severe oligoasthenoteratozoospermia (OAT) to azoospermia. 
Semen analysis was performed according to World Health Organization (WHO, 1992) 
guidelines. When more than one semen analysis was available, only the data of the first 
sample were used. In our centre, oligoasthenozoospermic men are candidates for ICSI if 
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their ejaculate contains less than 1.0x1 06 propulsive spermatozoa. Andrologic history and 
examination, family history and hormone measurements were performed. In addition, all 
men were offered chromosome analysis and screening for microdeletions of the AZFa, b 
and c region of the Y chromosome (Kremer eta/., 1997). In cases of Congenital Bilateral 
Absence of the Vas Deferens (CBAVD) the cystic fibrosis trans-membrane receptor gene 
was screened for mutations. 
Men with a documented cause for their subfertility such as previous sterilization, testicular 
malignancy, CBAVD, chromosomal abnormality or Y chromosome microdeletion were 
excluded from further analysis. 
In this study we selected all men whose family history showed that a brother was also 
facing fertility problems. The remaining men included in this study were randomly selected. 
The local institutional review board approved this study. 
Mutation analysis 
Genomic DNA was isolated from peripheral blood as described previously (Miller et a!., 
1988). The DAZLA gene has 11 exons. For exons 2-11 PCR fragments were generated. 
Primers were designed using the published sequence of the DAZLA gene, GB: U77467-
U77476 (Table 1). Exon 1, containing only the first 3 coding basepairs was not analysed. 
The size of the PCR fragments varied between 241 and 399 bp. Amplified fragments were 
analysed for single strand confirmation polymorphism (SSCP), using GeneGel Excel 
12.5/24 Kit (Pharmacia Biotech AB, Roosendaal). Fragments were stained with the DNA 
Silver Staining Kit (Pharmacia Biotech AB, Roosendaal). 
PCR fragments generating a shifted band were analysed by direct sequencing using the 
Big dye Terminator cycle sequencing (PE Biosystems, Foster City). The sequence 
reactions were run and analysed using an automated sequencer, 3700 (PE Biosystems, 
Foster City). 
Results 
We selected 44 men; 9 out of these 44 men were included because the family history 
showed that their brothers also faced fertility problems, the other 35 men were randomly 
selected. 
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The main clinical characteristics, testis volume, semen analysis, and hormone 
measurements of these males are shown in Table II. Thirty-seven men had 
oligoasthenoteratozoospermia, three men had asthenozoospermia and four men had 
azoospermia. The most frequently encountered abnormality was cryptorchidism (n = 6), 
followed by history of male adnexitis (n = 4), inguinal hernia (n = 3), and varicocele (n = 2). 
Clinical characteristics of the men with a brother facing fertility problems did not differ from 
the other men. 
A total of 25 aberrant shifts were identified by SSCP in the 44 men screened for mutations 
in the DAZLA gene. Sequence analysis revealed no alteration in the coding area and the 
splice sites when compared to the genomic structure (Chai eta/., 1997). 
Shifts in exon 4 and 5 were shown to be neutral polymorphisms. At 30 bp upstream of 
exon 4, a variant was found (A/C) and at 28 bp upstream exon 5 another variant was 
found (T/C; Figure 1 ). In a control group of 20 males the same distribution of these 
variants was detected (not shown). 
Table I. PCR primers for the DAZLA gene 
Exon 2 F: TGTAAAACGACGGCCAGTCTGAGCCTGAACTAACTTAGAATG 377 bp 
R: CAGGAAACAGCTATGACCGTTTGTAACAGGGCCCAAATC 
Exon3 F: TGTAAAACGACGGCCAGTTAAAATTAAAATTTTTGAATGCTG 332 bp 
R: CAGGAAACAGCTATGACCAGAGCTGGCAATAAACTTTTATCC 
Exon4 F: TGTAAAACGACGGCCAGTATTTTAGTCATGATCACTTCCG 371 bp 
R: CAGGAAACAGCTATGACCTGTAGTTCATGAACCTAGGTGC 
Exon 5 F: TGTAAAACGACGGCCAGTTCCAAGTCTTGGAAGTAAAGAC 268 bp 
R: CAGGAAACAGCTATGACCGATAAGCACCTTTTTGAAAAGC 
Exon 6 F: TGTAAAACGACGGCCAGTCAATCAGGAAACAAAATTTATG 353 bp 
R: CAGGAAACAGCTATGACCCCACAGAAGGTACGATGACTAC 
Exon 7 F: TGTAAAACGACGGCCAGTTTTTCATATTTTTGTTATATTGGG 285 bp 
R: CAGGAAACAGCTATGACCATGACAAACCATTCAGACAATTTG 
Exon 8 F: TGTAAAACGACGGCCAGTTATTATAACAACAAAGGAGCCAGC 301 bp 
R: CAGGAAACAGCTATGACCTAGGCATATATGACATGGAAAACG 
Exon 9 F: TGTAAAACGACGGCCAGTTTAGCTTTTTGAAGAATAAGTGGC 399 bp 
R: CAGGAAACAGCTATGACCTTTCTTTTACTATTTGGTCAAGCC 
Exon 10 F: TGTAAAACGACGGCCAGTGAAAGAGTGGTCTTTACATTAGTG 363 bp 
R: CAGGAAACAGCTATGACCAACTACATTATGTCAAGGTTCAGC 
Exon 11 F: TGTAAAACGACGGCCAGTAGAAATTTTCAGTAAAGTAAAAGG 246 bp 
R: CAGGAAACAGCTATGACCAGCTTAATATTCAAAACCAGCAAC 
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Figure 1. SSCP and sequence analysis showing the polymorphism found in intron 5 twenty-
eight base pairs upstream of exon 5 (IVS5-28T/C). Lane 1-3: patient DNA. 
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Table II. Testis volume, semen analysis and hormone measurements of the 44 males screened for mutations in DAZLA 
Patients Testis Volume Sperm concn Motility FSH a LH 0 Testosterone 
(n = 44) (ml) (x106 ml) (%propulsive) 
Local reference range >15 >20 >50 2.0-7.5 1.8- 9.5 11-45 
OATC 15.3±0.7 3.9 ± 3.5 27.6 ± 17.9 7.3 ± 0.7 3.8 ± 0.3 15.8 ± 1.0 
(n = 37) 
Asthenozoospermia 18.3 ± 2.9 51.7 ± 22.5 0 5.0 ± 2.7 2.6 ± 0.7 17.0 ±4.6 
(n = 3) 
Azoospermia 12.3 ± 1.0 0 0 14.3 ± 5.4 5.7 ± 0.8 18.0 ± 0.9 
(n =4) 
Note. Values are presented as Mean ± SD 
aFSH, follicle stimulating hormone; bLH, luteinizing hormone; cOAT, oligoasthenoteratozoospermia 
Discussion 
In 40-60% of cases, the aetiology of male subfertility remains unknown and has to be 
classified as idiopathic (de Kretser, 1997). It has been suggested that in cases of 
idiopathic male subfertility there may be a genetic origin (Tuerlings eta/., 1997). 
Some of these genetic factors are microdeletions of the Y chromosome and the CFTR 
gene. 
The frequency of Y chromosomal DAZ inclusive deletions occur in a frequency of 13% in 
azoospermic and 7% in severely oligospermic men, and 1 to 29% in subfertile men 
(Kremer eta/., 1997; Reijo, eta/., 1995; Silber eta/., 1998). This frequency is dependent 
on the definition of male subfertility and on the choice of Sequence Tagged Sites used for 
screening (Simoni eta/., 1999). There are more candidate genes on theY chromosome, 
which could play a role in male factor subfertility (Schnieders eta/., 1996; Lahn and Page, 
1997; Kent First eta/., 1999). 
Recently, an azoospermic man with a de novo point mutation in the Y chromosomal gene 
USP9Y has been described (Sun eta/., 1999). This study shows the importance of the 
deletion of this gene as seen subfertile men with an AZFa deletion. However, given the 
low frequency reported in this study (1/576 men) routine screening of this gene in ICSI 
candidates probably has no clinical relevance. 
Another common monogenic disorder present in subfertile men with CBAVD is Cystic 
Fibrosis (CF), caused by mutations in the CFTR gene. The frequency of CBAVD in 
subfertile men is low and the frequencies of the CFTR mutations among subfertile men do 
not differ from normal frequency (Tuerlings eta/., 1998a). 
Furthermore, an inactivating point mutation of the FSH receptor gene has been reported in 
some men with elevated serum FSH concentrations and abnormal sperm parameters 
(Tapanainen eta/., 1997). In a study of 28 men with a high level of FSH, no mutations 
were found in the FSH receptor gene (Tuerlings eta/., 1998b). 
Information on the genetic basis of male subfertility is important. The cause of male 
subfertility is often unknown and in this group of idiopathic male subfertility, genetic factors 
could be involved. DAZLA may be one of the genes important in the pathogenesis of male 
subfertility. 
To come to an aetiological diagnosis rather than a purely descriptive diagnosis is not only 
more satisfactory to the doctor, it will also be beneficial to patients. Coping with subfertility 
can be facilitated by a specific diagnosis and at risk relatives may be recognised earlier 
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(Meschede eta/., 1995; ln't Veld eta/., 1997). Only by the identification of the aetiology of 
male subfertility progress can be made towards a better therapy and prevention. In this 
way genetic risk for the offspring could be correctly evaluated and dealt with, especially 
nowadays since intracytoplasmic sperm injection circumvents a part of the natural 
selection mechanism. 
In this study we searched for mutations in the DAZLA gene in male subfertility. Disruption 
of the DAZLA gene in mice leads to loss of germ cells and absence of gamete production 
(Ruggiu eta/., 1997) resulting in azoospermia. Mutations in the human DAZLA gene may 
lead to oligoasthenoteratozoospermia in men comparable to the effect of the deletions of 
the Y chromosomal DAZ gene, and may be responsible for some of the familial cases of 
male subfertility (Lilford et at., 1994). No mutations were found, but two neutral 
polymorphisms were identified in the introns 4 and 5. It is not likely that DAZLA mutations 
have been missed in a majority of cases, although SSCP detects only between 80%-90% 
of all possible mutations and we did not analyse exon 1, containing only the first codon. 
Besides that with a study group consisting of 44 subfertile men statistical analyses shows 
that there is 95% certainty that the possible mutation frequency in the DAZLA gene is 
lower than 7%. Screening a larger group of patients, like has been performed for the 
USP9Y gene (Sun et at., 1999), might still result in finding a pathogenic mutation. 
Our data suggest that the DAZLA gene is not a major contributor to male subfertility. At 
this moment routine screening in ICSI men for possible mutations in the DAZLA gene 
does not seem relevant in clinical practice. 
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Abstract 
Purpose: Increased length of the GAG repeat in the androgen receptor gene may be 
related to male subfertility. Expansion to 38-62 GAG repeats leads to the 
neurodegenerative disorder with male infertility called Kennedy's disease. Recently it was 
suggested that slight expansion is related to male subfertility. In this study we investigated 
the association of male subfertility with the length of GAG repeats in the androgen 
receptor. 
Materials: GAG repeat length in the androgen receptor gene was investigated in 75 
subfertile men, who were mainly candidates for intracytoplasmic sperm injection. Sperm 
parameters varied from azoospermia to severe oligoasthenoteratozoospermia. The control 
group consisted of 70 men, who predominantly had bladder cancer. DNA was isolated 
from peripheral blood and genotyping was performed with polymerase chain reaction 
based methods. 
Results: No statistically significant difference in the mean length of the GAG repeat plus or 
minus standard deviation was noted in subfertile men and controls (21.7 ± 3.4 and 22.2 ± 
3.1 ). The length of the GAG repeat in the androgen receptor was not related to the degree 
of impaired spermatogenesis or clinical characteristics of the subfertile men. 
Conclusion: Increased length of GAG repeats in the androgen receptor gene is not a risk 
factor for male subfertility. 
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Introduction 
In the Netherlands 1/7 couples do not achieve pregnancy within 1 year of active sexual 
intercourse and at the end of their reproductive life span 2% to 7% remain childless 
(Beurskens eta/., 1995). Subfertility may have various causes in either partner. According 
to the World Health Organisation (WHO, 1992), in 20% of all cases the problem is 
predominantly male and in 38% it is predominantly female. To our knowledge the causes 
of defective spermatogenesis often remain unknown to date. Recently much attention has 
been given to genetic causes of male subfertility, such as chromosomal aberrations 
(Tuerlings eta!., 1998), microdeletions of the Y-chromosome (Kremer eta!., 1997) and 
other possible monogenetic causes. This attention is stimulated by the concern of potential 
transmission of genetic defects to offspring via intracytoplasmic sperm injection. 
Androgen has a critical role in regulating spermatogenesis. It acts through the androgen 
receptor, which is encoded by the androgen receptor gene. The androgen receptor is a 
member of the steroid receptor superfamily. After androgen is bound to the cytosolic 
androgen receptor, the receptor is activated. This activated androgen-androgen receptor 
complex translocates to the nucleus and binds to androgen-responsive elements, leading 
to regulation of transcription processes of downstream androgen dependent genes 
(Evans, 1988; Beato, 1989). It has been well documented that androgens acting via the 
androgen receptor in the Sertoli's cells cause the stimulation and maintenance of 
spermatogenesis. Moreover, suppression of endogenous androgen production has been 
used as a type of male contraception (Remy eta/., 1996). In contrast, administration of a 
sufficient dose of testosterone has been shown to maintain complete spermatogenesis in 
hypophysectomized animals (Buhl eta!., 1982). 
The androgen receptor gene (AR) is a candidate gene in male subfertility. Most patients 
with idiopathic male subfertility have normal serum levels of androgen, implying that 
defects in the AR may be involved in the aetiology of this condition. In 1979, Aiman eta/. 
postulated that defects in the AR gene may lead to partial or complete spermatogenic 
failure. 
This AR gene, which is located on the long arm of the X chromosome at Xq11-12, 
contains a polymorphic CAG repeat sequence in exon 1 that encodes a series of 
glutamine residues in the region of the androgen receptor protein associated with DNA 
transcription (Brown et a!., 1989). In vitro, the length of the CAG repeats inversely 
correlates with AR transcriptional activity (Kazemi et a/., 1995). A relatively short CAG 
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repeat is associated with an increased risk of prostate cancer, which is an androgen 
dependent tumor (Giovannucci et a/., 1997), whereas a length of 38-62 CAG repeats 
leads to Kennedy's disease, a condition associated with bulbar muscular atrophy, low 
virilization and depressed spermatogenesis (Nagashima et a/., 1988; La Spada et a/., 
1991 ). Tut et a/., (1997) reported that patients with 26 or more CAG repeats in the AR 
gene were at more than a 4-fold increased risk for impaired spermatogenesis. These 
findings indicate that some cases of male subfertility may be related to a high but normal 
range of 26-38 CAG repeats in the AR gene. 
Several groups reported conflicting results on the role of the CAG repeat length in the AR 
gene in cases of male subfertility (Tut eta/., 1997; Yoshida eta/., 1999; Down sing eta/., 
1999; Giwercman et a/., 1998; Dadze et a/., 2000). We investigated the hypothetical 
association of expansion of the CAG repeat of the AR gene with clinical characteristics 
among a group of Dutch subfertile men. 
Materials and Methods 
The study population consisted of 75 men who were mainly candidates for 
intracytoplasmic sperm injection, and who were randomly selected from a group of 253 
who attended our fertility clinic since 1998. Sperm parameters varied from azoospermia to 
severe oligoasthenoteratozoospermia. 
In our clinic subfertile men are candidates for intracytoplasmic sperm injection when their 
ejaculate contains less than 1.0x1 06 spermatozoa with propulsive motility (WHO, 1992). 
Andrologic history and examination were done and hormones were measured. In addition, 
all men were offered chromosome analysis and screening for microdeletions of the AZFa, 
b and c region of the Y chromosome (Hoefsloot et a/., 1997). In cases of Congenital 
Bilateral Absence of the Vas Deferens (CBAVD) the cystic fibrosis trans-membrane 
receptor gene was screened for mutations. 
In this study we excluded men with previous sterilisation, testicular malignancy, CBAVD, 
chromosomal abnormality or Y chromosome microdeletion. The patients signed an 
informed consent form for the use of DNA in anonymous studies of genetics and male 
subfertility. The local institutional review board approved this study. 
The control group consisted of 70 men who presented at the outpatient clinic of the 
department of urology between March and May 1997. They were asked to participate in a 
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study of the role of gene-environment interactions in urological disease. The group 
included men with diseases not known to be related to subfertility or to polymorphism in 
the androgen receptor gene, including bladder cancer in 61, erectile dysfunction in 3, 
kidney stones in 3 and vasectomy in 3. Patients with bladder cancer were over 
represented in this control group because they participated in another simultaneous study 
on gene-environment interactions. Consequently, their data were already available. 
After informed consent was obtained study participants were asked to complete a 
questionnaire and provide a blood sample. The questionnaire included questions on 
demographic items, smoking, diet and drinking habits, profession and previous diseases. 
For CAG repeat analysis genomic DNA was isolated from peripheral blood, as described 
previously (Miller eta/., 1988). 
The number of GAG-repeats in the AR gene polymorphism, was determined by 
polymerase chain reaction using the primers sense (5'-AGA GGC CGC GAG CGC AGC 
ACC TC-3') and antisense (5'-GCT GTG AAG GTT GCT GTT CCT CAT-3'). a-[32P]dATP 
was incorporated as a radioactive label. We performed denaturation at 95QC for 40 
seconds, annealing at 66QC for 40 seconds and elongation at 72QC for another 40 
seconds. After 35 cycles elongation was performed for another 10 minutes at 72QC. 
Samples were run on a 5% denaturating polyacrylamide gel for 3 hours at 100W. Gels 
were transferred to Whatmann 3-mm filter paper, dried, and exposed to X-ray film. Control 
samples were sequenced and used as standards to determine the size of the sample 
alleles under investigation. 
Statistical analysis was performed using commercially available software. The mean plus 
or minus standard deviations was calculated and compared by the t-tests. Spearman's 
correlation coefficients were calculated to analyse correlations of the length of the CAG 
repeat with clinical parameters. 
Power analysis was based on data from a previous study of the AR gene polymorphism 
(Bousema eta/., 2000). In that study controls appeared to have a mean repeat length plus 
or minus standard deviation of 21.9 ± 2.9. Similar values are reported in the literature. On 
power analysis we assumed a standard deviation of 3. With 70 cases and 70 controls we 
detected a difference in repeat length of 1.4 with a power of 80%. 
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Results 
The Table I lists main clinical characteristics of the 75 subfertile men, including testis 
volume, semen analysis and hormone measurements. A total of 61 men had 
oligoasthenoteratozoospermia, 4 mainly had an asthenozoospermia and 10 had 
azoospermia. The most common clinical abnormality was cryptorchidism in 22 cases, 
followed by a history of male adnexitis in 6, surgical correction of inguinal hernia in 9 and 
varicocele in 14. None of the study participants showed a sign of neuromuscular disease. 
Participants were predominantly white. Neither patients nor controls included men of 
Chinese or Indian ancestry, who are known to have a longer GAG repeat length (Sartor et 
a!., 1999). 
No statistically significant difference in the mean length of the GAG repeat was detected in 
subfertile men and controls (21.7 ± SD 3.4 and 22.2 ± 3.1, respectively). Figure 1 shows 
the distribution of GAG repeats in both groups. We did not identify a subgroup of subfertile 
men with an increased number of GAG repeats. Also, the number GAG repeats did not 
correlate with the number, the motility or the morphology of sperm, or with follicle-
stimulating hormone, the luteinizing hormone or testosterone. 
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Figure 1. Distribution of CAG repeat sizes in exon 1 of androgen receptor gene in subfertile men 
(white bars) and controls (black bars). 
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Table I. Testis volume, semen analysis and hormone measurements of 75 subfertile men studied for CAG repeat length of the 
androgene receptor gene 
Patients 
(n = 44) 
Local reference range 
OATC 
(n = 61) 
Asthenozoospermia 
(n =4) 
Azoospermia 
(n = 10) 
Testis Volume 
(ml) 
>15 
16.4 ± 4.3 
17.5 ± 5.0 
12.7±4.2 
Sperm concn 
(x106 ml) 
>20 
2.6 ± 3.0 
28.8 ± 11.8 
0 
Motility FSH a 
(% propulsive) 
>50 2.0- 7.5 
23.1±14.7 8.7 ± 5.3 
6.5 ± 6.0 9.1 ± 3.1 
0 19.4 ± 11.4 
Values are presented as Mean ± SD 
"FSH, follicle stimulating hormone; 0LH, luteinizing hormone; cOAT, oligoasthenoteratozoospermia 
LH 0 Testosterone 
1.8- 9.5 11-45 
4.7 ± 2.3 18.4 ± 8.3 
4.8 ± 0.6 17.5±5.0 
7.3 ± 3.9 17.1 ±5.2 
Discussion 
Our findings imply that male subfertility is not related to a high but normal range of 26-38 
GAG repeats in the AR gene. This result is in line with Swedish (Giwercman et at., 1998) 
and German (Dadze eta/., 2000) investigations. However, Tut eta/., (1997) reported in 
vivo and in vitro data that longer GAG repeats correspond with a less androgenic 
androgen receptor. This finding was corroborated by the work of Yang eta/., (1998) and 
Downsing et at., (1999). Up to 20% of Chinese men presenting with defective 
spermatogenesis and subfertility had an increased number of GAG repeats (Yang eta/., 
1998). Confusingly Komori et at., (1999) reported that a decrease in GAG repeats of 16 or 
less is strongly related to impaired spermatogenesis in infertile Japanese men. In 
accordance with studies of a predominantly white population our data do not provide any 
proof of a relationship of the length of the GAG repeat and the degree of impaired 
spermatogenesis or clinical characteristics of subfertile men. However, a strong conclusion 
cannot be drawn from our subgroup analysis due to small numbers. 
There are several possible explanations for the apparently conflicting data. The ethnic 
differences in the study populations yielded different findings in the European and Asian 
studies. It is well documented in the literature that the size of the GAG repeats in the AR 
gene varies in a race specific manner (Sartor et at., 1999). The prevalence of short GAG 
repeats (22 repeats or less) is high in black Americans (75%) and relatively low in Asians 
(49%). Another possible explanation is the choice of control group. Our control group 
mainly comprised patients with bladder cancer. Bladder cancer is normally not considered 
as an androgen dependent tumour but there have been observations that the inhibition of 
androgen production in male rats is related to a somewhat lower risk of N-butyi-N-(4-
hydroxybutyl)nitrosamine induced bladder cancer (lmada eta/., 1997). If it is also true in 
men, we may have underestimated the hypothesised association. On the other hand, our 
finding that the relationship of the polymorphism and male subfertility is similar in men with 
higher and lower sperm counts argues against a strong association. Moreover, the 
number of GAG repeats is in the same range as in other studies of white populations. 
Recently it was reported that the number of GAG repeats is especially increased in men 
with azoospermia (Yoshida et at., 1999; Mifsud et at., 2001; Casella et at., 2001 ). It was 
not confirmed in the 10 men with azoospermia in our study since mean GAG repeat length 
was 21.9 ± 2.8. However, 1 man in this study has a relatively high number of GAG repeats 
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(36). The only clinical feature of this man with subfertility was severe asthenozoospermia 
but to our knowledge this association has not previously been described in the literature. 
Currently we are not concerned about the possible increased risk of neurodegenerative 
diseases in children born after ICSI. Recently it was also shown that children born after 
ICSI have no increased length of CAG repeats in the AR (Cram eta/., 2000). 
Conclusions 
Male subfertility represents a heterogeneous aetiological entity. There is a need for more 
basic research into the causes and diagnostic approach of male subfertility. 
87 
References 
Aiman, J., Griffin, J.E., Gazak, J.M. eta/. (1979) Androgen insensitivity as a cause of infertility in 
otherwise normal men. N. Engl. J. Med., 300, 223-227. 
Beato, M. (1989) Gene regulation by steroid hormones. Cell, 56, 335-344. 
Beurskens,M.P., Maas,J.W., and Evers,J.L. (1995) [Subfertility in South Limburg: calculation of 
incidence and appeal for specialist care]. Ned. Tijdschr.Geneeskd., 139, 235-238. 
Bousema, J.T., Bussemakers, M.J., van Houwelingen, K.P. eta/. (2000) Polymorphisms in the 
vitamin D receptor gene and the androgen receptor gene and the risk of benign prostatic 
hyperplasia. Eur. Ural., 37, 234-8. 
Brown, C.J., Goss, S.J., Lubahn, D.B. eta/. (1989) Androgen receptor locus on the human X-
chromosome: regional localisation to Xq11-12 and description of a DNA polymorphism. Am J 
Hum. Genet., 44, 264-269. 
Buhl, A.E., Cornette, J.C., Kirton, D.T. et a/. (1982) Hypophysectomized male rats treated with 
polydimethylsiloxane capsules containing testosterone: effects on spermatogenesis fertility 
and reproductive tract concentration of androgen. Bioi. Reprod., 27, 183-188. 
Casella, R., Madura M.R., Mifsud A. eta/. (2001) The polymorphic glutamine size of the androgen 
receptor (AR) gene and testicular histology in non-obstructed infertile patients. Eur. Ural., 
39(suppl 5), 131. 
Cram, D.S., Song, B., Mclachlan, R.I. eta/. (2000) GAG trinucleotide repeats in the androgen 
receptor gene of infertile men exhibit stable inheritance in female offspring conceived after 
ICSI. Mol. Hum. Reprod., 6, 861-866. 
Dadze,S., Wieland,C., Jakubiczka,S. eta/ (2000) The size of the GAG repeat in exon 1 of the 
androgen receptor gene shows no significant relationship to impaired spermatogenesis in an 
infertile Caucasoid sample of German origin. Moi.Hum.Reprad., 6, 207-214. 
Downsing, A.T., Yang, E.L., Clark, M. et a/. (1999) Linkage between male infertility and 
trinucleotide repeat expansion in the androgen-receptor gene. Lancet, 354, 640-643. 
Evans, R.M. (1988) The steroid and thyroid hormone receptor superfamily. Science, 240, 889-899. 
Giovannucci, E., Stampfer, M.J., Krithivas, K. eta/. (1997) The GAG repeat within the androgen 
receptor gene and its relationship to protate cancer. Prac. Nat/. Acad. Sci. USA, 94, 3320-
3323. 
Giwercman, Y., Xu, C., Arver, S. eta/. (1998) No association between the androgen receptor gene 
GAG repeat and impaired sperm production in Swedish men. Letter to the editor. Clin. 
Genetics., 54, 435-436. 
Hoefsloot,L.H., Tuerlings,J.H., Kremer,J.A. eta/. (1997) PCR analysis of Y-chromosome deletions 
in subfertile men [letter; comment]. Lancet, 349, 1400. 
lmada. S., Akaza, H., Ami, Y. et a/. (1997) Promoting effects and mechanisms of action of 
androgen in bladder carcinogenesis in male rats. Eur. Ural., 31, 360-364. 
88 
Kazemi-Esfarjani, P., Trifiro, M.A., Pinsky, L. eta/. (1995) Evidence for a repressive function' of the 
long polyglutamine tract in the human androgen receptor: possible pathogenic relevance for 
the (CAG)n-expanded neuropathies. Hum. Mol. Genet., 4, 523-527. 
Komori, S., Kasumi, H., Kanazawa, R. eta/. (1999) GAG repeat lenght in the androgen receptor 
gene of infertile Japanese males with oligospermia. Mol. Hum. Reprod., 5, 14-16. 
Kremer,J.A., Tuerlings,J.H., Meuleman,E.J. eta/. (1997) Microdeletions of theY chromosome and 
intracytoplasmic sperm injection: from gene to clinic. Hum.Reprod., 12, 687-691. 
La Spada, A.R., Wilson, E.M., Lubahn, D.B. et a/. (1991) Androgen gene mutations in X-linked 
spinal and bulbar muscular atrophy. Nature, 352, 77-79. 
Mifsud, A., Sim, C.K., Boettger-Tong, H. eta/. (2001) Trinucleotide (GAG) repeat polymorph isms in 
the androgen receptor gene: molecular markers of risk for male infertility. Fertil. Steril., 75, 
275-281. 
Miller,S.A., Dykes,D.D. and Polesky,H.F. (1988) A simple salting out procedure for extracting DNA 
from human nucleated cells. Nucl. Acids Res., 16, 1215. 
Nagashima, T., Seko, K., Hirose, K. (1988) Familiar bulbospinal muscular atrophy associated with 
testicular atrophy and sensory neuropathy (Kennedy-Alter-Sung Syndrome): autopsy case 
report of two brothers. J. Neural. Sci., 87, 141-152. 
Remy, J.J., Couture, L., Rabesona, H. et a/. (1996) Immunization against exon 1 decapeptides 
from the lutrotropin I choriogonadotropin receptor or the follitropin receptor as a potential 
male contraceptive. J. reprod. lmmunol., 32, 37-54. 
Sartor, 0., Zheng, Q., Eastham, J.A. et a/. (1999) Androgen receptor gene GAG repeat lenght 
varies in a race-specific fashion in men without prostate cancer. Urology, 53, 378-380. 
Tuerlings,J.H., de France,H.F., Hamers,A. eta/. (1998) Chromosome studies in 1792 males prior 
to intra-cytoplasmic sperm injection: the Dutch experience. Eur.J.Hum.Genet., 6, 194-200. 
Tut, G.T., Ghadessy, F.J., Trifiro, M.A. et a/. (1997) Long polyglutamine tracts in the androgen 
receptor are associated with reduced transactivation, impaired sperm production and male 
infertility. J. Clin. Endocrinol. Metab., 82, 3777-3782. 
World Health Organization (1992). WHO Laboratory Manual for the Examination of Human Semen 
and Sperm-Cervical Mucus Interaction. Cambridge University Press, Cambridge, UK. 
Yang, E.L, Ghadessy, F., Wang, Q., eta/. (1998) Androgen receptor transactivation domain and 
control of spermatogenesis. Rev. Reprod., 3,141-144. 
Yoshida, K.l., Yano, M., Chiba, K. eta/. (1999) GAG repeat lenght in the androgen receptor gene is 
enhanced in patients with idiopathic azoospermia. Urology, 54, 1078-1081. 
89 

Chapter 6 
Can paternal mitochondrial DNA be transmitted to 
offspring or extraembryonic tissues after 
intracytoplasmic sperm injection? 
David R. Marchington 1, Martin S.G. Scott Brown 1, Victoria K. Lamb2 , Ron J.T. van Golde3 , 
Jan A.M. Kremer3, Joep H.A.M. Tuerlings4, Edwin C.M. Mariman4, Adam H. Balen2, 
Joanna Poulton 1 
1 University Department of Paediatics, John Radcliffe Hospital, Oxford, UK 
2 Reproductive Medicine Unit, Leeds General Infirmary, Leeds, UK 
3Department of Obstetrics and Gynaecology, University Medical Centre Nijmegen 
4Department of Human Genetics, University Medical Centre Nijmegen 
Submitted 
Abstract 
There is a risk that IntraCytoplasmic Sperm Injection (ICSI) may increase the transmission 
of mtDNA diseases to children born after this technique. Knowledge of the fate and 
transmission of paternal mitochondrial DNA is important since mutations in mitochondrial 
DNA have been described in oligozoospermic males. 
We have used an adaptation of solid phase mini-sequencing to exclude the presence of 
levels of paternal mtDNA in excess of 0.001% in ICSI families. This method is more 
sensitive than those used in previous studies and is sufficient to detect the likely paternal 
contribution (about 0.1-0.5% from simple calculations of expected dilution during 
fertilisation). Using this method we were able to detect less than 0.001% paternal mtDNA 
in a maternal mtDNA background. No paternal mtDNA was detected in the embryonic 
(blood or buccal swabs) tissue of children born after ICSI and in mainly extraembryonic 
tissue (placenta or umbilical cord). In conclusion, we did not detect paternal mtDNA in 
blood, buccal swabs, placenta or umbilical cord of children born after ICSI. We have 
found no evidence that ICSI increases the risk of paternal transmission of mtDNA and 
hence of mtDNA disorders. 
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Introduction 
It has been assumed that human mitochondrial DNA (mtDNA) is essentially maternally 
inherited because sperm mtDNA is selectively destroyed after fertilisation (Kaneda eta!., 
1995). MtDNA mutants can cause severe diseases in humans (Suomalainen, 1997) and 
cytoplasmic male sterility (CMS, or nonfunctional pollen) in higher plants (Young and 
Hanson, 1987). Hence mitochondrial dysfunction might also be a feature of human male 
infertility and mutations in mtDNA have been described in subfertile men (Folgero eta!., 
1993). 
Intracytoplasmic Sperm Injection (ICSI) has transformed the treatment of male infertility 
but has theoretical genetic risks. ICSI is an increasingly common treatment for infertility, 
particularly for men with low or absent sperm counts, or immotile sperm. Sperm are 
collected from ejaculates, or are harvested by PESA (percutaneous epidydimal sperm 
aspiration) or by aspiration/extraction from the testis (TESA, TESE), and a single sperm is 
injected into an oocyte. In some centres it is used in preference to simple in vitro 
fertilisation (IVF) due to its high success rate. One of the reasons for this success is that it 
bypasses a number of stages of natural fertilisation, including zona pellucida penetration 
and gamete membrane fusion. Major concerns are firstly, that this may also bypass the 
supposed mechanism (Kaneda eta!., 1995) by which paternal mtDNA is removed from the 
embryo. MtDNA is more likely to suffer free radical-induced damage than nuclear DNA 
(Yakes and Van Houten, 1997), so sperm that have undergone oxidative stress could 
deliver defective mtDNA to an oocyte even though the sperm nucleus is unaffected. 
Similarly, as sperm carry more mtDNA deletions than oocytes (Reynier eta/. 1998), there 
is more potential for passing on mtDNA disease. Secondly, it is clear that ICSI removes 
much of the selection against genes for male infertility (Page eta/., 1999; Phillipson eta/., 
2000; Silber eta!., 1998). This is particularly important in the case of mtDNA because it 
has been implicated in human male infertility (Folgero et a/., 1993; Ruiz-Pesini et a/., 
2000a; Ruiz-Pesini eta/. 200Gb). Transmission of mutated paternal mtDNA via ICSI may 
thus lead to progressive and debilitating disorders. 
In normal individuals the vast majority of mtDNAs are identical (homoplasmy) but in 
mtDNA disease heteroplasmy (coexistance of mutant and normal mtDNA) is common. 
Because a point mutation may become homoplasmic and hence the mtDNA founder of a 
maternal lineages within a single generation (the so-called bottleneck, Blok eta!., 1997), 
small quantities of exogenous mtDNA could have a profound effect. The paternal 
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component would comprise up to 0.5% of the 100,000 mtDNAs in each oocyte, but could 
potentially be amplified to a significant population in the progeny because of these unique 
genetics. 
Previous studies have not detected a paternal contribution to the mtDNA in offspring of 
ICSI pregnancies at levels in excess of 0.01-1% (Danan et a/., 1999; Houshmand eta/., 
1997; Torroni eta/., 1998). Furthermore these studies did not investigate extraembryonic 
tissue. This is important, because mtDNA may have an uneven distribution between 
different tissues in a single individual (Poulton et a/., 1995). Differences in the ratio 
between wild type and mutant DNA in different tissues, so called heteroplasmy, is well 
known for pathogenic mtDNA in mitochondrial diseases (Taylor eta/., 1997). If paternal 
mtDNA did survive after ICSI and replicate during development, this might mean that 
paternal mtDNA could be enriched in some tissues and diluted in others. 
We have adapted solid phase minisequencing, a highly sensitive method for quantitating 
mixed populations of mtDNAs, to exclude levels of down to 0.001% paternal mtDNA. In 
this study the origin of mtDNA was investigated in placenta, umbilical cord, blood and 
buccal swabs of children born following ICSI. 
Methods 
DNA was extracted by standard methods (Sambrook eta/., 1989). We obtained mtDNA 
sequence data for a 400 bp region of the first hypervariable region of the large noncoding 
region in ICSI parent-child pairs. M13 tagged primers; 
TGT AAAACGACGGCCAGTCTCAAATGGGCCTGTCCTTG (forward primer) and 
CAGGAAACAGCT ATGACCTTGATTTCACGGAGGATGGTG (reverse primer) were used 
to PCR amplify the region from bp 15875 to bp16421 using ABgene PCR Mastermix with 
1.5mM MgCI2. 5 pmoles of primer and 1 ul of DNA (at approx 50ng/ul) were used in a 50ul 
reaction volume. Amplifications were performed for 40 cycles (1 min each at 94°C, 55°C, 
72°C, with an initial denaturing step of 4 min at 94°C and a final extension of 10 min at 
72°C. Sequencing reactions used standard ABI Bigdye terminator chemistry and 
conditions and primers corresponding to the M13 tags (TGTAAAACGACGGCCAGT and 
CAGGAAACAGCTATGACCl Reactions were run on an ABI 377XL Prism DNA 
Sequencer. Polymorphic sequence variants that could be used to distinguish between 
paternal and maternal mtDNA were identified. This was followed by solid phase mini-
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sequencing. This is a highly sensitive method, involving sequence-specific incorporation 
of radionucleotides in a primer extension assay (see Figure 1 ). A forward primer 
AAGTAGCATCCGTACTAT and a 5' biotinylated reverse primer were used to PCR 
amplify the region of mtDNA bp15800 to bp16417 using the same conditions as for the 
PCR for sequencing, except that an annealing temperature of 50°C was used. 1 Oul PCR 
product was added to 15ul binding buffer (TE with 2M NaCI) and bound to the wells of a 
Streptavidin coated 96 well plate (ABgene) for 1 hour. Plates were washed 3 times with 
washing buffer (TE with 1M NaCI). 50ul of a PCR mix was added, denatured for 5 min at 
94°C and extended at 50°C for 10 min. The PCR mix contained 1.5mM MgCI2 , 0.1 U of 
Taq Polymerase, 5pmoles of a primer corresponding to the 18bp upstream of the 
polymorphic base change of interest and 27nmoles of a single 32P radiolabelled dNTP 
corresponding to either the maternal or the paternal sequence. The plate was washed 3 
times with washing buffer and 30ul denaturing buffer added (80% formam ide, 1 OmM 
EDTA (pH 8.0) 1 mg/ml xylene cyanol, 1 mg/ml bromophenol blue. The plate was heated to 
95°C for 5min and transferred to ice. 4ul samples were loaded onto 1 mm thick, 8cmx8cm 
8% acrylamide 1 xTBE, 7M urea gels and electrophoresed for 45 minutes at 180V. Gels 
were dried under heat and vacuum and exposed to storage phosphor screens for 
quantitation of radioactivity in a phoshorimager. 
Table I. Polymorphic base changes used to identify maternal and paternal m!DNA. 
Pregnancy Polymorphic base change 
Pregnancy 1 16296 T- C 
Pregnancy 2 16069 T- C 
Pregnancy 3 16239 T- C 
Pregnancy 4 16069 T- C 
Pregnancy 5 16189T-C 
Pregnancy 6 16267 T- C 
Pregnancy 7 16298 T- C 
Pregnancy 8 16298 T- C 
Pregnancy 9 16298 T- C 
Pregnancy 1 0 16256 T- C 
Pregnancy 11 16294 T- C 
Parental DNA was extracted from blood or buccal swabs, the first hypervariable region of the large 
noncoding region of mtDNA was amplified by PCR and sequenced using Bigdye cycle sequencing. The 
polymorphic changes identified were used to design detection primers encompassing the 18bp upstream 
of the polymorphism 
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Mother specific sequence G--
-------------c----- Biotin 
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32 
----- A-P 
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c Biotin 
t 32 
--A-P 
Biotin 
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removed after denaturation 
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----T------------- Biotin 
G-fY32 
C Biotin 
Remove excess dNTP, 
denature, electrophorese 
on 8% denaturing 
acrylamide gel 
32 ....32 
A-P I G-t-' represents the ratio of mother to father sequences in the original template 
Figure 1. Principles of solid phase mini-sequencing, utilising a G->A base change. The region of 
interest is amplified by PCR using a biotinylated reverse primer, to allow immobilisation of the 
product on a streptavidin coated plate. Excess reagents are removed and the plate washed. A 
single round of PCR is performed using a detection primer corresponding to the sequence 
immediately upstream of the polymorphism and a radiolabelled dNTP, corresponding to either the 
paternal or maternal sequence. This allows extension by 1 bp if the dNTP matches the sequence 
present. Separate reactions are performed to detect the 2 different sequences. Excess reagents 
are removed and the plate washed. The primer is removed by denaturation and electrophoresed 
on 8% acrylamide TBE/urea gels. The gel is dried and exposed to storage phosphor screens to 
detect radiolabelled primer. 
Results 
11 ICSI pregnancies were investigated. These ICSI pregnancies were all derived using 
ejaculated sperm. DNA was extracted from placenta (3), buccal swabs (3) or placenta, 
umbilical cord and blood (5). Parental DNA was extracted from either blood or from buccal 
swabs. Sequence analysis using Bigdye cycle sequencing demonstrated that there were 
usable mtDNA differences in all cases (Table 1). These were used to design sets of PCR 
primers that allowed the detection of the parent-specific sequences (Figure 1 ). Initially we 
obtained a notable background signal using solid phase mini-sequencing, which was not 
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abolished by washing or minor alterations in the conditions. Subsequent investigation of 
the cause of the background revealed that short PCR products were present which were 
not specific to either parent. However, acrylamide gel electrophoresis of the products of 
the primer extension (Figure 2) revealed that there was a high degree of specificity for the 
product of appropriate length. All detection primers were tested on mixes of paternal and 
maternal DNA samples mixed at ratios lower than those expected if paternal mtDNA was 
present in an embryo (that is, lower than 0.01 %) to confirm that we would detect it if 
present. Using this method we were able to detect less than 0.001% paternal mtDNA after 
mixing paternal mtDNA into a maternal mtDNA background (Figure 3). No paternal mtDNA 
was detected in any of the ICSI samples. 
e 
c 
0 ctl ctl ca ca ca ca (.) c c c c c c Qj Q) Q) Qj Qj Qj Qj (.) (.) Ctl ctl ctl Ctl Ctl Ctl Ctl s 0::: 0::: 0.. 0.. ::2: ::2: 
Father specific sequence dTTP 
e 
c 
0 ctl ctl ca ca ca ca (.) c c Qj c c E E Q) Q) Qj Qj Q) Q) (.) (.) Ctl ctl ctl Ctl Ctl Ctl Ctl s 0::: 0::: 0.. 0.. ::2: ::2: 
Mother specific sequence dCTP 
Figure 2. Solid phase mini-sequencing of a family in which there is a polymorphic C-> T base 
change in paternal mtDNA at bp 16269. Radiolabelled primer was detected by phosphorimaging 
after solid phase mini-sequencing as described in methods. Duplicate samples were analysed in 2 
sets of wells. The upper panel shows bands obtained by mini-sequencing using radiolabelled dTTP 
which corresponds to the paternal sequence. The lower panel shows bands obtained by mini-
sequencing using radiolabelled dCTP which corresponds to the maternal sequence. No paternal 
sequence was detected in the maternal or placental samples. No maternal sequence was detected 
in the paternal samples. Water controls tested negative for both sequences. 
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Figure 3. Solid phase mini-sequencing of sequential dilutions of paternal mtDNA (carrying a 
bp16069T polymorphism) into maternal mtDNA (bp16069C). To determine the sensitivity of the 
method paternal mtDNA was mixed with maternal mtDNA in ratios encompassing those expected 
in an embryo in which paternal mtDNA was present. Radiolabelled primer representing paternal 
sequence was detected by phosphorimaging after solid phase mini-sequencing as described in 
methods. No paternal sequence was detected in a water negative control or 100% maternal 
mtDNA but was detectable when paternal mtDNA was mixed with maternal mtDNA down to 
0.0001%. 
Discussion 
In normal individuals there is generally a single population of identical mtDNA 
(homoplasmy). Two mechanisms probably underlie this. On the maternal side, the so-
called mtDNA bottleneck during oogenesis ensures that all of the 100,000 mtDNAs in a 
normal oocyte arise from a small number or single mtDNA founder. On the paternal side, 
the mitochondrial bottleneck has an anatomical basis, and it is arguable that the minute 
contribution of sperm mtDNA to the zygote must be fully functional if it is to win the race 
against other sperm to the oocyte. While it is commonly held that mtDNA is exclusively 
maternally inherited, paternal mtDNA can be detected in abnormal human embryos at the 
blastocyst stage (St John J, 2000) and mouse studies have shown that paternal 
mitochondria may persist in the zygote for several days (Cummins et a/., 1999). 
Furthermore, ICSI alters both the time course of early development of the zygote (Tesarik 
et a/., 1994) and potentially the dose of the paternal contribution to mtDNA. The use of 
immature sperm types including epididymal and testicular sperm might increase the risk of 
paternal mtDNA inheritance. Between meiosis and the end of spermatogenesis there is an 
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8-10 fold reduction in mtDNA copy number per cell (Hecht et a/. 1984), reducing the 
number of paternal mtDNA molecules available for potential transmission in mature 
spermatocytes. Sperm mitochondria are ubiquinylated during spermatogenesis, this is 
masked during epididymal passage but unmasked and amplified after fertilisation, 
targeting the sperm mitochondria for destruction in the 2-4 cell embryo (Sutovsky eta/., 
2000). This process appears to be dependent on species-specific recognition, raising the 
possibility that in abnormal sperm development or immature sperm this 
recognition/destruction system may be defective. 
Our adaptation of solid phase minisequencing, has improved its sensitivity and enabled us 
to exclude levels of down to 0.001% paternal mtDNA in both embryonic and extra 
embryonic tissues in 11 children born following ICSI using ejaculated sperm, compared 
with the expected level of 0.1% to 0.5%. It argues against a possible 
compartmentalization of the injected sperm tail in the fertilized oocyte, which theoretically 
could lead to relatively high levels of paternal mtDNA in either embryonic or 
extraembryonic tissues. It lends further support to the results of other groups who have 
obtained negative results in embryonic tissues, using less sensitive techniques (Danan et 
a/., 1999; Houshmand eta/., 1997; Torroni eta/., 1998). 
Investigating the potential for paternal inheritance of mtDNA is important for 2 reasons. 
Firstly, ICSI eliminates the selection pressures that normally maintain genetic fitness 
(Phillipson et at., 2000; Silber et at., 1998). By eliminating the anatomical basis of the 
mitochondrial bottleneck, ICSI may select for mtDNA mutations causing male infertility. 
Secondly, population geneticists routinely use mtDNA haplotypes to trace population 
migrations and infer divergence times based on mtDNA diversity. These studies assume 
that mtDNA does not recombine. However, recent reanalyses suggest that this critical 
assumption may be incorrect (Eyre-Walker et at., 1999). The proposal that mtDNA might 
recombine requires the mixing of mtDNA from 2 disparate lineages. This infers co-
existence of paternal and maternal mtDNA in a single cell. 
In conclusion, we did not detect paternal mtDNA in blood, buccal swabs, placenta or 
umbilical cord of children born after ICSI. We have found no evidence that ICSI increases 
the risk of paternal transmission of mtDNA and hence of mtDNA disorders. 
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Abstract 
Couples dealing with microdeletions of the Y chromosome have to make decisions about 
their reproductive future. Do they opt for intracytoplasmic sperm injection (ICSI), artificial 
insemination with donor insemination (AID) or no treatment? We analysed this decision in 
28 couples and investigated the role of the counsellor and the counselling process on the 
final decision of the couple. Ten counsellors from six fertility clinics in The Netherlands and 
Belgium were interviewed about their genetic counselling of couples dealing with 
microdeletions. The answers to the questionnaire were converted to 11 dichotomous 
variables. Of the 1627 tested men in the six centres, 37 (2.3%) had a microdeletion in the 
AZFc region, a subregion of the AZF region on the Y chromosome important for normal 
spermatogenesis. The decisions of 28 of them could be analysed. Most couples chose 
ICSI (79%). The remaining couples chose donor insemination (7%) or refrained from 
treatment (14%). Several variables, including the counselling procedure, the counsellor 
and the available treatments in the fertility centre, influenced the decision of the couple. In 
conclusion, most couples dealing with microdeletions in the AZF region choose ICSI. 
Several aspects of the process of genetic counselling appear to be related to the final 
decision. 
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Introduction 
Men with microdeletions of the Y chromosome and their wives have to make decisions 
about their reproductive future. Do they choose intracytoplasmic sperm injection (ICSI), 
artificial insemination with donor semen (AID) or no treatment? Little is known about this 
decision-making and the role of genetic counselling. 
Microdeletions in the azoospermia factor (AZF) region of theY chromosome have been 
described in oligozoospermic and azoospermic men (Tiepolo eta/., 1976; Ma eta/., 1992; 
Vogt eta/., 1992; Reijo eta/., 1996; Pryor eta/., 1997; Kremer eta/., 1998). Most deletions 
are found in the AZFc region (Simoni eta/., 1998). After the introduction of ICSI (Palermo 
eta/., 1992), men with microdeletions in the AZF region could father children despite their 
severe oligozoospermia or azoospermia. Recently, transmission of microdeletions to sons 
via ICSI has been described (Silber eta/., 1998). So, presumably men with microdeletions 
will transmit the deletion, as well as the related fertility problem, to their sons. 
Many in-vitro fertilization (IVF) clinics offer their patients with severe oligozoospermia or 
azoospermia testing for microdeletions in the AZF region. If a deletion is found, a decision 
has to be made by the couple. Different authors have emphasized the importance of 
genetic counselling in this process (Mau eta/., 1997; Pauer eta/., 1997; Tuerlings eta/., 
1997). As stated before, little is known about the impact of having a microdeletion on 
further decision-making on reproductive options. In the present study, we analysed this 
decision-making and investigated the relationship between some aspects of the process of 
genetic counselling and the final decision. 
Materials and Methods 
In order to obtain information about the genetic counselling and reproductive decisions 
taken by couples dealing with microdeletions in the AZF region of the Y chromosome, 14 
fertility clinics in The Netherlands and Belgium were contacted and asked to participate in 
the study. 
In the participating clinics, counsellors were interviewed about the genetic counselling of 
couples dealing with microdeletions of the Y chromosome. A questionnaire containing 30 
questions was used, focusing on the information given about Y deletions and the 
consequences for the offspring, the treatment options available and the counsellors' own 
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opinion about Y deletions. Counselling on ICSI included information about microdeletions 
on the Y chromosome being the cause of the fertility problem and the risk of transmitting 
fertility problems to their male offspring. Counselling on AID included the information that 
there is no increased risk from the use of genetically abnormal spermatozoa. Furthermore, 
the reproductive decisions of the individual couples were documented. This information 
was gathered under supervision of a representative of the centre and handled 
anonymously. 
Subsequently, we analysed the relationship between the answers of the counsellor to the 
questionnaire and the final decision. The answers to the questions were converted to 11 
dichotomous variables that were thought to be related to the decisions of the couple (Table 
1). Statistical analysis was performed by chi-square tests. 
Results 
Study group 
Fourteen IVF centres were contacted to participate in the study (until August 1998). One 
centre did not respond. In two centres, diagnostic tests to detect Y deletions were not 
offered to the patients. In two centres, the patients were referred to other centres for 
diagnostic tests. Three centres offered diagnostic research on Y deletions, but no Y 
deletions were detected. In the remaining six centres (five in The Netherlands and one in 
Belgium), 1627 men were tested and 37 men appeared to have a microdeletion in the 
AZFc region of the Y chromosome (2.3%). One couple did not want to be genetically 
counselled and eight couples had not taken a decision at the time of the study. These nine 
couples were excluded from the study. 
The mean age of the men in the remaining 28 couples was 34.7 years (range 24-48). The 
mean age of the women was 31.9 years (range 23-43). 
Genetic counselling 
The 28 couples in the six centres were counselled by 10 different counsellors: four clinical 
geneticists, three gynaecologists, two andrologists and one embryologist. The counselling 
was performed during one to three sessions with one or two counsellors. 
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Table I. Dichotomous variables related to the counselling of men with Y deletions, questions 
asked and answers given to the counsellors, and the interpretation of the answers (in italics). 
Reproductive decisions towards: intracytoplasmic sperm injection (ICSI), artificial insemination with 
donor semen (AID) or no treatment. 
Variables Questions Answers 
Frequency of counselling 
about Y deletions 
On how many occasions do you 3 or more: frequent counselling about 
counsel couples about Y deletions? Y deletions 
What do you tell about the Sons inherit the deletion and Adequacy of counselling 
about consequences for 
sons 
consequences of Y deletions for probably will have fertility problems: 
sons? adequate counselling about Y 
deletions 
Thoroughness of counselling How thoroughly do you counsel 
about Y deletions couples about Y deletions? (on a 
scale from 1 to 1 0) 
6 or more: thorough counselling 
about Y deletions 
Thoroughness of counselling How thoroughly do you counsel 6 or more: thorough counselling 
about ICSI in general couples about ICSI in general? (on a about ICSI in general 
scale from 1 to 1 0) 
Thoroughness of counselling How thoroughly do you counsel 
about risks of ICSI for the about risks of ICSI for the offspring? 
offspring (on a scale from 1 to 1 0) 
Opinion of the counsellor Do you think that a Y deletion is a 
6 or more: thorough counselling 
about risks of ICSI for the offspring 
6 or more: Y deletions are serious 
about the seriousness of Y serious defect? (on a scale from 1 to defects according to counsellor 
deletions 1 0) 
Own decision of the If you (or your partner) would have a Yes: counsellor chooses for ICSI 
counsellor Y deletion, would you choose ICSI? 
Availability of ICSI in the Are both ICSI and AID available in No, only ICSI: only ICSI available 
department of the counsellor your department? 
Availability of AID in the Are both ICSI and AID available in No, only AID: only AID available 
department of the counsellor your department? 
Experience of counsellor How many men with Y deletions did 6 or more: experienced counsellor 
you counsel? 
Directivity of the counsellor How directive are you as a 6 or more: directive counsellor 
counsellor? (on a scale from 1 to 1 0) 
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Couples' reproductive decisions 
Twenty-two couples choose ICSI (79%). Of the six couples who did not choose ICSI, two 
couples opted for AID (7%), and four couples decided to refrain from either form of 
treatment (14%). 
The variables derived from the answers to the questionnaire, and their statistical analysis 
using chi-square test are shown in Table II. Seven variables were significantly related to 
the final decision. Four of these seven variables were significantly related to the choice for 
ICSI: adequate counselling about Y deletions (P = 0.01), thorough counselling about Y 
deletions (P = 0.002), thorough counselling about risks of ICSI for the offspring (P = 0.02) 
and only ICSI available in the department of the counsellor (P = 0.04). Three of the seven 
variables were significantly related to the choice for the alternatives of ICSI: Y deletions are 
serious defects according to the counsellor (P = 0.02), only AID available in the 
department of the counsellor (P = 0.002) and directive counsellor (P = 0.002). 
Discussion 
Our data show that about 80% of the couples dealing with microdeletions in the AZFc 
region choose ICSI rather than AID, adoption or no treatment. This high frequency is 
consistent with the findings of a Dutch study describing reproductive decisions of couples 
dealing with chromosomal abnormalities (Giltay eta/., 1998). The decisions of the couples 
in this study and in our study are not influenced by financial motives, since the ICSI 
treatment is almost completely reimbursed in the Netherlands and partially in Belgium. 
One may conclude that testing for microdeletions is not useful: with testing most couples 
choose ICSI, whereas without testing probably most people will also choose ICSI. We do 
not agree with this conclusion. First of all, a reasonable percentage of the couples decided 
to refrain from ICSI after testing. Furthermore, little is known about the consequences and 
risks of ICSI. Therefore we think that we have the obligation to inform the couple about 
what we do know. We have to inform them in an optimal way and offer all ICSI men with 
severe oligozoospermia or azoospermia testing for microdeletions in the AZF region. After 
genetic counselling, the couple can make their own and well-informed choice about their 
reproduction. 
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Table II. The variables related to the counselling of 23 men with Y deletions (Table I) and the 
final decision of the couple 
Variables Frequency of Couples' Couples' x2 P-value 
variables decision decision 
(n = 28) ICSI (n = 22) No ICSI (n = 6) 
Frequent counselling about Y 13 12 2.72 0.10 
deletions 
Adequate counselling about Y 13 13 0 6.62 0.01 
deletions 
Thorough counselling about Y 19 18 9.17 0.002 
deletions 
Thorough counselling about ICSI in 16 14 2 1.77 0.18 
general 
Thorough counselling about risks of 16 15 5.11 0.02 
ICSI for the offspring 
Y deletions are serious defects 8 4 4 5.43 0.02 
according to counsellor 
Counsellor chooses for ICSI 20 17 3 1.72 0.19 
only ICSI available 10 10 0 4.24 0.04 
only AID available 6 2 4 9.28 0.002 
Experienced counsellor 17 15 2 2.40 0.12 
Directive counsellor 6 2 4 9.28 0.002 
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Each counsellor tries to counsel in an objective way and wants to think that the couple 
makes a free decision. However, this seems not to be the case. Our data show that the 
decision of the couple to choose ICSI or its alternatives is related to a number of variables 
of the process of genetic counselling. The clinic of the counsellor is important: if only ICSI 
is available more couples choose ICSI, and if AID is the only available treatment more 
couples choose AID. Additionally, the counsellor is important: if he or she has the opinion 
that microdeletions are serious defects and if he or she counsels in a directive way, more 
couples refrain from ICSI. Finally, the process of counselling is important: if this process is 
judged by the counsellor as thorough and adequate, more couples choose ICSI. 
We performed a multicentre study to get a large study group. However, the numbers 
remain too small to perform a multivariate analysis on the data. Because the analysed 
variables are not independent, care must be taken when interpreting each individual 
variable. Moreover, we only demonstrated a statistical relationship between the variables 
and the final decision and not a causal relationship. 
Pre-implantation genetic diagnosis (PGD) and sex-selection is an alternative strategy for 
couples dealing with microdeletions. However, this possibility was not available in the six 
centres studied. We know that there are clinics in Belgium that offer PGD to couples 
dealing with microdeletions, but the results have not been published until now. 
Only 37 of the 1627 tested men had a microdeletion in the AZFc region (2.3%), which is 
lower than the frequency in earlier studies (reviewed by Simoni et a/., 1998). This may be 
due to the fact that a majority of the tested men had oligozoospermia and not 
azoospermia, since ICSI with surgically retrieved spermatozoa is not allowed in The 
Netherlands. Microdeletions are found more frequently in azoospermic men than in 
oligozoospermic men (Simoni eta/., 1998). An alternative explanation for the relatively low 
frequency may be publication bias of positive results in earlier studies. 
We conclude that most couples dealing with microdeletions of the Y chromosome choose 
ICSI and that a minority choose an alternative. Several aspects of the process of genetic 
counselling are related to the decision-making. Each counsellor should be aware of this 
phenomenon and should try to counsel in an objective and optimal way, so that the 
couples can make well-informed choices about their reproductive future. 
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Abstract 
Microdeletions of the azoospermia factor (AZF) region of the Y chromosome occur in 
between 1 and 29% of oligozoospermic and azoospermic men, and most deletions are 
found in the AZFc region. These men can father children when intracytoplasmic sperm 
injection (ICSI) is used, but the success rate is unclear. Thus, the success rate of 19 ICSI 
treatments in eight couples with a microdeletion in the AZFc region of the Y chromosome 
was analysed retrospectively. These were compared with a control group of 239 ICSI 
treatments in 107 couples undergoing ICSI treatment with ejaculated spermatozoa. The 
fertilization rate was significantly lower in the group of Y-deleted men (55%; 95% Cl: 41-
69%) compared with controls (71%; 95% Cl: 67-74%; P < 0.01). The embryo quality was 
also significantly poorer among Y-deleted men (P < 0.001 ). Pregnancy, implantation and 
take-home baby rates were not significantly lower in the Y-deleted group. This study 
shows that ICSI in oligozoospermic men with microdeletions in the AZFc region of the Y 
chromosome leads to a lower fertilization rate and poorer embryo quality. 
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Introduction 
The azoospermia factor (AZF) region of theY chromosome has been described previously 
(Tiepolo and Zuffardi, 1976), based on the observation of cytogenetic deletions in infertile 
men. Many studies have investigated the role of this region in spermatogenesis. Until now, 
it has been suggested that some of the genes in the Yq11 region control spermatogenesis 
(Ma eta/., 1993; Reijo eta/., 1995; Lahn and Page, 1997). This region can be divided into 
three non-overlapping regions of theY chromosome: AZFa, band c (Vogt eta/., 1996). 
Microdeletions of the Y chromosome occur in between 1% and 29% of subfertile men 
(Foresta et a/., 1997; Kremer et a/., 1997; Van der Ven eta/., 1997). The frequency is 
dependent on the definition of male subfertility and on the choice of sequence tagged sites 
used for screening (Simoni eta/., 1999). The AZFc locus containing the DAZ gene cluster 
is the most frequently deleted region of the Y chromosome in men with non-obstructive 
infertility (Kostiner et a/., 1998; Simoni et a/., 1998). Histologically, these deletions are 
associated with various spermatogenetic alterations, including Sertoli cell-only syndrome, 
maturation arrest and hypospermatogenesis. 
Following the introduction of intracytoplasmic sperm injection (ICSI), it was possible for 
men with a microdeletion of the Y chromosome to father children, despite their severe 
oligozoospermia or azoospermia, using ejaculated or surgically retrieved spermatozoa. 
When a microdeletion of the Y chromosome is diagnosed, it is important that a couple is 
informed about their reproductive options. These options are ICSI, artificial insemination 
with donor semen, or no treatment. Most infertile couples (79%) with a microdeletion of the 
Y chromosome choose ICSI as treatment for their fertility problem (Nap eta/., 1999). The 
couple should also take into account the success rates of these options, besides the fact 
that when ICSI is used, the male offspring inherit the same deletion and presumably the 
related fertility problem (Mulhall eta/., 1997). 
Although many reports have detailed the success rate of ICSI treatment, virtually no 
information is available (other than a few case reports) regarding the success rates of ICSI 
in couples with severe oligozoospermia due to microdeletions of theY chromosome. In the 
present study, the outcome of ICSI treatment using spermatozoa from men with a 
microdeletion of the Y chromosome was compared with that of ICSI treatment using 
spermatozoa from oligozoospermic men without this deletion. 
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Materials and Methods 
Patient selection 
In our clinic, subfertile men are candidates for ICSI if their ejaculate contains <1 06 
spermatozoa with propulsive motility (WHO a and b; World Health Organization, 1992). 
Since 1996, these men have been screened for microdeletions of the AZFa, b and c 
regions of theY chromosome (Hoefsloot eta/., 1997). 
The fertilization rate, embryo quality, pregnancy rate, implantation rate and take-home 
baby rate after ICSI in couples in which the man had microdeletions of theY chromosome 
and couples without this genetic disorder were compared retrospectively. Observations 
were commenced when oocytes were able to be punctured at the time of oocyte retrieval. 
The success of ICSI treatment is mainly influenced by maternal age, and whether the 
subfertility is primary or secondary (Sherins eta/., 1995; Abdelmassih eta/., 1996; Stolwijk 
eta/., 2000). For this reason, controls with a primary subfertility which had been treated 
within the same year and at the same age as one of the patients, were considered. Among 
this group, only couples who had started their first ICSI cycle in 1996 or later were 
included. Thus, matching was carried out without using a fixed matching ratio. 
Because of possible interference with the outcome of ICSI treatment, the following couples 
were excluded from the control group: (i) chromosomal abnormalities in the male ICSI 
candidate; (ii) cryopreserved spermatozoa used for ICSI; (iii) using ejaculated spermatozoa 
from a man with a vaso-vasostomy; and (iv) ICSI treatment performed because of total 
failure of previous IVFtreatment, despite normal sperm parameters. 
/CS/ treatment 
Ovarian stimulation was performed by means of a long protocol of gonadotrophin-
releasing hormone (GnRH) agonist, that was started on day 21 of the previous cycle, 
followed by human menopausal gonadotrophin (HMG). Oocyte retrieval occurred 36 h 
after HCG injection, and ICSI was performed according to a published technique (Palermo 
eta/., 1992). Fertilization rates were scored 18-22 h after the ICSI procedure, with respect 
to injected oocytes. On day 3 after oocyte retrieval the embryos were scored for cell 
number and percentage of fragmentation using a modification of a previously published 
scoring system (Bolton eta/., 1989): no fragmentation = excellent; <1 0% fragmentation = 
good; > 10% fragmentation = fair. The best embryos were selected for embryo transfer. 
Before 1997, a maximum of three embryos was transferred; however, since January 1997 
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the maximum number of transferred embryos has been two. Clinical pregnancy was 
defined as a positive (>50 IU/1) urinary B-HCG test on day 18 after oocyte retrieval. An 
ongoing pregnancy was defined as one or more gestational sacs in utero, 5 weeks after 
embryo transfer. The implantation rate per embryo was defined as the fraction of 
transferred embryos developing to gestational sac. The take-home baby rate was defined 
as a dichotomous variable: one (or more) child per pregnancy was considered to be a 
positive result, and the ratios were calculated in relation to an embryo transfer and in 
relation to an oocyte retrieval. 
Statistical analysis 
Two sample tests according to Student and Wilcoxon have been used with respect to 
number of oocytes per oocyte retrieval, percentage of injected oocytes per retrieval 
(injection rate), and the fertilization rate. 
Fisher's exact tests were carried out with respect to the categorical variable for embryo 
quality of the transferred embryos and the dichotomous variables for the occurring of 
pregnancy, ongoing pregnancy, take-home baby rate per embryo transfer and take-home 
baby rate per oocyte retrieval. Testing according to Wilcoxon's two sample test was also 
performed with respect to the implantation rate of embryos transferred. Only SAS 
procedures were used. 
In order to justify the above statistical analyses, a more sophisticated approach was 
applied by taking into account the patient dependence of cycle results. First, an alternative 
analysis was performed with respect to fertilization rate on the basis of a general linear 
mixed model with random patient effects (SAS procedure mixed). In addition, an 
alternative analysis was carried out with respect to the pregnancy and take-home baby 
rates on the basis of a logistic regression analysis with random patient effects (SAS macro 
GLIMMIX). A P-value 0.05 was considered to be significant. 
Results 
Between 1996 and 1998, a total of 300 men with <1 06 spermatozoa with propulsive motility 
in their ejaculate (azoospermia) was screened for microdeletions in the AZF region of the 
Y chromosome. 
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0 Table I. Results ICSI treatment until fertilisation rate of the couples dealing with Y deletion and the controls 
No. of oocytes collection procedures (OPU) 
No. of cycles with injected oocytes 
No. of embryo transfers (% of OPU) 
Mean± SO (range) no. of oocytes per OPU 
Mean ±SO (range) no. of injected per OPU in% 
Mean ± SE of fertilisation rate in % (95% confidence interval) 
c Mean± SE of fertilisation rate in % (and 95% confidence interval) 
Y deletion 
8 couples a 
19 
18 
17 (89%) 
8.1 ± 4.0 (1-20) 
79 ± 28 (0-100) 
55± 7(41,69) 
54± 7 (41 ,68) 
Controls 
107 couples 
239 
238 
230 (96%) 
9.6 ± 4.9 (1-32) 
82 ± 18 (0-100) 
70 ± 2 (67,74) 
71 ± 2 (68,75) 
P-value 
0.19 b 
0.39 b 
0.01 b 
0.02 c 
a One of these couples had no injected oocytes, because of azoospermia at the time of ICSI 
b P-values according to Student's two sample test. Because of the skewness of distributions also the non parametric Wilcoxon's two sample test has 
been applied, leading to the same conclusion (respectivelyp=0.20, 0.96, 0.03) 
c Results according to a general linear mixed model with a couple as a random effect 
Table II. Embryo quality score of the transferred embryos and their number in each group of the scoring system in couples dealing with 
Y deletion and the controls 
Embryo quality Definition Y deletion Controls 
Excellent No fragmentation 7 (19%) 220 (49%) 
Good <1 0% fragmentation 10 (27%) 143 (32%) 
Fair Fragmentation > 10% 20 (54%) 86 (19%) 
Total 37 449 
Significant difference between the two groups with respect to the distribution of embryo quality according to Fisher's exact test (P < 0.001) 
1\) 
Table Ill. Pregnancy, implantation and take home baby rate of the couples dealing withY deletion and the controls 
Y deletion Controls 
17 Embryo Transfers 230 Embryo Transfers 
Clinical pregnancy rate per embryo transfer (in % ± SE) 3 (18%±9%) 73 (32%±3%) 
b Clinical pregnancy rate per embryo transfer in % ± SE 18% ± 26% 33%±7% 
Ongoing pregnancy per embryo transfer (in % ± SE) 3 (18%±9%) 70 (30%±3%) 
Implantation rate in%± SE 14%±9% 18%±2% 
Take home baby rate per embryo transfer (in%± SE) 3 (18% ± 9%) 60 d (26% ± 3%) 
b Take home baby rate per embryo transfer in%± SE 17% ± 28% 28%±8% 
a P-values according to Fisher's exact test for a 2 x 2 -table 
b Results according to a generalized linear mixed model (logistic regression analysis with random sample effects) 
c P-values according to Wilcoxon's two sample test 
d Including 2 cycles with an ongoing pregnancy, but with unknown outcome at the closing date of data collection 
P-value 
0.28 a 
0.25 b 
0.41a 
0.36 c 
0.57 a 
0.42b 
Among these men, eight (2.7%) appeared to have a microdeletion in the AZFc region of 
the Y chromosome. No microdeletions were detected in the AZFa orb regions. The mean 
sperm count among these men was 2.3x1 06 per ml, with 19% propulsive spermatozoa. All 
eight couples suffered from primary subfertility; the mean(± SD) age was 34 ± 5 years for 
females, and 36 ± 5 years for males. 
The outcome after ICSI treatment until fertilization of couples with an AZFc deletion (n = 8) 
and control couples (n = 1 07) is shown in Table I. In the former group, 19 retrieved oocytes 
resulted in a significantly lower fertilization rate of 55% (95% Cl: 41-69%) compared with 
71% (95% Cl: 67-7 4%) in the control group (P = 0.01 ). In addition, the embryo quality was 
significantly poorer (P < 0.001) among the group of Y-deleted men (Table II). 
In 17 of the 19 cycles, embryos could be transferred in theY-deletion group. No fertilization 
occurred in two cases: in one case this was because the man had azoospermia at the time 
of the ICSI procedure; in the other case there was no fertilization of the single oocyte that 
had been injected. The pregnancy rate, implantation rate and take-home baby rate per 
embryo transfer were not significantly lower in theY-deleted group (Table Ill). 
The take-home baby rate was also calculated per oocyte retrieval procedure, but was not 
significantly different for the Y-deleted and control groups (16% versus 25% respectively). 
Five healthy female babies were born as a result of the three pregnancies. 
Discussion 
In this study it was found that ICSI with ejaculated spermatozoa from men with a 
microdeletion in the AZFc region of the Y chromosome resulted in a reduced fertilization 
rate and embryo score. Although in IVF the fertilization rate may be affected by sperm 
and/or oocyte factors, success rates after ICSI are most likely not related to sperm 
parameters (Mansour eta/., 1995; Nagy eta/., 1995). The injection rate and number of 
oocytes were not significantly different between the two groups in this study. Furthermore, 
it was apparent that the same staff, using the same protocols during the same time period, 
performed the ICSI procedures. 
It remains unknown how spermatozoa with an AZFc deletion influence the fertilization rate 
and embryo quality. Until now, it has been thought that the main function of the AZFc 
region of theY chromosome is its involvement in spermatogenesis. It may be postulated 
that either the quality of the spermatozoa or the sperm function in fertilization and embryo 
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development is impaired due to the AZFc deletion. The current study might indicate that Y 
bearing spermatozoa of these men have a lower chance of fertilization and normal embryo 
development. If this were the situation, it would only occur in male embryos, and result in a 
lower male:female ratio. Therefore, it would be interesting to investigate the sex of the 
supernumerary embryos in those couples with an AZFcdeletion. 
This hypothesis is supported in the current Y deleted group, because only daughters were 
born to these couples. However, male offspring have been born after ICSI using 
spermatozoa from men with an AZFc deletion (Page eta/., 1999). 
As argued above, it may be important to maximize the available number of good quality 
embryos in couples with an AZFc deletion, perhaps by attempting to increase the number 
of oocytes collected. In this way the number of embryos available for transfer can be 
increased. 
No significant difference was found in the take-home baby rate after ICSI treatment in 
couples with microdeletions in the AZFc region of the Y chromosome, although due to the 
low frequency of microdeletion of the Y chromosome in oligozoospermic men the number 
of patients in this study was small. Research on a larger group of men may show an 
influence on both pregnancy and take-home baby rates. If the pregnancy and take-home 
baby rates in the current study are considered to be true rates, then increasing the number 
of ICSI treatments with oocyte retrieval in couples with Y deletions to at least 150 and 375 
respectively would be required to reach statistical significance at the 5% level, assuming a 
power of 80% for the statistical test. 
In the present group of patients we were confronted with azoospermia in one patient at the 
time of ICSI, though pre-treatment semen analysis from this patient revealed 
oligozoospermia. Men with an AZFc deletion sometimes have azoospermia. In The 
Netherlands it is not permissible at present to use spermatozoa from epididymal or 
testicular origin (TESE), and such men can only be treated at a fertility centre in another 
country. A progressive reduction in sperm number over several months has been 
described in some men with AZFc deletions (Girardi eta/., 1997; Simoni eta/., 1997), and 
it is these men who may benefit from early detection combined with cryopreservation of 
their semen. 
Although in some centres Y chromosome deletion analysis is still not offered, it is feasible 
that a couple can benefit from testing. First, little is known about the origin of male 
subfertility and about the consequences and risks of ICSI. Furthermore, it has been shown 
that a reasonable percentage (21 %) of couples with a microdeletion of theY chromosome 
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decide to refrain from ICSI treatment (Nap eta/., 1999). Therefore, we consider that we 
have an obligation to inform the couple with regard to their situation, and only then can 
they make a well-informed choice about their reproductive status. Moreover, as argued 
above, the finding of a Y chromosome microdeletion might be an adverse prognostic 
finding for future treatment, and patients must be informed of the situation and possible 
prognostic aspects (Krausz eta/., 2000). Deletions including and extending beyond the 
AZFc region (AZFb+c and AZFa+b+c) are associated with a total absence of testicular 
spermatozoa (Silber et a/., 1998), and the presence of AZFb deletion is a significantly 
adverse prognostic finding for TESE (Brandel! et a/., 1998). Nonetheless, mature 
spermatozoa have been found in ~50% of azoospermic patients with AZFc deletions. The 
present study adds to the ongoing discussion that couples with an AZFc deletion show a 
poorer outcome in ICSI treatment. However, further investigation using larger numbers of 
couples with AZFc microdeletions of the Y chromosome is required to study the possible 
prognosis of such deletions on ICSI treatment. 
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Abstract 
Purpose: Genetic aspects of male subfertility and the novelty of intracytoplasmic sperm 
injection (ICSI) as a new technique can influence the development of zygotes and children 
born after ICSI. Therefore, we evaluated the outcome of ICSI compared to in vitro 
fertilisation. 
Methods: Data from medical records of in total 233 pregnancies and the follow-up of 132 
children born after IVF and 120 after ICSI were retrospectively analysed. 
Results: No differences were found between ICSI and IVF for early embryonic 
development and obstetric outcome. In both groups the rate of women undergoing 
prenatal chromosomal diagnosis was low, 30.0%. The congenital malformation rate was 
3.0% after IVF and 1.7% after ICSI, which was not significantly different. Follow-up on 
development of children born after IVF and ICSI also showed no significant differences. 
Conclusions: Our results indicate that at this moment ICSI is a safe procedure. However 
a consistent prospective follow-up is still mandatory to exclude possible risks. 
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Introduction 
It is important to accumulate information about the safety of intracytoplasmic sperm 
injection (ICSI), because of theoretical risks and the novelty of the procedure. Collecting 
data on preembryonic development, obstetric and perinatal outcome and follow-up of 
children born after ICSI could indicate possible deleterious effects of ICSI on the normal 
development. 
Attempts to alleviate male-factor fertility problems through in vitro fertilisation (IVF) have 
resulted in low rates of success for men with abnormal sperm characteristics. ICSI, a 
technique that allows microinjection of a single spermatozoon into the oocyte cytoplasm, 
has been proven a successful alternative in treating male-factor subfertility (Palermo eta!., 
1992). 
Since the introduction of this technique there has been concern about the risks, although 
theoretically, of the ICSI procedure (DeJonge and Pierce, 1995; Vogt, 1995; Meschede et 
a!., 1995; Patrizio, 1995; Persson eta!., 1995): (i) Risks related to the ICSI technique: (a) 
the manipulative procedure itself, (b) injection of foreign material, (c ) mechanical 
activation of the oocyt, and (d) exclusion of the prezygotic selection processes. (ii) The use 
of abnormal sperm: (a) an increased frequency of constitutional chromosomal abnormali-
ties (De Braekeleer and Dao, 1991) and/or (b) chromosomal abnormalities in sperm 
(Moosani et a/., 1995), and (c) an underlying 'genetic' disorder (Froster, 1995) which 
causes male subfertility (e.g. cystic fibrosis and Y chromosome deletions) (Kremer eta/. , 
1997), (d) gamete maturation could be impaired in epididymal or testicular sperm (Ariel et 
a!., 1994). 
Micro-injection of spermatozoa, that have been selected from men with combined defects 
of sperm motility, morphology and concentration might lead to an increased incidence of 
abnormal embryos. These factors might influence the development of the zygote and 
increase the risk of abnormal offspring. 
There have been only a limited number of studies on the follow-up of ICSI. Most studies 
describe the successful experiences of ICSI in treating male subfertility (Calderon et al., 
1995; Palermo et al., 1995). 
At this moment follow-up studies show no abnormalities after ICSI. However Bonduelle et 
a/., (1998a) reports that there is a significant increase in chromosomal abnormalities after 
ICSI. Reclassification of birth defects of the prospective follow-up study from Brussels 
showed an increased risk of having a major birth defect (Kurunczuk and Bower, 1997). 
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Recently Bowen et a/., (1998) showed an increased risk of mild delays in mental 
development at 1 year in children conceived by ICSI. These results are not confirmed by 
the Brussels group (Bonduelle eta/., 1998b). 
More follow-up data on ICSI should be evaluated because of theoretical risks, the novelty 
of the procedure and the limited number of controversial follow-up results. Therefore we 
evaluated the safety of ICSI by comparing data of ICSI to IVF. 
Materials & Methods 
Patients included in this study became pregnant following treatment with IVF (group 1) or 
ICSI (group 2), in the year 1995, at the Reproductive Medicine service of the lnstitut 
Dexeus, Barcelona, Spain. In total, 1136 patients started a cycle of IVF or ICSI resulting in 
1 026 oocyte-collections. 
Technical procedures relating to methods of ovarian stimulation, oocyte collection, embryo 
culture and transfer, sperm preparation and microinsemination procedures were reported 
earlier (Calderon eta/., 1995; Boada eta/., 1997). ICSI was performed in cases of male-
factor fertility problems with impaired semen parameters or unexplained fertilization failure. 
Ejaculated semen was used in 90.1% of the cases. 2.7% had a microsurgical epididymal 
sperm aspiration and 7.2% had a testicular sperm extraction. 
Azoospermic men were offered chromosomal analysis, and in cases of congenital 
absence of the vas deferens, couples were screened for cystic fibrosis mutations. These 
couples were informed about their possible risks of cystic fibrosis and chromosomal 
abnormalities and subsequently a prenatal diagnosis was offered. 
Couples undergoing IVF or ICSI were also offered the possibility of prenatal chromosomal 
diagnosis by chorionvillus biopsy or amniocentesis in all cases of ICSI and in advanced 
maternal age (IVF and ICSI). 
We collected data from medical records on (a) early embryonic development, (b) obstetric 
outcome, ( c) perinatal outcome, and (d) follow-up of children born after IVF or ICSI. In all 
couples included in this study oocytes had been fertilized by either IVF or ICSI. In 11 
couples oocytes had been fertilized either by IVF or ICSI. Both treatments were initiated 
because of mild impaired semen parameters. In this group of patients it was not possible 
to determine the origin of the developing embryo and they were excluded from the study. 
130 
Two hundred thirty-three women had an ongoing pregnancy defined by a positive 
ultrasound after 8/9 weeks of gestation. Spontaneous abortion (n = 40) or an ectopic 
pregnancy (n = 3) occurred in 43 of 233 pregnancies. Patients were phoned and asked for 
cooperation when pregnancies proceeded beyond 20 weeks gestation. They were asked 
for additional information about obstetric outcome, perinatal outcome and follow-up of the 
children as noted by their medical doctor. In cases of any abnormality more information 
was collected from the gynaecologist and/or the pediatrician. With the use of standardized 
questionnaires we were able to collect complete data on 183 (92%) of 190 pregnancies 
proceeding beyond 20 weeks gestation. 
A widely accepted definition of major malformations was used, namely, malformations that 
generally cause functional impairment or require surgical correction. The remaining 
malformations were considered minor (Bonduelle eta/., 1996). Weights, lengths and head 
circumferences at birth and at the time of this study were compared to the Catalan national 
scale (Cyan eta/., 1998). Physical and mental development were also compared to this 
scale at the age of 1, 3, 5, 7, 9, 12, 15 and 18 months by a paediatrician. Furthermore, 
additional information on development was evaluated by standardized telephonic 
questionnaires compared to the age of the children (0.5 untill 1.5 years old). 
Data were statistically analysed using Student's t-test for comparison between ICSI and 
IVF. A P value of< 0.05 (two-tailed) was taken to represent statitiscal significance. 
Results 
Overall the mean maternal age was 33.67 years (range 25-44, SO 3.83): for IVF 34.3 
years (range 25-44, SD 3.94) and for ICSI, 33.1 years (range 25-44, SD 3.63). The mean 
maternal age in couples treated with ICSI was significantly (P < 0.05) lower than in the 
IVF-treated couples. The mean paternal age was not different in IVF or ICSI and was 
overall 35.9 years (range 25-69, SD 5.38). 
Preconceptional risk and risks during pregnancy like smoking, medication and diseases 
during pregnancy were equally divided in both groups. 
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Early pregnancy data 
The fertilisation rate was lower after ICSI (50.6%) than conventional IVF (66.4%), which is 
probably due to the learning process of ICSI. Embryo quality (Piachot eta/., 1990) was the 
same in IVF and ICSI cycles. 
The ongoing pregnancy rate per transfer was 27% after IVF and 23.2% after ICSI. 
Vanishing twins and triplets defined by the decrease in the number of gestational sacs 
and/or fetal heart activity per ongoing pregnancy was 9 of 120 (7.5%) in IVF and 7 of 113 
(6.2%) in ICSI. The rates of spontaneous abortion before 20 weeks of gestation were 22 of 
120 (18.3%) in IVF and 18 of 113 (15.9 %) in ICSI. 
Ectopic pregnancy, an ongoing pregnancy implanted outside the uterus, was observed 
after IVF in only 3 of 120 (2.5%) pregnancies. 
The overall ongoing pregnancy rate after 20 weeks of gestation was 190 of 233 (81.5%). 
Chromosomal analysis 
One chromosomal abnormality, 45,XY, t(13q, 14q) was found in 1 of 23 azoospermic men 
(4.3%).This couple at risk of inheriting a chromosomal abnormality was informed about 
possible risks and a prenatal chromosomal diagnosis was offered when a viable 
pregnancy was established . 
Prenatal diagnosis was performed using amniocentesis in all cases. The rate of couples 
undergoing this diagnosis was 57 of 190 = 30 %, the same rate in both groups. Although 
this screening was offered in all cases of ICSI, advanced maternal age was the main 
reason after IVF or ICSI. In two cases of ICSI pregnancies, amniocentesis showed an 
abnormal karyotype. One was inherited from the father and one was 'de novo'. The rate of 
a de novo chromosomal abnormality per performed karyotype detected by prenatal 
diagnosis karyotype is 1/28 (3.6%) after ICSI (Table 1). 
Table I. Abnormal prenatal karyotypes 
Result Origen 
45,XY, t(13q, 14q) Inherited father 
45, XO De novo 
Outcome 
Healthy liveborn 
Selective abortion * 
*Twin pregnancy, the other fetus had a normal karyotype 
132 
Maternal age 
36 
31 
Paternal age 
39 
33 
Obstetric outcome 
The overall mean gestational age was 38 weeks (range 25-42, SD 2.82) and did not differ 
between the two groups. The rate of multiple pregnancy was the same in IVF and ICSI. 
Overall 120 of 183 (65.6%) were singletons, 57 of 183 (31.1 %) twins and 6 of 183 (3.3%) 
triplets. 
Prematurity, live birth before 37 weeks of gestation, occurred in 22 of 96 (22.9%) after IVF 
and in 15 of 87 (17.2%) after ICSI. Prematurity was associated mainly with multiple preg-
nancy, and subsequently there was an increase in problems occurring at birth, 16% in 
twins and 43% in triplets. Problems occurring at birth were the same in the groups of 
children born after IVF, 12 of 132 (9.1 %), or ICSI, 11 of 120 (8.3%). All these children 
needed to spend some time in the incubator for observation due to prematurity. Additional 
problems at birth were of respiratory (n = 5), cerebral (n = 2) and intestinal (n = 1) origin. 
The mode of delivery is summarized in Table II. The rate of deliveries without any 
problems (spontaneous vaginal and elective cesarean deliveries) was 66.7%. The 
remaining cases had instrumental vaginal or urgent cesarean deliveries. No statistical 
differences were discovered between the two groups. 
Table II. Mode of delivery 
Mode of delivery IVF (n = 96) ICSI (n = 87) TOTAL (n = 183) 
Spontaneous vaginal delivery 37/96 27/87 64/183 
(38.5%) (31.0%) (34.9%) 
Instrumental vaginal delivery 6/96 8/87 14/183 
(6.3%) (9.2%) (7.7%) 
Elective cesarean section 28/96 30/87 58/183 
(29.2%) (34.5%) (31.7%) 
Cesarean section on indication 25/96 22/87 47/183 
(26.0%) (25.3%) (25.7%) 
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Perinatal and neonatal data 
The number of children born from 183 pregnancies beyond 20 weeks gestation was 252 
(132 IVF and 120 ICSI). 
Stillbirth, intrauterine fetal death after 20 weeks of gestation, was 4 of 132 (3.0%) and 1 of 
120 (0.8%) after IVF and ICSI respectively. The total of liveborns was 247: 128 after IVF 
and 119 after ICSI. 
The early neonatal death, death of a live-born infant during the first days after birth, was 1 
of 128 = 0.8% in IVF and 2 of 117 = 1.7% in ICSI. Tables Ill and IV show the perinatal 
mortality cases, the sum of stillbirth and early neonatal death (no statistical differences). 
Table Ill. Perinatal mortality 
Definition 
Stillbirth 
Early neonatal death 
Perinatal mortality 
IVF 
4/132 (3.0%) 
1/128 (0.8%) 
3.8% 
Table IV. Clinical history of perinatal mortality 
Number of children Gestational age 
34.5 
2 25 
41 
37.5 
28.5 
2 26 
ICSI 
1/120 (0.8%) 
2/117 (1.7%) 
2.5% 
IVF /ICSI 
IVF 
IVF 
IVF 
IVF 
ICSI 
ICSI 
Total 
5/252 (2.0%) 
3/245 (1.2%) 
3.2% 
Cause 
Intrauterine growth retardation 
in twin pregnancy 
Cervical incompetence 
Fetal Asphexia 
( occlussion of birth cord) 
Exencefaly 
(died 3 days after birth) 
Abruptio placenta 
Cerebral hemorrhage died 
2 I 4 days after birth * 
* In this triple pregnancy the third child died because of hydrocephalus after 4 months of age 
The female I male ratio was equally divided and there were no differences between 
children born after IVF and ICSI. 
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Neonatal measurements for 252 children are listed in Table V. Birthweight and head 
circumference compared to the gestational age were not significantly different between 
both groups. Children born after ICSI were significantly 1.1 em less tall than children born 
after IVF. However this difference was within the normal range of length compared to 
gestational age in the national catalan register. 
Table V. Neonatal measurements 
Method Birthweight (g) Birthlength (em) Head circumference (em) 
IVF (n = 132) 2939 48.9 * 34.6 
SD 695.7 2.7 1.9 
ICSI (n = 120) 2857 47.8 * 33.8 
SD 575.3 3.6 2.0 
Total (n = 252) 2898 48.4 34.2 
SD SD= 654.7 SD = 3.3 SD = 2.0 
* P-value = 0.025 in t-test 
Congenital malformations are listed in Table VI. The rate of major congenital malformation 
was 4 of 132 (3.0%) after IVF and 2 of 120 (1.7%) after ICSI, the differences being 
nonsignificant. Minor malformations were not observed in medical reports or in telephonic 
standardized questionairres. 
Table VI. Congenital malformations 
IVF 
4/132 (3.0%) 
Exencefaly 
Hemivertebrae 
Hydronefrosis * 
Vesica-ureteric reflux* 
Malformation 
ICSI 
2/120 (1.7%) 
Pes equinovarus 
Hydronephrosis* 
Total 
6/252 (2.4%) 
*Clinical evaluation showed no gross anatomical genito-urinary tract malformation 
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Follow-up of children born after IVF and /CS/ 
All children surviving the perinatal period (n = 244) were between 0.5 and 1.5 years old at 
the time of the study. Follow-up data were compared to the Catalan national 
developmental scale. Measurements of weights, lengths and head circumferences of the 
children at the time of the study were not significantly different between IVF and ICSI. 
Problems occurring during the development of children born after IVF and ICSI are divided 
into physical problems or mental developmental problems. We found no significant 
differences between IVF and ICSI for physical and/or mental development. Developmental 
problems, both physical and mental, were discovered in 3 of 127 (2.4%) children after IVF 
and in 4 of 117 (3.4%) after ICSI. The developmental delays were minor and of unknown 
origin. 
There were two children who needed medical treatment: one child born after IVF had 
recurrent convulsions and mental developmental delay and one child born after ICSI 
needed treatment because of hypothyroidism. 
Discussion 
It is important to accumulate information on ICSI, whether the zygotes develop normally 
into children who do not show more abnormalities at birth and during their development. 
This is important not only because of the risks on theoretical grounds, but also because of 
the novelty of this technique. 
The effects of micromanipulation during ICSI are probably limited. Our results did not show 
any difference on the early embryonic development between the two groups. This has also 
been shown in animal models (Bras et a!., 1994; Motoisho et a!., 1996). This study and 
others (Calderon et a/., 1995; Wisanto et a/., 1996) indicate a limited effect on early 
embryonic development. However, deleterious effects could still be discovered and there 
is a risk of parthenogenetically activating an oocyte. This could induce a higher incidence 
of maternally derived chromosomal abnormalities, especially in women of advanced age. 
We did not discover any significant differences between IVF and ICSI for obstetric 
outcome, perinatal outcome and follow-up of children born after ICSI. The congenital 
malformation rate after ICSI was not significantly different from IVF and seemed to be in 
the same range of the national register 1.6 % (Salvador eta/., 1997). 
136 
The relatively high rate of cesarean section, prematurity, and problems at birth in our study 
could be caused by increased maternal age and/or multiple pregnancy due to multiple 
embryo transfer. The high rate of cesarean section after IVF or ICSI might also be due to 
the final decision of the physician and couple, choosing, in their opinion, the best method 
of delivery after long-term fertility problems. 
At this moment follow-up studies (Bonduelle et a/., 1996; Bonduelle et a/. 1998a/b; 
Govaerts et at. 1998; Palermo et at. 1996; van Steirteghem et at., 1998; Wennerholm et at. 
1996) show a normal obstetric outcome, no increase in congenital malformations and 
normal development of children born after ICSI. However, there are some concerns that 
ICSI might somehow be responsible for an increased frequency of chromosomal 
abnormalities and fertility problems in children born after ICSI (Bonduelle et at., 1998a; In 't 
Veld et at., 1995; Kremer et at., 1997). At present they do not show phenotypic 
abnormalities in children born after ICSI (Bonduelle et at., 1998b). Moreover, Bowen et at., 
(1998) showed a significant developmental delay in children born after ICSI. Our results 
show a normal development of children born after ICSI, but the national Catalan 
developmental scale (Cyan et at., 1998) may not be accurate enough to detect 
developmental impairment after ICSI. 
Prospective studies are prone to detect a higher rate of abnormalities than retrospective 
studies (Simpson, 1996). We did not discover any minor malformation, which could be due 
to our retrospective study design. Comparing data on an international basis can be influen-
ced by the difference in data collection. Most centres have only a limited and retrospective 
study on the risks in ICSI (van Steirteghem et at., 1998). Conclusions on the risks in ICSI 
can thus be controversial (Bonduelle eta/., 1996; Bonduelle eta/., 1998a/b; Bowen eta/., 
1998; Van Steirteghem et at., 1998). 
Prenatal chromosomal diagnosis in our centre in the year 1995 was 30% in both groups, 
although couples were informed about the genetic risks of ICSI. A low uptake of prenatal 
diagnosis in ICSI is reported earlier (Payne and Matthews, 1995). Because of the risk of 
miscarriage, the present follow-up results, and the unknown phenotypic consequence of 
some chromosomal abnormalities, people may decide not to have a prenatal 
chromosomal diagnosis. In the prospective study from Brussels (Bonduelle eta/., 1998a) 
the uptake of prenatal diagnosis was 55%. 
We discovered one case of a de novo chromosomal abnormality (1/28; 3.6%). The 
numbers are too small to be of statistical value. Small numbers and screening patients at 
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high risk could be responsible for high frequency of chromosomal abnormalities (In 't Veld 
et at., 1995). 
Male candidates for ICSI should have a detailed genetic work-up: family history, 
chromosomal analysis, detection genes involved in spermatogenesis, and genetic 
counseling (Tuerlings et at., 1997). It is important to indicate the group at risk for 'genetic' 
abnormalities, although their origin is difficult to detect (Bonduelle et at., 1998a; Van Opstal 
et at., 1997). The affected couple needs to understand the risks for the offspring and what 
preventive measures can be taken. In some cases of genetic abnormalities the couple can 
be offered a prenatal diagnosis (Baschat et at., 1996; Testart et at., 1996). 
More investigation is needed concerning genetic causes in males selected for ICSI and 
the risk(s) for the offspring. Our results show that ICSI is a safe procedure, but 
international prospective follow-up is still mandatory. 
Acknowlodgements 
The authors wish to thank the biologists of the lnstitut Universitari Dexeus for assistance, and M. Bergmans, 
D. Braat, J. Hanekom, J. Kremer and J. Tuerlings for their critical reading of the manuscript. This study was 
financially supported by the SWOL, Stichting Wetenschappelijk onderzoek Limburg. 
138 
References 
Ariel, M., Cedar, H., Me Carrey, J. et a/. (1994) Developmental changes in methylation of 
spermatogenesis-specific genes include reprogramming in the epididymis. Nat. Genet., 7, 69-
73. 
Baschat, A., Kupker, W., AI Hasani, S. (1996) Results of cytogenetic analysis in men with severe 
subfertility prior to intracytoplasmic sperm injection. Hum. Reprod., 11, 330-333. 
Boada, M., Coroleu, B., Calderon, G. (1997) Results of the IVF program at the Institute 
Universatari Dexeus 1996. Prog. Obst. Gin., 40, 691-699. 
Bonduelle, M., Wilikens, A., Buysse, A. eta/. (1996) Prospective follow-up study of 877 children 
born after ICSI, with ejaculated epididymal and testicular spermatozoa and after replacement 
of cryopreserved embryos obtained after ICSI. Hum. Reprod., 11: Suppl 4, 131-159. 
Bonduelle, M., Aytoz, A., Van Assche, E. eta/. (1998a) Incidence of chromosomal aberrations in 
children born after assisted reproduction through intracytoplasmic sperm injection. Hum. 
Reprod., 13, 783-788. 
Bonduelle, M. (1998b) Mental development of 201 ICSI children at 2 years of age. Lancet, 
research letter, 352, 1553. 
Bowen, J., Gibson, F., Leslie, G. (1998) Medical and developmental outcome at 1 year for children 
conceived by intracytoplasmic sperm injection. Lancet, 351, 1529-1534. 
Bras, M., Dumoulin, J., Pieters, M. eta/. (1994) The use of a mouse zygote quality control system 
for training purposes and toxicity determination in an ICSI program. Hum. Reprod., 9, 23-24. 
Calderon, G., Belil, 1., Aran, B. eta/. (1995) Intracytoplasmic sperm injection versus conventional 
in-vitro fertilization: first results. Hum. Reprod., 10, 2835-2839. 
Cyan Eds (1998) Taula de desenvolupmant psicomotor, Departament de Sanitat i Seguritat Social, 
Generalitat de Catalunya, Barcelona. 
De Braekeleer, M. and Dao, T. (1991) Cytogenetic studies in male infertility: a review. Hum. 
Reprod., 6, 245-250. 
DeJonge, C. and Pierce, J. (1995) Rewards and risks in ICSI. Hum. Reprod., 10, 2518-2528. 
Froster, U. (1995) Genetische risiken bei In Vitro Fertilisation. Geburtsh. Frauenheilk., 55,121-126. 
Govaerts, 1., Devreker, F., Koenig, I. et a/. (1998) Comparison of pregnancy outcome after 
intracytoplasmic sperm injection and in-vitro fertilization. Hum. Reprod., 13, 1514-1518. 
In 't Veld, P., Brandenburg, H., Verhoeff, A. eta/. (1995) Sex chromosomal abnormalities and ICSI. 
Lancet, 346, 773-77 4. 
Kremer, J., Tuerlings, J., Meuleman, E. eta/. (1997) Microdeletions of the Y chromosome and 
ICSI: from gene to clinic. Hum. Reprod., 12:687-691. 
Meschede, D., De Geyter, C., Kurinczuk, J. et a/. (1997) Birth defects in infants conceived by 
intracytoplasmic sperm injection: an alternative interpretation. BMJ, 315, 1260-1266. 
139 
Moosani, N., Pattinson, H., Carter, M. eta/. (1995) Chromosomal analysis of sperm from men with 
idiopathic infertility using sperm karyotyping and fluorescence in situ hybridization. Fertil. 
Steril., 64, 811-817. 
Motoishi, M., Goto, K., Tomita, K. et a/. (1996) Examination of the safety of intracytoplasmic 
injection procedures by using bovine zygotes. Hum. Reprod., 11, 618-620. 
Nieschlag, E. eta/. (1995): Genetic risk in micromanipulative assisted reproduction. Hum. Reprod., 
10, 2880-2886. 
Palermo, G., Joris, H., Devroey, P. (1992) Pregnancies after intracytoplasmic injection of single 
spermatozoon into an oocyte. Lancet, 340,17-18. 
Palermo, G., Cohen, J., Alikani, M. eta/. (1995) Development and implementation of ICSI. Reprod. 
Fertil. Dev., 7, 211-218. 
Palermo, G., Colombero, L., Schattman, G. eta/. (1996) Evolution of pregnancies and initial follow-
up of newborns delivered after intracytoplasmic sperm injection. JAMA, 276, 1893-1897. 
Patrizio, P. (1995) Intracytoplasmic sperm injection (ICSI): potential genetic concerns. Hum. 
Reprod., 10, 2520- 2523. 
Payne, D. and Matthews, C. (1995) ICSI - Clinical results from the reproductive medicine unit, 
Adelaide. Reprod. Fertil. Dev., 7, 219-227. 
Plachot, M., Mandelbaum, J., Junca, A. eta/. (1990): Qualite de l'oocyte et de l'embryon et resultat 
de Ia FIV. Contraception Fert. Sex., 18, 636-638. 
Persson, J., Peters, G., Saunders, D. et a/. (1996) Genetic consequences of ICSI. Hum. 
Reprod., 11, 921-932. 
Salvador, J. and Plasencia, A. (eds) (1997) Registre de defectes congenits de Ia Ciutat de 
Barcelona. Servei d'lnformacio Sanitaria. lnstitut de Ia Salut. lnstitut de Ia Salut Publica. 
Ajuntament de Barcelona. 
Simpson, J. (1996) Registration of congenital anomalies in ART populations: pitfalls. Hum. 
Reprod., 11, Suppl 4:81-88. 
Testart, J., Gautier, E., Brami, C. eta/. (1996) Intracytoplasmic sperm injection in infertile patients 
with structural chromosome abnormalities. Hum. Reprod., 11, 2609-2612. 
Tuerlings, J., Kremer, J., Meuleman, E, eta/. (1997) The practical application of genetics in the 
male infertility clinic. J. Andr., 18, 576-581. 
Van Opstal, D., Los, F., Ramlakhan, S. eta/. (1997) Determination of the parent of origin in nine 
cases of prenatally detected chromosome aberrations found after intracytoplasmic sperm 
injection. Hum. Reprod., 12, 682-686. 
Van Steirteghem, A., Bonduelle, M., Hamberger, L. et a/. (1998) Assisted reproduction by 
intracytoplasmic sperm injection: a survey on the clinical experience in 1994 and the children 
born after ICSI, carried out until 31 December 1993. Hum. Reprod., 11, Suppl 4:160-186. 
Vogt, P. (1995) Genetic aspects of artificial fertilization. Hum. Reprod., 10, Suppl. 1 :128-137. 
Wennerholm, U., Bergh, C., Hamberger, L. (1996) Obstetric and perinatal outcome of pregnancies 
following intracytoplasmic sperm injection. Hum. Reprod., 11, 1113-1119. 
140 
Wisanto, A., Bonduelle, M., Camus, M. eta/. (1996) Obstetric outcome of 904 pregnancies after 
intracytoplasmic sperm injection. Hum. Reprod., 11, Suppl 4:121-130 
141 

General Discussion 
General Discussion 
This thesis describes the familial occurrence and the search for genes involved in male 
subfertility together with its clinical consequences. In Part I we presented the results of the 
family studies in male subfertility and the familial occurrence and phenotypes of subfertile 
men. In Part 2 the search for different genes involved in human male subfertility is 
described. No new genes could be identified using linkage analysis and candidate gene 
research. In the last part, 3, of this thesis we presented our studies on the clinical 
implications of the genetic aspects of male subfertility. The influence of counselling, the 
decision-making and the outcome of treating couples dealing with microdeletions of the Y 
chromosome is described. Lastly, we presented a retrospective follow-up study on ICSI. 
Up till now ICSI seems to be a safe procedure, but prospective follow-up studies are still 
needed to warrant the safety of ICSI. 
Family studies in male subfertility 
We showed that male subfertility appears to have a familial occurrence. Autosomal 
recessive, sex limited autosomal dominant or X-linked inheritance may be involved. 
However, fertility problems among relatives are underestimated using a family history, 
probably due to information bias. Knowledge of fertility problems travels selectively among 
families causing substantial misclassification. This misclassification hinders quantitative 
assessment of familial clustering. 
Identification of subfertile men with a positive family history may be influenced by this 
"taboo bias". Male subfertility is a difficult topic to discuss. When taking a family history we 
obtain data on fertility problems in the family second handed. Involuntary childlessness 
may be the only hint that the couple faced fertility problems. The exact origin of the fertility 
problem among male relatives can only be identified by performing the standard clinical 
investigation. 
The taboo on fertility problems among subfertile men and their family members has 
hindered the coopertion undergoing a clinical investigation on fertility problems in these 
relatives. 
On the other side the hypothesis of a familial occurrence of male subfertility may also be 
discussed because of another bias called: recall bias. In other words differences found in 
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this case control study may be caused by the fact that subfertile men are better informed 
on fertility problems in their families than their controls. Our study confirms the earlier 
results on the familial occurrence of male subfertility (Budde et a/., 1984; Lilford et a/., 
1994; Meschede eta/., 2000). A new finding in this family study is the increase of male 
subfertility among men on the maternal side of the subfertile men. Therefore we 
hypothesize an X-linked inheritance in these families. A recent study on the abundance of 
X-linked expressed in mice spermatogonia may support this hypothesis (Wang et a/., 
2001 ). 
In the study on the phenotypic characteristics it is shown that subfertile men with a familial 
occurrence of male subfertility more often have normal levels of FSH and LH. This 
phenomenon is also observed in men with microdeletions in the AZFc regions. The 
pathogenesis of the genetic aspects in these men probably disturbs spermatogenesis 
without interfering with the hormonal function of the Sertoli cells. It should also be noted 
that studying the single cases of male subfertility show higher levels of FSH sometimes 
accompanied by cryptorchidism. These observations are stimulated by the fact that some 
candidate genes of cryptorchidism have been described (Krausz eta/., 2000; Gianotten et 
a/., 2001 ). 
This clinically well-defined group of subfertile men was the basis for our search on the 
molecular genetic aetiology of male subfertile. 
Molecular genetic studies in male subfertility 
We searched for the genetic aetiology of male subfertility using two strategies: (a) Linkage 
analysis and (b) Candidate gene analysis. Unfortunately, we have not been able to identify 
new genes involved in male subfertility. 
Two out of 253 families were cooperative and suitable for a linkage analysis. In this thesis 
we described X-linkage analysis in one family with 5 subfertile maternal nephews. The 
pedigree suggested an X-linked inheritance, but this could not confirm by molecular 
linkage analysis. So we hypothesize the existence of an autosomal dominant trait of male 
subfertility with sex limited expression. 
In addition we investigated the role of the candidate genes DAZLA and the Androgen 
receptor gene in male subfertility. In the DAZLA gene no pathogenic mutations could be 
145 
identified. In addition we found no correlation between the length of the CAG repeat in the 
AR gene and male subfertility. 
Two factors may be important in the difficulty to identify the molecular genetic origin of 
male subfertility. The frequency of chromosomal abnormalities and microdeletions of theY 
chromosome is higher in azoospermic men than in men with an OAT. Our group of 
subfertile men mainly have an OAT instead of an azoospermia. The size of the group 
subfertile men at risk for a genetic aetiology like azoospermic men may be too small. 
Secondly, candidate genes in male subfertility like DAZLA are first identified in the mouse 
model. Candidate genes, although proven in knock out animal models, may not always be 
important in humans. 
ICSI is the choice of treatment in severe male subfertility nowadays and bypasses a 
number of stages of natural fertilization. There is a risk that ICSI may increase the 
transmission of paternal mitochondrial DNA. Knowledge of the fate and transmission of 
paternal mitochondrial DNA is important since mutations in mitochondrial DNA have been 
described in oligozoospermic males. This risk seems limited, as we found no evidence that 
ICSI increases the risk of paternal transmission. 
Counselling and outcome of intracytoplasmic sperm injection 
Counselling the couple on the genetic aspects of male subfertility enables them to make 
their own and well-informed choice about their reproduction. Therefore it is important to 
study the clinical implications of the genetic aspects in male subfertility. These aspects 
influence the counselling, decision-making and outcome of the treatment. It is shown that 
most couples dealing with a microdeletion of theY chromosome choose ICSI. Counsellors 
should be aware of the phenomenon that several aspects of genetic counselling are 
related to the decision making of the couple as shown in couples dealing with 
microdeletions of the Y chromosome. Probably this is also the case when counselling 
couples with other forms of male subfertility with a genetic origin. In this thesis it is shown 
that most couples dealing with a microdeletion of the Y chromosome choose ICSI. In a 
study by Giltay et a/., (1999), the majority (56%) of the couples with a chromosome 
abnormality present in the subfertile male partner did not refrain from ICSI. 
Problems in studying counselling and reproductive decisions in genetically determined 
male subfertility are the relatively low frequency of each specific genetic abnormality 
146 
among subfertile men. Another important aspect is that it seems unethical to perform a 
study in which some couples get counselling and others not. However, this theoretical 
study design is necessary to evaluate correctly the influence of the diverse aspects of 
counselling and decision-making. 
When a microdeletion of the Y chromosome is diagnosed our study shows that most 
couples choose ICSI (Nap eta/., 1999). The couple should also take into account that the 
success rates may be decreased when using ICSI, besides the fact that the male offspring 
inherits the same deletion and presumably the related fertility problem (Mulhall et a/., 
1997). We demonstrated a decreased fertilisation rate and embryo quality after ICSI in 
oligozoospermic men with microdeletions in the AZF c region of the Y chromosome. The 
pregnancy rate and take home baby rate is also lower among these couples, but larger 
numbers of couples are required to study the possible prognosis of such deletions on ICSI 
treatment. 
In general, it is of outmost importance to investigate the safety of ICSI as a new assisted 
reproductive technique. Therefore, in every clinic performing ICSI follow-up studies are 
necessary. In a retrospective follow-up study we have shown that ICSI seems to be a safe 
procedure. However the retrospective study design, the small number of pregnancies after 
ICSI with surgical retrieved spermatozoa and the inability to study the long term follow-up, 
influences the accuracy of this and other studies. 
Future follow-up study by Bonduelle et a!., (2001) confirms earlier results and shows no 
increase of congenital malformations even after ICSI in men with very low sperm 
parameters. Althlough, others find that the number of de novo chromosomal abnormalities 
in ICSI children is increased (1.6%) especially after the use of testicular sperm (Bajirova et 
a!., 2001 ). Investigating the safety of ICSI needs a blinded study design with appropriate 
control groups and data collection that allows correction of confounding factors. 
Guidelines for the counselling of couples undergoing ICSI 
How should we apply the current knowledge on the genetic aspects of male subfertility 
and the outcome of ICSI in clinical practice? The couple should be informed in an optimal 
and objective way so they can make their own well-informed decision, desirably based on 
(inter)national guidelines. A questionnaire from the European Society of Human 
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Reproduction (ESHRE) on the way of screening and counselling of ICSI patients in the 
different countries shows that there are many differences (Kremer eta/., 2000). 
First the couple should be informed that the aetiology of male subfertility is often unknown 
and subsequently no other treatments are available. Most of the time ICSI remains the 
only treatment for the couple to have offspring of both partners. But people should also 
have the opportunity to choose for donor insemination, adoption or to remain childless. 
The information on the complications of the medication and the chance of multiple 
pregnancies in ICSI should be similar as in conventional IVF. Furthermore the information 
should be focussed on the specific theoretical risks of ICSI. These can be divided into the 
theoretical risks of the ICSI procedure itself or the risks of using abnormal sperm. 
The risk of using abnormal sperm is important, because of the increased frequency of a 
chromosomal abnormality in subfertile men and the possibility of a microdeletion of the Y 
chromosome. The investigation of these two possible genetic abnormalities should be 
offered to the subfertile men of the couple undergoing ICSI. In cases of a genetic 
abnormality a (genetic) counsellor can inform them on the aetiology and the 
consequences. In cases of a CBAVD a CFTR mutation screening should be offered to the 
male and female partner following the same procedure as mentioned above. 
At this moment it is known that there is an increase of male subfertility among relatives of 
subfertile men. Genetic factors probably play an important role, but couples can not be 
informed on the exact risk of transmitting the fertility problem to the offspring. Moreover, a 
genetic factor cannot be ruled out even if the family history does not show a (male) relative 
with fertility problems. The value of family history in male subfertility should still be 
evaluated. In some particular cases it may be helpful finding the correct diagnosis and 
counsel the couple, like in Kartagener's syndrome and globozoospermia. 
At this moment there is no evidence that ultrasound during a pregancy established after 
ICSI is indicated. Invasive prenatal karyotyping after ICSI is discussed, because of the 
increased risk of de novo chromosomal abnormality in children born after ICSI (1.66% vs. 
0.8%). However the risk is only slightly increased and the procedure can induce a 
miscarriage. Moreover the chromosomal abnormalities are often sex chromosomal 
abnormalities and balanced translocations and the risks for the offspring seem limited. 
Care must be taken that many ICSI couples choose advanced ultrasound exam instead of 
screening the ICSI offspring. This is still under debate and more research is needed to 
indicate that advanced ultrasound is an appropriate screening device in ICSI pregnancies. 
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Overall, couples should be informed that ICSI seems to be a safe and successful 
treatment. Unfortunately, the long-term follow-up data on ICSI are unknown and the 
couples and the professional people involved in the treatment of ICSI have to deal with 
these uncertainties. In the Netherlands the Dutch Society of Obstetrics and Gynaecology 
have provided a patient information brochure, documenting information and bottlenecks 
when choosing ICSI (Giltay eta/., 2001 ). 
Research on male subfertility 
In the last decades no new treatment in male subfertility has been successful. Only in the 
rare case of a deficiency of gonadotropic hormones subfertile men can be treated with 
pulsatile Gonadotropin Releasing Hormones (GnRH) or gonadotropins (Nieschlag, 2000). 
Other treatments do not focus on the improvement of semen parameters and this is 
stimulated by the fact that the exact aetiology of male subfertility is unknown. 
Evidence based medicine is considered as the state of the art in good clinical practice. 
However, medical doctors and patients often seek treatments that are based on theoretical 
ground or are so called experienced or authority based (Comhaire, 2000). This tendency is 
stimulated by the fact that often no cause is found and no treatment is available. In this 
time era the dominating factor in management decisions should not be based on the 
physician's personal authority and experience. The situation makes it tempting for some 
physicians to apply innumerable empirical therapeutic procedures whose effectiveness 
remains uncertain. Many errors in judgement - not only in andrology- can be attributed to 
this attraction to meddlesome but unproven treatments. 
Further research should be performed by the rules of evidence-based andrology. 
Hopefully, because of the decreasing taboo on sexuality and probably on fertility problems 
it will become easier to study male subfertility. Research depends on the cooperation of 
subfertile men. 
In our studies we were confronted with the taboo on discussing fertility problems. The 
impact of fertility problems on sociopsychological factors influences coping with fertility 
problems and the supposed stigma associated with subfertility. For instance in research 
on donor insemination it is shown that the stigma associated with infertility forces secrecy 
and lack of openness (Turner and Coyle, 2000). In a recent study by Conrad eta/., (2001) 
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it was shown that some subfertile men developed psychosomatic problems coping with 
the fertility problems, so called alexithymia. 
The last decades it is commonly known that fertility problems can be caused by female as 
well as male factors. This development changed the position of men in their contribution to 
reproduction. During history and in different cultures men were considered the head of a 
family associated with strength and leadership. Subfertility seems to be controversial with 
these aspects. One may now consider a new explanation for the story in the old-testament 
of Abraham and Sarah who remained childless. The current explanation is that Sarah 
suffered from fertility problems. It is time to consider the fact that Abraham successfully 
treated his fertility problem marrying a young superfertile woman. 
The changes in the western world are gradually influencing the position of the modern 
man and will eventually influence his social position in reproduction. Hopefully research on 
male subfertility will benefit from these changes. 
Concluding remarks 
In this thesis we have found clinical evidence for still unknown genetic factors in male 
subfertility. This knowledge can be used for counselling the couple dealing with male 
subfertility. It is important to continue the data collection on clinical characteristics and 
family history of subfertile men. A large number of clinically well-defined male subfertility 
may facilitate the search for new candidate genes involved in male subfertility. Male 
subfertility represents a heterogeneous etiological entity. There is a need for more basic 
research into the causes and the clinical approach of male subfertility. 
The clinical impact of these genetic factors involved in male subfertility deserves further 
study. The dialogue between people working in the field of reproductive medicine and 
molecular geneticists will be required to imply new genetic knowledge in clinical practice. 
Important aspects for future research are cost-effectiveness of genetic aspects and 
diverse ethical consequences. It can be argued if people benefit from information on the 
(genetic) risks in ICSI and the change of transmitting fertility problems. Moreover, people 
have the right choosing not to be informed on the genetic aspects of male subfertility. The 
increasing knowledge on the genetic origin of disorders, like male subfertility, will probably 
lead to more ethical concerns. 
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11NLEIDING 
ICSI is de afkorting van intracytoplasmatische sperma-injectie. Men brengt hierbij in het 
laboratorium een zaadcel via een zeer dunne naald in een eicel om deze te bevruchten. 
Het is dus een behandeling om een zwangerschap te Iaten ontstaan. 
In deze folder gaan we kort in op de redenen voor een ICSI- behandeling en het verloop 
ervan. De gynaecoloog en de patientenvereniging Freya kunnen u meer informatie geven. 
Ook is een cd-rom verkrijgbaar die de behandeling in beeld en geluid uitlegt. 
Hier komen vooral gezondheidsrisico's aan bod. Het accent ligt op de gezondheidsrisico's 
voor het kind en de mogelijke onderzoeken voor het begin van de behandeling en tijdens 
de zwangerschap. 
2 WAT ZIJN REDENEN VOOR ICSI? 
De belangrijkste reden voor een ICSI-behandeling is een zeer laag aantal beweeglijke 
zaadcellen. Ook als na twee behandelingen met IVF (in vitro fertilisatie) geen bevruchting 
is opgetreden of als zich antistoffen in het sperma bevinden, kan de mogelijkheid van ICSI 
ter sprake komen. 
3 HOE GEBEURT ICSI? 
Bij een ICSI-behandeling dient men net als bij IVF hormonen aan de vrouw toe. Deze 
hormonen Iaten in de eierstokken een groot aantal follikels (met vocht gevulde blaasjes) 
groeien. In iedere follikel bevindt zich een eicel. Na ongeveer twee weken 
hormoonbehandeling prikt de arts deze follikels onder echo-controle aan. De zo verkregen 
eicellen bevrucht men daarna in het laboratorium. Als er uit de bevruchte eicellen 
embryo's ontstaan, plaatst de arts die een paar dagen later in de baarmoeder. 
Het verschil tussen IVF en ICSI is de manier waarop de bevruchting in het laboratorium 
gebeurt. Bij IVF brengt men een eicel sam en met ongeveer 100.000 zaadcellen en wacht 
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men op spontane bevruchting door een van de zaadcellen. Bij ICSI brengt een 
laboratoriummedewerker een enkele zaadcel in een eicel. 
4 GEZONDHEIDSRISICO'S VOOR DE VROUW BIJ ICSI 
Zowel bij ICSI als bij IVF worden de eierstokken met hormonen gestimuleerd en 
aangeprikt, en plaatst de arts meestal twee of soms meer embryo's in de baarmoeder. De 
zeldzame complicaties die hierbij kunnen ontstaan, zijn voor beide behandelingen 
dezelfde: 
- overstimulatie, een ernstig ziektebeeld met klachten van snelle gewichtstoename, hevige 
buikpijn en/of misselijkheid, 
- bloeding of infectie na het aanprikken van follikels. 
De gezondheidsrisico's van deze behandelingen op langere termijn voor vrouwen zijn 
onbekend. Zowel bij IVF als bij ICSI geeft men hormonen om follikels te Iaten groeien. 
Daardoor maken de eierstokken veel oestrogene hormonen. Er is weliswaar een verband 
aangetoond tussen langdurig gebruik van oestrogenen voor andere doeleinden en een 
Iicht verhoogde kans op borst- en baarmoederkanker, maar een dergelijke relatie is tot nu 
na IVF- en ICSI-behandelingen niet gevonden. Gegevens over deze risico's op de lange 
termijn zijn echter nog niet beschikbaar. Hetzelfde geldt voor de kans op eierstokkanker. 
Als gevolg van beschadiging door het rijpen en aanprikken van meerdere follikels is 
theoretisch een verhoogde kans op dit soort kanker denkbaar. 
Ook hier geldt: tot nu toe is geen verhoogde kans op eierstokkanker aangetoond, maar 
gegevens over de gezondheid van vrouwen vele jaren na een IVF- of ICSI-behandeling 
zijn er nog niet. 
5 GEZONDHEIDSRISICO'S VOOR KINDEREN DIE NA ICSI GEBOREN ZIJN 
5.1 Risico's die samenhangen met de bevruchting buiten het lichaam 
Zowel bij IVF als bij ICSI vindt bevruchting buiten het lichaam plaats. Dit brengt voor beide 
behandelingen (theoretische) risico's mee, die bij ICSI niet minder zijn dan bij IVF. Zij 
hangen samen met (onbekende) effecten van de gebruikte hormoonbehandelingen om 
veel follikels te Iaten rijpen en om in de baarmoeder geplaatste embryo's zo goed mogelijk 
te Iaten innestelen en groeien. 
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Daarnaast zijn er de risico's die samenhangen met het verblijf van de te bevruchten eicel 
buiten het lichaam. In het verleden zijn in Nederland publicaties verschenen over o.a. 
hepatitis (geelzucht)-infecties en bevruchting door een zaadcel niet van de partner. Door 
middel van zeer strenge veiligheidsvoorschriften die men aan het laboratorium stelt, 
probeert men dit soort risico's zo veel mogelijk te voorkomen. 
5.2 Risico's die samenhangen met het terugplaatsen van meer embryo's 
Als de arts meer embryo's terugplaatst, is niet aileen de kans op een zwangerschap 
grater, maar ook de kans op een meerling. Ouders die sterk naar een kind verlangen, 
verwelkomen meerlingen vaak met open armen. Meestal realiseren zij zich niet dat een 
meerlingzwangerschap nogal eens problemen voor de kinderen met zich meebrengt. Zo 
komt vroeggeboorte bij tweelingen viermaal vaker voor dan bij eenlingen, en is de kans op 
sterfte tienmaal grater. Daarnaast hebben kinderen die te vroeg geboren worden ook 
meer kans op een vertraagde ontwikkeling. 
5.3 Risico's die samenhangen met de ICSI-procedure 
Bij ICSI brengt men een zaadcel met een injectienaald in een eicel. Men beschadigt zo de 
wand van de eicel, en bovendien komt de punt van de injectienaald binnenin de eicel. Ook 
de vloeistof waarin de zaadcel in het laboratorium wordt bewaard, komt in de eicel terecht. 
Of dit alles voor het kind op lange termijn gevolgen heeft, is nog niet bekend. 
Bij een spontane bevruchting (ook bij IVF) proberen vele zaadcellen tegelijk in de eicel 
door te dringen. 
Uiteindelijk lukt het slechts een zaadcel om de eicel te bevruchten. Men spreekt daarom 
wei van natuurlijke selectie (een wedstrijd tussen zaadcellen waarbij er maar een winnaar 
is). Bij ICSI kiest men altijd een normaal uitziende zaadcel, maar of dit 'de beste' is, valt 
niet te zeggen. De natuurlijke selectie ontbreekt dus. 
5.4 Risico's die samenhangen met de reden voor ICSI 
Mannelijke vruchtbaarheidsproblemen zijn de belangrijkste redenen voor ICSI. Soms 
speelt bij deze problemen erfelijkheid een rol. 
Chromosoomafwijkingen bij de man 
Chromosomen dragen onze erfelijke informatie. Ze bevinden zich in de celkernen van aile 
cellen. Elke celkern bevat 23 paar chromosomen, waarvan twee geslachtschromosomen. 
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Geslachtschromosomen geeft men aan met de letters X en Y. Zo hebben vrouwen twee 
X-chromosomen (XX), en mannen een X- en een Y-chromosoom (XY). 
Bij mannen met vruchtbaarheidsproblemen komen twee soorten chromosoomafwijkingen 
voor: afwijkingen van de geslachtschromosomen en afwijkingen van de autosomen (aile 
andere chromosomen). Bij mannen die verminderd vruchtbaar zijn, komt ongeveer 
vijfmaal vaker een chromosoomafwijking voor dan in de algemene bevolking. 
Bij een afwijking van de ges/achtschromosomen heeft een man bijvoorbeeld een extra 
geslachtschromosoom X of Y. Mannen met zo'n chromosoomafwijking hebben behalve de 
vruchtbaarheidsproblemen vaak geen duidelijke andere verschijnselen. 
Bij een afwijking van de autosomen bestaat vaak de situatie dat twee stukken van twee 
verschillende chromosomen onderling van plaats verwisseld zijn (gebalanceerde 
translocatie). Bij deze man of vrouw zijn er verder geen verschijnselen. lemand met een 
gebalanceerde translocatie heeft een grotere kans op het krijgen van een kind met een 
ongebalanceerde chromosoomafwijking, waarbij bijvoorbeeld een stukje chromosoom 
ontbreekt. 
Kinderen met zo'n ongebalanceerde chromosoomafwijking zijn altijd verstandelijk 
gehandicapt en hebben ook vaak ernstige aangeboren afwijkingen. Soms zijn de 
afwijkingen zo ernstig dat het kind in de baarmoeder al overlijdt en de zwangerschap 
voortijdig tot een einde komt. 
DNA-afwijkingen bij de man 
De bouwstof van chromosomen is DNA. Soms ontbreekt een stukje DNA van het Y-
chromosoom. Men spreekt dan van V-de/etie. Deze DNA-afwijking komt voor bij enkele 
procenten van mannen met verminderde vruchtbaarheid. Een man met een Y-deletie 
geeft deze afwijking door aan zijn zoon, die dan vrijwel zeker later ook 
vruchtbaarheidsproblemen zal hebben, al is de ernst daarvan moeilijk te voorspellen. 
Een andere DNA-afwijking die voorkomt bij mannen met vruchtbaarheidsproblemen kan 
wijzen op een verhoogde kans op taaislijmziekte (cystische fibrose). Het is mogelijk dat de 
man een bepaalde vorm van deze ziekte heeft of het gen voor deze ziekte bij zich draagt 
(dragerschap). Een bepaa/de vorm van taais/ijmziekte uit zich in een aangeboren 
afwijking van de zaadleiders. Er zijn dan helemaal geen zaadcellen in het zaad aanwezig. 
De afwijking van de zaadleiders is hier het enige verschijnsel van de ziekte. Verderop 
bespreken wij methoden om in zo'n situatie uit de bijbal of de testikel zaadcellen te winnen 
waarmee men vervolgens ICSI kan uitvoeren. Dragerschap voor taaislijmziekte heeft 
geen betekenis voor iemands gezondheid of vruchtbaarheid. Hoewel men vroeger dacht 
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dat mannen met vruchtbaarheidsproblemen vaker drager waren, heeft onderzoek 
uitgewezen dat dragerschap bij hen niet vaker voorkomt dan bij normaal vruchtbare 
mannen. Daarom doet men in Nederland bij mannen met vruchtbaarheidsproblemen geen 
routineonderzoek naar dragerschap voor taaislijmziekte. 
Onbekende ertelijke tactoren 
Uit stamboomonderzoek blijkt dat in sommige families vaker mannelijke 
vruchtbaarheidsproblemen voorkomen dan in andere. Onbekende erfelijke factoren spelen 
hierbij waarschijnlijk een rol. Toch is niet te voorspellen hoe groot de kans op verminderde 
vruchtbaarheid is voor een man of jongen uit zo'n familie. 
Onderzoek van de man 
Alvorens ICSI te starten, adviseren artsen chromosoomonderzoek en soms onderzoek 
naar een Y-deletie. Dit zijn bloedonderzoeken. De uitslag duurt 6-12 weken. Bij een 
afwijkende uitslag bespreekt als regel een klinisch geneticus (medisch specialist op het 
gebied van erfelijke ziekten) de gevolgen, zoals de kans op een aangeboren afwijking of 
vruchtbaarheidsproblemen voor een zoon. Als de uitslagen normaal zijn, is er geen 
verhoogde kans op ernstige aangeboren afwijkingen of ziekten bij het kind. 
MESA en TESE 
Hierboven noemden wij reeds de mogelijkheid om zaadcellen uit de bijbal te verkrijgen. Dit 
gebeurt via een techniek die 'microchirurgische epididymale sperma-aspiratie' (MESA) 
wordt genoemd. Omdat de risico's van deze behandeling nog niet voldoende bekend zijn, 
is de MESA-techniek op het tijdstip dat deze folder wordt geschreven (2001) slechts in 
enkele ziekenhuizen in Nederland toegestaan. 
Afwezigheid van de zaadleiders als gevolg van een bepaalde vorm van taaislijmziekte kan 
een reden zijn voor MESA. Wanneer nu de vrouw draagster is van deze ziekte, dan is de 
kans groot dat het kind een ernstige vorm van taaislijmziekte krijgt. 
Dit geldt ook voor een andere behandeling, testiculaire sperma-extractie (TESE), waarbij 
men zaadcellen uit de testikel haalt. TESE is in Nederland niet toegestaan. Bij paren die 
een MESA of TESE-behandeling (in het buitenland) overwegen, doet men vaak 
voorafgaand in Nederland DNA-onderzoek om te bepalen of de man zo'n vorm van 
taaislijmziekte heeft en of zijn partner draagster is. Zo is de kans op een kind met 
taaislijmziekte te voorspellen. 
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5.5 Aile risico's voor kinderen geboren na ICSI op een rij 
Vatten we genoemde risico's samen, en kijken we ook naar ander onderzoek, dan zijn de 
volgende conclusies mogelijk: 
- De kans op een zwangerschap die eindigt met de geboorte van een kind is bij ICSI even 
groat als bij 'gewone' IVF, ongeveer 15-20% per behandeling. 
- Van de zwangerschappen die door ICSI ontstaan eindigt ongeveer 25% in een 
miskraam. Dit percentage is even hoog als bij IVF. 
- De belangrijkste tot nu toe bekende gezondheidsproblemen voor kinderen geboren na 
ICSI- (en IVF-) zwangerschappen zijn het gevolg van meerlingzwangerschappen. Deze 
zwangerschappen eindigen vaker in een vroeggeboorte, met meer kans op blijvende 
handicaps. 
- Op dit moment tonen de meeste onderzoeken aan dat ICSI-kinderen niet meer kans op 
een aangeboren afwijking hebben dan op andere wijze verwekte kinderen. Zo is voor 
kinderen uit de algemene bevolking de kans op een aangeboren afwijking zo'n 3%. 
Sommige onderzoekers vinden meer kleine aangeboren afwijkingen na ICSI, maar 
anderen kunnen dit niet bevestigen. 
- Aileen bij een vader met een gebalanceerde translocatie (chromosoomafwijking waarbij 
twee stukjes van twee verschillende chromosomen van plaats verwisseld zijn), is er een 
vergrote kans op ernstige aangeboren afwijkingen. 
Bij vaders met een Y-deletie krijgt een zoon vrijwel zeker later ook 
vruchtbaarheidsproblemen. Maar ook binnen families waar veel mannelijke 
vruchtbaarheidsproblemen voorkomen, is de kans groat dat zonen eveneens deze 
problemen zullen hebben, al is geen Y-deletie aangetoond. 
- ICSI-kinderen hebben een geringe kans op een chromosoomafwijking waarbij er een 
extra chromosoom is. Het gaat hierbij niet om een extra chromosoom 21, zoals bij het 
Downsyndroom, maar om een extra geslachtschromosoom. Deze kans is klein (ongeveer 
1 %). Kinderen met een extra geslachtschromosoom ontwikkelen zich vrijwel altijd 
normaal, terwijl ook hun uiterlijk normaal is. 
-Ten aanzien van de verstandelijke ontwikkeling beschrijft een onderzoek vooral bij 'ICSI-
jongens' een geringe achterstand. Andere onderzoeken bevestigen deze bevindingen niet. 
- Net als bij IVF zijn er bij elke ICSI-behandeling onbekende gezondheidsrisico's, die 
samenhangen met laboratoriumprocedures buiten het lichaam en hormoongebruik rond 
de bevruchting. 
160 
- De gevolgen van het niet plaatsvinden van de 'natuurlijke selectie' bij ICSI zijn onbekend. 
Deze gegevens Iaten zien dat vroeggeboorte bij meerlingzwangerschappen de 
belangrijkste tot nu toe bekende oorzaak is van mogelijke gezondheidsproblemen van 
ICSI-kinderen. Naarmate een bevalling vroeger plaatsvindt, is de couveuseopname 
langduriger en de kans op handicaps of sterfte grater. Evenals niet-ICSI-kinderen hebben 
ICSI-kinderen ongeveer 3% kans op een aangeboren afwijking. 
6 IS ICSI EEN REDEN VOOR EXTRA ONDERZOEK TIJDENS DE ZWANGERSCHAP? 
Vrouwen van 36 jaar en ouder kunnen op grond van hun leeftijd overwegen 
chromosoomonderzoek door middel van een vruchtwaterpunctie of vlokkentest te Iaten 
verrichten, omdat zij iets meer kans hebben op een kind met het Downsyndroom. Een 
kansberekeningtest door middel van bloedonderzoek (tripel-test) of echo (nekplooimeting) 
behoort eveneens tot de mogelijkheden. 
Meer informatie daarover vindt u in de brochure Prenatale diagnostiek a/s u 36 )oar of 
ouderbert.. 
Bij ICSI op jongere leeftijd bespreken sommige artsen ook een vlokkentest of een 
vruchtwaterpunctie, hoewel een vlokkentest moeilijk kan zijn bij een meerling. Beide 
onderzoeken brengen een kleine kans (0,3-0,5%) op een miskraam mee. Het is van 
belang te weten dat door ICSI de kans op een kind met een chromosoomafwijking als het 
Downsyndroom niet verhoogd is. 
De Iicht verhoogde kans (1 %) op een kind met een afwijking van de 
geslachtschromosomen is voor artsen geen reden om een abortus te bespreken of te 
adviseren. Er zijn dus eigenlijk geen goede redenen om aileen in verband met ICSI een 
vlokkentest of vruchtwaterpunctie te doen. Deze onderzoeken geven geen antwoord op 
aile genoemde onzekerheden die met een ICSI-behandeling gepaard gaan. Ouders die 
kiezen voor ICSI, kiezen daarmee welbewust voor een aantal onzekerheden over 
langetermijngevolgen voor hun kind en voor de vrouw. Zeker bij paren die sterk naar een 
kind verlangen is dit een moeilijke keuze, die u gerust met de arts kunt bespreken. 
Toch kan welbewust kiezen voor 'het onzekere' eraan bijdragen dat u zich later niet 
afvraagt: 'Waarom is mij dit niet verteld?' 
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7 VERSCHILLENDE ONDERZOEKEN TIJDENS DE ZWANGERSCHAP OP EEN RIJ 
De hieronder genoemde onderzoeken zijn tijdens de zwangerschap mogelijk en worden 
vaak vergoed. Veel artsen twijfelen aan het nut van deze onderzoeken, als ze aileen 
worden gedaan omdat er een ICSI-behandeling heeft plaatsgevonden. 
7.1 Uitgebreid echoscopisch onderzoek 
Bij dit onderzoek beoordeelt men de verschillende organen van het kind bij 18-20 weken 
zwangerschap. Ernstige, grate aangeboren afwijkingen ziet men hierbij doorgaans wei, 
maar ICSI-kinderen hebben niet meer kans op dit soort afwijkingen. Kleinere, meestal 
minder ernstige aangeboren afwijkingen ziet men bij dit onderzoek snel over het hoofd. 
7.2 Vlokkentest of vruchtwaterpunctie 
Bij deze onderzoeken vindt chromosoomonderzoek van het kind plaats. Het is de vraag of 
deze onderzoeken bij ICSI zinvol zijn. De kans op een chromosoomafwijking als gevolg 
van ICSI is gering (1 %). Bovendien betreft het hier meestal een 
geslachtschromosoomafwijking, die geen ernstige verschijnselen geeft. Oak moet u 
rekening houden met een kans op een miskraam van een in principe goede 
zwangerschap als gevolg van een vlokkentest (0,5%) of een vruchtwaterpunctie (0,3%). 
Meer informatie over de vlokkentest en de vruchtwaterpunctie vindt u in de brochure 
Prenatale diagnostiek bij aangeboren of erfe/ijke aandoeningen. In die brochure 
staat ICSI overigens niet vermeld als reden voor zo'n onderzoek. De informatie over de 
tripel-test en de nekplooimeting gaat over de kans op een kind met het Downsyndroom; 
deze kans is niet verhoogd bij ICSI. De tripel-test en de nekplooimeting zeggen weinig 
over de kans op geslachtschromosoomafwijkingen. 
Bij ouders die zelf een chromosoomafwijking hebben is de situatie anders; voor hen is het 
vaak wei zinvol een vlokkentest of een vruchtwaterpunctie te overwegen. 
8 ONDERZOEK BIJ KINDEREN DIE NA ICSI GEBOREN ZIJN 
Op dit ogenblik vindt in Nederland geen onderzoek op latere leeftijd plaats van aile ICSI-
kinderen. Misschien gebeurt dit wei in de toekomst. De mogelijkheid bestaat dat het 
ziekenhuis waar de ICSI plaatsvond, u te zijner tijd benadert om mee te doen aan 
onderzoek van uw kind(eren). Waarschijnlijk gaat het dan om eenvoudig onderzoek naar 
de gezondheidstoestand, de verstandelijke ontwikkeling en het gedrag, waaronder de 
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manier van bewegen. Medewerking is nooit verplicht, maar wordt wei op prijs gesteld om 
een beter antwoord op bovengenoemde onzekerheden te geven. 
9 MEER INFORMATIE OVER ICSI 
Meer informatie is te verkrijgen bij Freya, Patientenvereniging voor vruchtbaarheidsproblematiek, 
Postbus 476, 6600 AL Wijchen; tel. (024) 645 10 88, fax (024) 645 46 05; website www.freya.nl ; e-
mail secretariaat@freya.nl . Als zwanger worden niet vanzelf gaat. Cd-rom, verkrijgbaar in de 
boekhandel. NVOG-VSOP-brochures: Prenatale diagnostiek a/s u 36 jaar of ouder bent 
Prenatale diagnostiek bij aangeboren of erfelijke aandoeningen. 
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Summary 
Introduction 
In the Netherlands, every one out of seven couples does not achieve a pregnancy within one 
year of active sexual intercourse. This subfertility may have various causes in either partner. 
According to the World Health Organization (WHO), in 20 percent of all cases the problem is 
predominantly male and in 38 percent predominantly female. Male subfertility is frequently 
associated with a gross reduction in the number of sperm (oligozoospermia) and/or the 
abnormal motility of sperm (asthenozoospermia) and/or with abnormal morphology of the 
sperm (teratozoospermia). Mostly, all these parameters are impaired in male subfertility, so 
called OAT= OligoAsthenoTeratozoospermia. 
The cause of this male subfertility remains unknown in 40% of all cases. Recently, much 
attention has been given to genetic causes of male subfertility such as chromosomal 
aberrations, microdeletions of theY chromosome and other possible monogenetic causes 
of male subfertility. This attention is stimulated by the increasing knowledge of genetics 
and the recently finished documentation of the human genome, called the Human 
Genome Project. On the other hand people are concerned that via intracytoplasmic sperm 
injection (ICSI) there is a potential transmission of genetic defects to the offspring. 
In this thesis we have tried to answer the following questions: 
The first part - Part I - of this thesis describes the familial occurrence of male subfertility. 
We continue in Part II with the molecular genetic search for genes involved in male 
subfertility. In this strategy we have used both linkage analysis as candidate gene 
research. In the last and third part of this thesis - Part Ill -we present three studies on the 
clinical implications of the genetic aspects involved in male subfertility. 
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Part I 
In chapter 1 the survey on the familial occurrence of male subfertility is presented. 
Surprisingly the frequency of subfertility among relatives was reported lower than among 
the responders that filled out the questionnaire and their family tree. Probably the 
frequency of fertility problems is underestimated among relatives. Knowledge on fertility 
problems travels selectively among families causing substantial misclassification. Male 
subfertility is a difficult subject to discuss and gives rise to this "Taboo Bias". 
The next chapter, 2, describes the familial occurrence of male subfertility among relatives 
of subfertile men. The frequency of male subfertility is increased among brothers and 
maternal uncles of subfertile men. Besides the hypothesized autosomal inheritance in 
male subfertility, the higher frequency of male subfertility among maternal uncles may be 
due to X-linked inheritance. 
These subfertile men with a positive family history more often have normal serum levels of 
FSH and LH. This can indicate a disturbed spermatogenesis and an intact hormonal 
feedback mechanism. Another clinical phenomena is the diminished motility of 
spermatozoa in this group of men with a possible genetic origin of their fertility problem. 
No final conclusions can be drawn, because of the taboo bias described in chapter 1. The 
differences found between the family history of the subfertile men and their controls may 
also be caused by recall bias. In other words, subfertile men may be better informed on 
fertility problems in their families than in our survey. 
Part II 
In chapter 3 an X-linkage analysis is described in a family of a subfertile men with 5 
subfertile maternal nephews. The pedigree suggested an X-linked inheritance, but this 
could not be confirmed by molecular linkage analysis. We hypothesised an autosomal 
dominant trait with sex limited expression. 
In chapter 4 and 5 we present the results on the role of respectively the candidate genes 
DAZLA and the Androgen receptor gene. This DAZLA gene showed no pathogenic 
mutations in subfertile men. For the Androgen receptor gene we could not confirm the 
controversial results on the expansion of the CAG repeat length. 
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Chapter 6 is a completely different kind of molecular genetic research in the discussion on 
genetic disorders in male subfertility and its clinical implications. Mutations in mitochondrial 
DNA of subfertile men are described. If these subfertile men father children via ICSI these 
children might be at risk for a mitochondrial disease. In collaberation with an English 
research institute this risk seems limited. No transmission of paternal mitochondrial DNA 
via ICSI was detected. 
Part Ill 
In the last part of this thesis we describe some clinical consequences of the genetic 
aspects of male subfertility. 
In chapter 7 it is shown that 79% of the men with a microdeletion of the Y chromosome 
choose ICSI. This means that they accept the risk that their son(s) probably develop(s) an 
impaired spermatogenesis and a fertility problem. This choice is mainly influenced by: (a) 
the opinion of the counsellor if Y deletions are a serious defect, (b) the fertilisation 
techniques available in the department and (c) if the counsellor considers his counselling 
direct. 
Chapter 8 shows that subfertile men with a microdeletion of the Y chromosome can 
influence the treatment. Our results show a decreased fertilisation rate and embryo quality 
after ICSI using sperm from these men. This may also have an effect on the pregnancy 
rate and take home baby rate, but larger numbers of couples are required to study the 
possible prognosis of such deletions on ICSI treatment. The last chapter, 9, of this thesis 
confirms earlier and later results on the follow-up of ICSI. We have observed no statistical 
increase of abnormalities after ICSI for: preembryonic development, obstetric and neonatal 
outcome and follow-up of children born after ICSI. At this, moment ICSI seems a 
successful and safe technique. However, a prospective follow-up study on ICSI and 
appropriate control groups will hopefully confirm present results. 
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Main conclusions 
This thesis shows clinical evidence for still unknown genetic factors involved in male 
subfertility. Up till now, our molecular genetic search for a new gene involved in male 
subfertility has been unsuccessful. Future research may be successful in the search 
among this heterogeneous disorder of male subfertility. The next step will be to supply the 
optimal and objective information for subfertile men and their partners. 
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Samenvatting 
lntroductie 
Een op de zeven paren in Nederland kan binnen een jaar van onbeschermde 
samenleving geen zwangerschap bewerkstelligen. Deze zogenaamde subfertiliteit kan 
verschillende oorzaken hebben bij zowel man als vrouw. Volgens de wereld 
gezondheidsorganisatie (WHO) bestaat er in 20% van de gevallen een mannelijke 
oorzaak en in 38% van de gevallen is er met name een vrouwelijke oorzaak voor de 
subfertiliteit. De mannelijke subfertiliteit wordt meestal veroorzaakt door een verminderde 
zaadkwaliteit. Zo kunnen er zich te weinig zaadcellen in de zaadlozing bevinden 
(oligozoospermie), een verminderde beweeglijkheid van zaadcellen optreden 
(asthenozoospermie) en/of een te hoog percentage van afwijkende vormen van 
zaadcellen voorkomen (teratozoospermie). Vaak zijn aile bovengenoemde parameters 
verminderd en dit wordt dan afgekort tot OAT= OligoAsthenoTeratozoospermie. 
De oorzaak van deze verminderde zaadkwaliteit blijft echter vaak onbekend. De laatste 
jaren bestaat er veel aandacht voor de genetische oorzaken van deze mannelijke 
subfertiliteit zoals (1) chromosomale afwijkingen, (2) microdeleties van het Y chromosoom 
en (3) andere mogelijke monogenetische oorzaken van mannelijke subfertiliteit. Deze 
aandacht voor genetische oorzaken wordt enerzijds gestimuleerd door de toename in 
kennis van de genetica en de recente afronding van het in kaart brengen van het 
menselijke genetische materiaal, het Human Genome Project. Anderzijds is er 
bezorgdheid random de overdracht van genetische afwijkingen aan het nageslacht door 
de nieuwe voortplantingstechniek van intracytoplasmatische sperma injectie (ICSI). 
Daarom hebben wij getracht in dit proefschrift een aantal vraagstellingen te beantwoorden: 
In het eerste deel - Deel I -van dit proefschrift wordt het onderzoek beschreven naar het 
familiair voorkomen van mannelijke subfertiliteit. Vervolgens worden er in het tweede deel 
- Deel II - een aantal studies gepresenteerd van onze moleculair genetische zoektocht 
naar mogelijke genen die betrokken zijn bij mannelijke subfertiliteit. Hierbij hebben we 
zowel koppelingsonderzoek als mutatieonderzoek in kandidaatgenen toegepast. 
In het laatste en derde deel - Deel Ill - van dit proefschrift onderzochten wij een aantal 
klinische implicaties van de gevonden genetische afwijkingen. 
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Deell 
In hoofdstuk 1 zijn de resultaten beschreven van het populatieonderzoek naar het 
familiair voorkomen van mannelijke subfertiliteit. Opvallend resultaat van deze studie is dat 
de frequentie van vruchtbaarheidsproblemen bij familieleden lager is dan bij degene die de 
vragenlijst invulde. De frequentie van vruchtbaarheidsproblemen bij familieleden wordt dus 
onderschat. Dit kan hoogstwaarschijnlijk worden verklaard doordat men in families niet 
volledig op de hoogte is van elkaars vruchtbaarheidsproblemen. Mannelijke 
vruchtbaarheidsproblemen is een moeilijk bespreekbaar onderwerp en geeft dus 
mogelijke aanleiding voor deze "Taboe Bias". 
Het volgende hoofdstuk, 2, beschrijft het familiair voorkomen van mannelijke 
vruchtbaarheidsproblemen. Broers en ooms aan moederszijde van subfertiele mannen 
lijken vaker vruchtbaarheidsproblemen te ondervinden. Naast de eerder gesuggereerde 
autosomale overerving van mannelijke subfertiliteit kan de hogere frequentie van 
vruchtbaarheidsproblemen van ooms aan moederszijde en broers oak wijzen op 
geslachtsgebonden overerving. Bovendien zijn de serumwaarden van het Follikel 
Stimulerend Hormoon en het Luteinizerend hormoon bij mannen met zo'n positieve 
familieanamnese statisch lager en vallen vaker binnen de normaalwaarden. Dit kan wijzen 
op een intact endocrienologisch feedback mechanisme bij een gestoorde 
spermatogenese. Daarnaast is de motiliteit van de zaadcellen lager, in deze groep 
mannen met een mogelijke genetische oorsprong voor hun vruchtbaarheidsprobleem. 
Definitieve conclusies kunnen echter nag niet worden getrokken. In hoofdstuk 
beschreven we al de taboe bias. Het verschil in familiair voorkomen van mannelijke 
subfertiliteit kan mogelijk oak worden verklaard door het beter op de hoogte zijn van 
dergelijke problemen in families van de subfertiele man, zogenaamde recall bias. 
De klinische karakteristieken van subfertiele mannen met een positieve familieanamnese 
vertonen vaker bovengenoemde klinisch statistische verschillen, maar de groep is 
fenotypisch heterogeen. 
Deelll 
In hoofdstuk 3, wordt het koppelingsonderzoek van het X chromosoom beschreven van 
de familie van een subfertiele man met 5 subfertiele neven. De stamboom suggereert 
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duidelijk een geslachtsgebonden overerving bij deze subfertiele mannen die allen een 
zeer slechte zaadkwaliteit hebben. Dit kon met moleculair genetisch onderzoek niet 
worden bevestigd en daarom hebben we geconcludeerd dat er mogelijk sprake is van 
autosomale dominante overerving met geslachtsgebonden expressie. 
In de hoofdstukken 4 en 5 presenteren we respectievelijk de resultaten van de mogelijke 
rol van het DAZLA gen en het Androgeen receptor gen bij mannelijke subfertiliteit. In het 
DAZLA gen konden geen pathogenetische mutaties worden aangetoond. In het 
onderzoek van de androgen receptor konden wij de controversiele resultaten betreffende 
de toename van de lengte van CAG repeats ook niet bevestigen. 
Hoofdstuk 6 vormt een geheel ander moleculair genetisch onderwerp bij de discussie 
rondom genetisch afwijkingen bij mannelijke subfertiliteit en de mogelijke klinische 
consequenties. Er zijn namelijk mutaties beschreven in het mitochondriaal DNA van 
subfertiele mannen. Dit kan een risico vormen, omdat deze mannen tegenwoordig door 
ICSI kinderen kunnen voortbrengen. In deze gezamenlijke studie met een Engelse 
onderzoeksgroep zijn er echter geen aanwijzingen gevonden voor paternale transmissie 
van mitochondriaal DNA door ICSI. 
Deellll 
In het laatste deel van dit proefschrift beschrijven we een aantal klinische consequenties 
van de genetische aspecten van mannelijke vruchtbaarheidsproblemen. In hoofdstuk 7 
wordt getoond dat 79% van de mannen met een microdeletie van het Y chromosoom toch 
kiezen voor een ICSI behandeling. Zij aanvaarden hierbij dus het risico dat zonen later 
misschien ook vruchtbaarheidsproblemen krijgen. Deze keuze werd met name be"lnvloed 
door: (a) de mening van de voorlichter over de ernst van microdeleties op het Y 
chromosoom, (b) het aileen maar voor handen zijn van donor inseminatie op de afdeling 
van de voorlichter en (c) de directheid van het gesprek door de voorlichter. 
Hoofdstuk 8 laat zien dat het hebben van zo'n microdeletie op het Y-chromosoom ook 
zijn invloed kan uitoefenen op de behandeling. Zo bleek dat bij deze zeldzame 
aandoening de fertilisatiegraad en embryokwaliteit verlaagd zijn. Mogelijk heeft dit ook 
effect op de zwangerschapskans, maar door de kleine onderzoeksgroep kan hier nog 
geen uitspraak over gedaan worden. 
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Het laatste hoofdstuk, 9, van dit proefschrift bevestigt de resultaten van de follow-up 
gegevens van eerder en later verschenen onderzoek. ICSI lijkt op dit moment een 
succesvolle en veilige techniek. Echter prospectief onderzoek met een zo adequaat 
mogelijke controlegroep laat hier hopelijk ook op langere termijn geruststellende resultaten 
van zien. 
Conclusies 
In dit proefschrift zijn er dus aanwijzingen gevonden voor de mogelijke genetische origine 
van mannelijke subfertiliteit. De moleculair genetische zoektocht naar een nieuw gen dat 
hierbij betrokken is heeft echter nog niet tot een nieuwe doorbraak geleid. 
Toekomstig onderzoek zal hopelijk leiden tot een aantal belangrijke genen die betrokken 
zijn bij de heterogene aandoening van mannelijke subfertiliteit. Het is dan voorts belangrijk 
dat al deze informatie beschikbaar moet zijn voor de mannen met een 
vruchtbaarheidsprobleem. 
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